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Chapter 1
Emerging concepts in gastric neoplasia
Heritable gastric cancer and polyposis disorders
Rachel S van der Post and Fátima Carneiro
Surgical Pathology Clinics (in press)
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Introduction to hereditary gastric cancer
FAMILIAL GASTRIC CANCER – INTRODUCTION
Most (>80%) gastric carcinomas are sporadic; familial aggregation occurs in 10 to 
20% of patients and fewer than 3% can be attributed to known inherited causes.1 
Gastric carcinomas diagnosed at advanced stage have a poor prognosis; every 
effort should be made to prevent or detect it at early stages when potentially 
curable. Familial gastric carcinoma can be classified as hereditary diffuse gastric 
cancer, familial intestinal gastric cancer, and familial gastric cancer when the 
histologic subtype is unknown.2 Advanced gastric cancers are often classified 
as “poorly differentiated adenocarcinoma” at the time of biopsy, although an 
attempt should be made to categorized them according to the World Health 
Organization or Laurén schemes. The latter classifies tumors as intestinal and 
diffuse types; tumors that cannot be placed in one of these categories are 
considered indeterminate and mixed type.3 The purpose of this review was 
to describe the histologic and clinical characteristics of several gastric cancer 
syndromes, including other primary malignancies and types of gastrointestinal 
polyps. This article focuses on important histopathologic features and emerging 
concepts in (1) hereditary diffuse gastric cancer, (2) familial intestinal gastric 
cancer, (3) gastric adenocarcinoma and proximal polyposis of the stomach and 
similar polyposis syndromes, as well as (4) other hereditary cancer syndromes, 
as enumerated in Tables 1 and 2. 
HEREDITARY DIFFUSE GASTRIC CANCER
CDH1 germline mutation
Identification of CDH1 germline mutations in the Maori population defined 
a newly recognized autosomal dominant cancer-susceptibility syndrome 
termed “hereditary diffuse gastric cancer.”4 Following this discovery, many 
families around the world with clustering of gastric cancer have been tested 
to identify novel CDH1 germline mutations. CDH1 encodes E-cadherin, a 
transmembrane calcium-dependent protein with important roles in cell-cell 
adhesion at the adherens junctions.5,6 Germline CDH1 alterations can affect the 
entire coding sequence and include small frameshifts, splice-site, nonsense, 
and missense mutations, as well as large rearrangements.7 Most truncating 
mutations are pathogenic and several missense mutations have a deleterious 
effect on E-cadherin function.8 Individuals with germline CDH1 mutations 
have a single functional CDH1 allele. Inactivation of the wild-type allele by a 
somatic second-hit molecular mechanism (ie, promoter hypermethylation, loss 
11
1of heterozygosity) leads to biallelic inactivation and development of diffuse 
gastric cancer.9–12 Biallelic CDH1 inactivation leads to loss of E-cadherin function 
and abnormal immunohistochemical staining for E-cadherin compared with 
complete membranous staining in normal epithelium.11–14 Aberrant E-cadherin 
staining patterns include absence of immunoreactivity, weak membranous 
staining, “dotlike” staining, and cytoplasmic staining.15 Individuals with a 
pathogenic germline CDH1 mutation are at 60% to 70% increased risk for diffuse 
gastric cancer and women are at risk for lobular breast cancer (40%).1,16 There is 
no evidence that individuals with CDH1 mutations are at significantly increased 
risk for other cancer types. Testing of germline CDH1 mutations is recommended 
in families that fulfill one of the following three criteria:1
1. Two or more documented cases of GC at any age in first- or second-degree 
relatives, with at least one confirmed DGC;
2. Personal history of DGC before the age of 40 years;
3. Personal or family history (first- or second-degree relatives) of DGC and 
lobular breast cancer, one diagnosed before the age of 50 years. 
In addition, genetic testing can be considered in families with bilateral or 
multiple cases of lobular breast cancer before the age of 50 years; families with 
clustering of DGC and cleft lip/cleft palate and; any patient that is diagnosed with 
in-situ or pagetoid spread of signet ring cells.1 Prophylactic total gastrectomy 
is advised for individuals with a proven pathogenic germline CDH1 mutation.1 
These resection specimens generally show no specific gross abnormalities, 
but multiple invasive intramucosal cancers (pT1a) are almost always detected 
when the entire stomach is processed for histology (Fig. 1A).13,17,18 In most cases, 
these tiny (<0.1–10 mm) foci are restricted to the superficial mucosa. They are 
composed of relatively small signet ring cells at the neck-zone level that enlarge 
toward the mucosal surface.14 Foci are found throughout the stomach and even 
in gastric metaplasia beyond the pylorus.1 Two typical precursor lesions of 
intraepithelial signet ring cell carcinoma include signet ring cell carcinoma in situ 
(Tis) and pagetoid spread of signet ring cell carcinoma. The former is defined as 
a disorganized proliferation of signet ring cells that replaces normal glandular 
epithelial cells, but is confined by the basement membrane. Pagetoid spread 
of signet ring cells appears as a linear proliferation of signet ring cells between 
normal epithelial cells and the basement membrane (see Fig. 1B). Confirmation 
of these precursors by an experienced histopathologist is recommended 
because benign signet cell–like changes may mimic these lesions.1 Most 
resection specimens contain few, or no precursor lesions despite the presence 
12
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of numerous foci of intramucosal signet ring cell carcinomas. It is not clear how 
long early lesions of hereditary diffuse gastric cancer can remain indolent and 
predicting progression of disease is challenging. Inactivation of the second CDH1 
allele is an early event, but other driver alterations that may play a role in the 
pathogenesis of diffuse gastric cancer have not been clarified. Early hereditary 
diffuse gastric cancers have an “indolent” phenotype and contain uniform 
signet ring cells with low Ki- 67 labeling and normal p53 immunoexpression. 
Advanced hereditary diffuse gastric cancers display an “aggressive” phenotype 
with a mixture of pleomorphic cells, increased Ki-67 staining, and aberrant p53 
expression.15 Advanced gastric carcinomas associated with a pathogenic CDH1 
germline mutation, often show gastric wall thickening due to diffuse infiltration 
by cancer cells. Although hereditary diffuse gastric carcinomas are histologically 
indistinguishable from sporadic diffuse gastric cancers, the presence of in situ 
lesions, pagetoid spread, or multifocal intramucosal signet ring cells in otherwise 
normal mucosa, are important clues.
A                      B
Figure 1) A. Typical CDH1-associated intramucosal signet ring cell carcinoma (H&E, original 
magnification 100x) B. Pagetoid spread of signet ring cells (H&E, original magnification 250x)
CTNNA1 germline mutation 
Approximately 60% to 70% of families that fulfill the current testing criteria 
for hereditary diffuse gastric cancer lack germline CDH1 mutations.16,19,20 Three 
families with clustering of diffuse gastric cancer have been reported to carry 
germline CTNNA1 mutations.16,21 CTNNA1 encodes a-E-catenin, which is involved 
in intercellular cell adhesion and forms a complex with b-catenin to bind the 
cytoplasmic domain of E-cadherin to the cytoskeleton.22–24 Diffuse gastric cancers 
identified in CTNNA1 mutation carriers can show loss of immunohistochemical 
staining for a-E-catenin with preservation of E-cadherin. The clinical features of 
these kindreds are similar to those of families with CDH1-mutations and include 
13
1intramucosal signet ring cell carcinomas, but available data are not sufficient to 
make a statement regarding disease penetrance.21
Other mutations described in hereditary diffuse gastric cancer
Hansford and colleagues16 reported results from targeted sequencing of 55 
cancer-associated genes in 144 families with hereditary diffuse gastric cancer 
who lacked detectable germline CDH1 mutations. They identified 2 families 
with germline CTNNA1 mutations, as well as truncating germline mutations in 
BRCA2, PRSS1, ATM, PALB2, SDHB, STK11, and MSR1.16 These results do not 
suggest a new type of hereditarydiffuse gastric cancer, but reflect clustering of 
diffuse gastric cancer that is sometimes seen in the context of familial cancer 
syndromes. Other germline mutations affecting MAP3K6 and MYD88 have been 
described, but their significance is not known.25,26 It is possible that some families 
have abnormalities at the CDH1 locus or changes affecting proteins that interact 
with E-cadherin pathway that have not yet been identified. Next-generation 
sequencing and similar methods may identify other genes responsible for 
hereditary diffuse gastric cancer in the future.
FAMILIAL INTESTINAL GASTRIC CANCER (FIGC)
Patients with familial intestinal gastric cancer are at increased risk for intestinal-
type gastric carcinoma. Definitional criteria for this disorder depend on the 
incidence of gastric carcinoma in the population. In 1999, the International 
Gastric Cancer Linkage Consortium proposed diagnostic criteria analogous 
to the Amsterdam criteria in high-incidence countries (eg, Portugal, Japan).2 
Diagnostic criteria for countries with low incidence include at least 2 first-degree 
or second-degree relatives affected by intestinal-type gastric cancer, with 1 
diagnosed before the age of 50 years; or 3 or more relatives with intestinal-type 
gastric cancer diagnosed at any age.2 The diagnosis should be considered when 
there is a history of intestinal-type gastric cancer in families without polyposis. 
Familial intestinal gastric cancers show no histologic features that distinguish 
them from sporadic intestinal-type gastric cancers. One family with clustering of 
intestinal-type gastric cancer and heterozygous mutations in the immunity gene 
IL12RB1 was reported, but additional research is required to determine whether 
such mutations increase gastric cancer risk.27 No other inherited mutations have 
been reported in patients with familial intestinal gastric cancer. Helicobacter 
pylori eradication seems to be themost important strategy for preventing 
gastric cancer in first-degree relatives of patients with gastric cancer.28
14
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1GASTRIC POLYPOSIS AND GASTRIC CANCER 
PREDISPOSITION 
Background 
Most gastric polyps are sporadic, consist mostly of epithelial elements, and they 
are related to high rates of H pylori infection. Gastric polyps that develop in 
patients with a polyposis syndrome are often multiple and can be divided into 
the following:
o Fundic gland polyps seen in gastric adenocarcinoma and proximal 
polyposis of the stomach, complete and attenuated familial 
adenomatous polyposis, and MUTYH-associated polyposis syndromes.
o Hamartomatous polyps seen in Peutz-Jeghers syndrome, juvenile 
polyposis syndrome, and Cowden (phosphatase and tensin homolog 
[PTEN] hamartoma tumor) syndrome.
Other syndromes in which gastric polyps are sometimes reported include 
neurofibromatosis type 1, McCune-Albright syndrome, and Cronkhite-Canada 
syndrome, the latter of which is likely a nonheritable immune-mediated 
disorder. There is no definite increased gastric cancer risk among patients with 
neurofibromatosis type 1, McCune-Albright syndrome, or Cronkhite-Canada 
syndrome.29
FUNDIC GLAND POLYPOSIS SYNDROMES
Gastric adenocarcinoma and proximal polyposis of the stomach 
(GAPPS)-related gastric polyposis and cancer
In 2012, gastric adenocarcinoma and proximal polyposis of the stomach was 
recognized as a heritable form of gastric cancer. Affected kindreds exhibit a 
specific clinicopathologic phenotype with 10 to hundreds of fundic gland polyps 
involving oxyntic mucosa, occasional hyperplastic and adenomatous polyps, and 
an increased risk for intestinal-type or mixed-type gastric adenocarcinoma.30 
The gastric antrum and pylorus are typically spared, and the small intestine and 
colon are unaffected.31 Li and colleagues32 recently described point mutations in 
the Adenomatous Polyposis Coli (APC) gene promoter 1B that cosegregated with 
disease in 6 families afflicted by gastric adenocarcinoma and proximal polyposis 
of the stomach. These point mutations specifically affect the promoter 1B of 
APC and lead to an increased risk of gastric polyps and adenocarcinoma, but 
affected families do not have the full familial adenomatous polyposis phenotype 
16
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and have a low risk for colonic polyposis and colorectal cancer.32 To date, 9 
families with gastric adenocarcinoma and proximal polyposis of the stomach are 
reported worldwide; the youngest patient presented with generalized gastric 
adenocarcinoma at the age of 26 years.30,32–34
Familial adenomatous polyposis (FAP) and gastric fundic gland 
polyposis
Fundic gland polyps are the most common polyp type in Western countries, 
comprising almost 80% of all gastric polyps.35 They characteristically contain 
cystically dilated oxyntic glands lined by parietal and chief cells. Fundic gland 
polyposis is a frequent gastric manifestation of familial adenomatous polyposis, 
which is an autosomal dominant syndrome caused by a pathogenic mutation in 
APC leading to hundreds to thousands of colorectal polyps and adenocarcinoma. 
Patients with attenuated forms of disease have fewer colorectal polyps (<100), but 
similar upper endoscopic manifestations compared with familial adenomatous 
polyposis. Gastric findings include predominantly fundic gland polyps (Fig. 2), 
as well as fewer foveolar-type adenomas and pyloric gland adenomas that may 
show high-grade dysplasia in rare cases.36 In Western countries, gastric cancer 
is extremely rare and lifetime risk does not seem to be increased compared 
with the healthy population.37–40 Patients with familial adenomatous polyposis 
usually undergo upper gastroendoscopy primarily for surveillance of duodenal 
and ampullary adenomas and cancer.41
 A                      B
Figure 2) A. Fundic gland polyp with low grade dysplasia associated with FAP (H&E, 
original magnification 100x) B. Magnification of dysplastic area of figure 2 A (H&E, original 
magnification 250x)
17
1MUTYH-associated polyposis (MAP) and gastric fundic gland 
polyposis
MUTYH-associated polyposis is an autosomal recessive syndrome caused by 
mutations in the MUTYH gene. Approximately 10% to 30% of patients develop a 
limited number of gastric polyps, mostly fundic gland polyps and adenomas.42,43 
A recent study reported a nine fold higher incidence of gastric cancer in 
monoallelic MUTYH mutation carriers.44 Patients with MUTYH-associated 
polyposis regularly undergo upper gastroendoscopy for surveillance of duodenal 
polyps and cancer.39,42
GASTRIC HAMARTOMATOUS POLYPOSIS 
Hamartomatous gastric polyps occur in the context of Peutz-Jeghers syndrome, 
juvenile polyposis syndrome, Cowden (PTEN hamartoma tumor) syndrome, 
and McCune-Albright syndrome. Many of these lesions lack specific histologic 
features that allow their separation from each other and sporadic hyperplastic 
polyps.29,45
Peutz-Jeghers syndrome
Peutz-Jeghers syndrome is caused by a germline mutation in LKB1 (STK11). 
Gastric polyps show a less developed arborizing pattern of smooth muscle 
compared with hamartomatous polyps in the colon. Gastric cancer risk is 
increased among patients with Peutz-Jeghers syndrome with a cumulative 
lifetime risk of 29% from age 15 to 64 years.46 It is unknown whether the gastric 
polyps are precursors to cancer, or an epiphenomenon; dysplasia is rarely seen 
in Peutz-Jeghers polyps of the stomach.39
Juvenile polyposis 
Juvenile polyposis syndrome is a rare disorder characterized by multiple 
juvenile polyps in the colorectum, small intestine, and stomach that is caused 
by a germline mutation in SMAD4 or BMPR1A. Clinical criteria for a diagnosis 
include (1) 5 or more juvenile polyps in the colorectum, (2) any number of 
juvenile polyps in other parts of the gastrointestinal tract, or (3) any number of 
juvenile polyps in a patient with a family history of juvenile polyps.41 Juvenile 
gastric polyps usually range up to 2 to 3 cm in greatest dimension, but approach 
9 to 10 cm in some patients (Fig. 3A, B).47 Massive juvenile polyposis of the 
stomach can simulate Ménétrier disease. Polyps may be “stroma-rich” with 
elongated filiform projections, smooth outer surfaces, prominent stromal 
18
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edema with mixed inflammation, and flat surface epithelium with occasional 
dilated glands or cysts (see Fig. 3C).47 Other polyps are “epithelium-rich” with 
convoluted foveolar epithelium, surface hyperplasia, and little stromal edema 
(see Fig. 3D).47 Loss of SMAD4 immunostaining occurs in gastric juvenile polyps 
and can be used as a prescreening method; lesional epithelium shows decreased 
staining intensity or absence of staining compared with normal epithelium, 
but results may be difficult to interpret.39,47,48 Foveolar-type dysplasia occurs in 
approximately 32% of patients with numerous gastric polyps.47 Gastric cancer 
risk is approximately 10% to 30% among patients with SMAD4 mutations.41,47 
Complete or partial gastrectomy may be considered for patients with massive 
gastric polyposis, high-grade dysplasia, and/or cancer.41
A                      B
C                      D
Figure 3) A. Macroscopic image of gastrectomy specimen of a patient with a germline SMAD4 
mutation and massive gastric polyposis B. Overview image of juvenile polypoid projections (H&E, 
original magnification 10x) C. Stroma-rich juvenile polyp (H&E, original magnification 100x) D. 
Epithelium-rich juvenile polyp (H&E, original magnification 100x)
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Phospatase and tensin homolog hamartoma tumor syndrome 
(including Cowden syndrome)
PTEN hamartoma tumor syndrome comprises a heterogeneous group of 
disorders, including Cowden (most cases), Bannayan-Riley-Ruvalcaba, and 
Proteus syndrome, all of which result from various germline mutations in 
PTEN. Patients with Cowden syndrome have mucocutaneous tricholemommas 
and papillomas, thyroid lesions, fibrocystic disease and breast cancer, and 
a spectrum of gastrointestinal polyps including hamartomatous polyps, 
adenomas, and ganglioneuromas.49 Gastric polyps are present in almost all 
patients with Cowden syndrome and are usually numerous. Gastric polyps are 
small and usually simulate sporadic hyperplastic polyps without dysplasia.50,51 It 
is likely that patients are at increased risk for gastric cancer of both intestinal-
type and diffuse-type.52,53
OTHER HEREDITARY CANCER SYNDROMES IN 
WHICH GASTRIC CANCER RISK IS INCREASED 
Gastric cancer is increased in patients with germline mutations in BRCA1/2, as 
well as patients with Lynch syndrome and Li-Fraumeni syndrome. Although 
families sometimes meet the phenotypic criteria for hereditary diffuse gastric 
cancer or familial intestinal gastric cancer, patients presumably benefit most 
from surveillance strategies based on the mutated gene.
Lynch syndrome and gastric cancer risk
Lynch syndrome is caused by germline mutations in one of the DNA mismatch 
repair genes: MLH1, PMS2, MSH2, or MSH6. Mutations in EPCAM, which is directly 
upstream to MSH2, can also lead to silencing of MSH2 from transcription. Lynch 
syndrome is associated with colorectal and endometrial cancer. The frequency 
of gastric cancer ranges from 0.2% to 3.0% depending on patient population, 
gender, and the gene that is mutated.41,54 The cumulative gastric cancer risk is 
2% to 6% by the age of 70 years in most Western countries.41,54,55 There seems 
to be no clustering of gastric cancer in most families with Lynch syndrome. In 
view of the relatively low risk of gastric cancer and lack of established benefit, 
surveillance is not recommended among patients with gastric cancer in 
Europe.56 On the other hand, American guidelines state that gastroscopy can be 
considered in individuals with Lynch syndrome at age 30 to 35 years with testing 
for, and eradication of, H pylori. Recommendations and evidence for ongoing 
regular surveillance are lacking, but gastric screening may be considered in 
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1affected patients.
41 A Finnish study did not find a difference in rates of polyps, H 
pylori infection, atrophy, or intestinal metaplasia between individuals with, and 
without, Lynch syndrome.57 Lee and colleagues58 suggested that pyloric gland 
adenomas may be a precursor to gastric cancer in Lynch syndrome, but others 
have not substantiated these results. Approximately 75% of individuals with 
Lynch syndrome show an intestinal phenotype and most show microsatellite 
instability.55,59,60
Li-Fraumeni syndrome and gastric cancer risk
Li-Fraumeni syndrome is caused by a TP53 germline mutation and characterized 
by an increased cancer risk for a wide spectrum of tumors starting at young age, 
including sarcomas, brain tumors, leukemia, and carcinomas of breast, lung, 
and stomach. Individuals with Li-Fraumeni syndrome have a cumulative risk of 
gastric cancer of approximately 5%; both intestinal-type and diffuse-type have 
been reported.61–63
Hereditary breast and ovarian cancer and gastric cancer risk
Hereditary breast or ovarian cancer syndrome is caused by BRCA1 or BRCA2 
germline mutations. It is one of the most well-defined and most common 
hereditary syndromes. A meta-analysis of more than 30 studies reported a relative 
risk of gastric cancer of approximately 1.7.64 Details about histopathological 
characteristics are not reported. 
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Aim of the thesis
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1AIMS AND OUTLINE OF THE THESIS
The aim of this thesis is to gain more knowledge considering clinicopathological 
and molecular characteristics of familial and early-onset gastric cancer. Studies 
have been performed to evaluate the hereditary gastric cancer guidelines, to 
explore histopathological characteristics and to investigate known and novel 
predisposing genetic causes of familial and early-onset gastric cancer. The thesis 
has been divided into three parts: research focusing on (1) clinical criteria and 
guidelines, (2) diagnostics: gastroscopy and histopathology and (3) predisposing 
genetic causes of gastric cancer. 
Clinical criteria and guidelines
- In chapter 2 the CDH1 testing criteria were evaluated in the Netherlands.
- In chapter 3 the updated hereditary diffuse gastric cancer clinical guidelines 
with an emphasis on germline CDH1 mutation are presented.
Diagnostics: gastroscopy and histopathology
- In chapter 4 the yield of upper endoscopy in first-degree relatives of 
hereditary diffuse gastric cancer patients without a germline mutation in 
CDH1 was investigated. 
- In chapter 5 histopathological characteristics of early-onset and/or familial 
gastric adenocarcinoma are described.
- In chapter 6 the usefulness of HNF4A immunohistochemistry has been 
examined in gastric and breast carcinomas. 
Predisposing genetic causes of gastric cancer
- In chapter 7 the results of exome sequencing to identify candidate 
predisposition genes for familial gastric cancer are reported. 
- In chapter 8 the novel putative predisposing gastric cancer genes CTNNA1, 
MAP3K6 and MYD88 were tested in a large European cohort of early-onset 
and/or familial gastric cancer patients.
In the final chapter the studies presented in this thesis are summarized, 
discussed and future research perspectives are given. 
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Chapter 2
Accuracy of Hereditary Diffuse Gastric Cancer Testing 
Criteria and Outcomes in Patients with a Germline 
Mutation in CDH1
Rachel S van der Post, Ingrid P Vogelaar, Peggy Manders, Lizet E van der Kolk, Annemieke 
Cats, Liselotte P van Hest, Rolf Sijmons, Cora M Aalfs, Margreet GEM Ausems, Encarna 
B Gómez García, Anja Wagner, Frederik J Hes, Neeltje Arts, Arjen R Mensenkamp, J Han 
van Krieken, Nicoline Hoogerbrugge, Marjolijn JL Ligtenberg 
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ABSTRACT 
Germline mutations in the cadherin 1, type 1, E-cadherin gene (CDH1) cause a 
predisposition to gastric cancer. We evaluated the ability of the internationally 
accepted hereditary diffuse gastric cancer (HDGC) criteria to identify individuals 
with pathogenic mutations in CDH1, and assessed their outcomes. These criteria 
are: families with 2 or more cases of diffuse-type gastric cancer (DGC), with at 
least 1 patient diagnosed before the age of 50; families with 3 or more cases of 
DGC; families with 1 DGC before the age of 40; and families with a history of 
DGC and lobular breast cancer, with 1 diagnosis before the age of 50.
We collected results of a CDH1 mutation analysis of 578 individuals from 499 
families tested in the Netherlands between 1999 and 2014 (118 families met the 
HDGC criteria for testing and 236 did not; 145 families with incomplete data 
and/or availability of only first-degree relatives). Data were linked with family 
histories and findings from clinical and pathology analyses. The Kaplan-Meier 
method and Cox regression analysis were used to evaluate overall survival of 
patients with and without CDH1 mutations.
In a cohort study in the Netherlands, the HDGC criteria identify individuals with 
a germline CDH1 mutation with a positive predictive value of 14% and 89% 
sensitivity. There were 18 pathogenic CDH1 mutations in 499 families (4%); 16 
of these mutations were detected in the 118 families who met the HDGC criteria 
for testing. One pathogenic CDH1 mutation was detected in the 236 families 
who did not meet HDGC criteria and 1 in the 145 families with incomplete data 
and/or availability of only first-degree relatives. No CDH1 mutations were found 
in the 67 families whose members developed intestinal-type gastric cancer, 
nor in the 22 families whose members developed lobular breast cancer. Among 
patients who fulfilled the HDGC criteria and had pathogenic CDH1 mutations, 
36% survived for 1 y and 4% survived for 5 y; among patients who fulfilled the 
HDGC criteria but did not carry pathogenic CDH1 mutations, 48% survived for 
1 y and 13% survived for 5 y (P=.014 for comparative survival analysis between 
patients with and without a CDH1 mutation).
All individuals with a CDH1 mutation had a personal or family history of diffuse 
gastric cancer. Patients with gastric cancer and germline CDH1 mutations had 
shorter survival times than patients who met the HDGC criteria but did not have 
CDH1 mutations.
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INTRODUCTION
Gastric cancer is the fifth most common malignancy in the world and with 723,000 
deaths, the third leading cause of cancer-related mortality.1 There are substantial 
differences in gastric cancer incidences between and within continents, countries 
and regions, and between ethnic groups.2 Both environmental exposures as well 
as genetic constitution contribute to this extensive variation. Around 8-30% of 
gastric cancer patients have a positive family history.3-7 Like in other western 
countries, the incidence of non-cardia gastric cancer in the Netherlands has 
declined markedly during the last century.8 The annual incidence has declined 
from 1950 cases in 1990 to 1435 cases in 2014, which accounts for 1.5% of all 
new cancer cases.9 
Hereditary diffuse gastric cancer (HDGC) can be caused by heterozygous 
germline mutations in CDH1.10 This gene encodes the cell adhesion protein 
E-cadherin. Loss of E-cadherin affects epithelial architecture, cell adhesion 
and cell polarity, which can lead to sustained cell division and invasion.11, 12 
Individuals with a heterozygous germline CDH1 mutation have a lifetime risk of 
56-70% to develop diffuse gastric cancer (DGC) and women have an additional 
risk to develop lobular breast cancer (LBC) of approximately 42%.13
To guide clinicians selecting patients eligible for CDH1 mutation analysis, 
clinicopathological guidelines were developed and proposed in 1999 by the 
International Gastric Cancer Linkage Consortium (IGCLC).14 The detection rate 
of CDH1 mutations in selected, relatively small series fulfilling the original HDGC 
criteria14 was 30-50%.15, 16 These criteria included: (i) two or more documented 
cases of DGC, with at least one patient diagnosed before the age of 50, or (ii) 
three or more cases of DGC, independent of age of diagnosis.14 In the updated 
clinical guidelines of 2010, the HDGC criteria were broadened with the addition of 
two criteria: (iii) one DGC before the age of 40 without a family history of gastric 
cancer and (iv) personal or family history of DGC and LBC one diagnosis before 
the age of 50; since CDH1 mutations were also detected in these patients.17 
The aims of this study were to examine the predictive value of the 2010 HDGC 
criteria for clinical management and to assess the outcome of gastric cancer 
patients tested. The CDH1 mutation detection rate was determined in a large 
set of families that were tested for germline CDH1 mutations in a diagnostic 
setting in the Netherlands. All tested individuals were retrospectively classified 
according to the HDGC criteria. 
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METHODS
Patients
In this study we included all individuals who were tested for germline CDH1 
mutations between January 1999 and January 2014 in the genome diagnostic 
laboratory of the department of Human Genetics, Radboud university medical 
center, Nijmegen, the Netherlands. All patients had received genetic counseling 
at one of the following national centers: the Netherlands Cancer Institute 
(Amsterdam), VU University Medical Center (Amsterdam), University Medical 
Center Groningen (Groningen), University Medical Center Utrecht (Utrecht), 
Academic Medical Center (Amsterdam), Maastricht University Medical Center 
(Maastricht), Leiden University Medical Center (Leiden), Erasmus University 
Medical Center (Rotterdam) or Radboud university medical center (Nijmegen). 
Testing for CDH1 mutations was performed after the indication for testing had 
been determined by a clinical geneticist, usually after a multidisciplinary team 
meeting. It was, however, not required for cases to meet the recommended 
testing criteria that were used at time of inclusion (either the 1999 or 2010 
criteria). All participating individuals consented to genetic testing. 
Mutation analysis
Genomic DNA was extracted from peripheral blood leukocytes (n=531) or from 
formalin-fixed paraffin-embedded tissue without neoplastic cells (n=47). The 
entire coding sequence of CDH1 (NM_004360), including splice junctions, was 
amplified using polymerase chain reaction followed by Sanger sequencing using 
standard procedures. Primer sequences and PCR conditions are available on 
request. Furthermore, DNA extracted from peripheral blood leukocytes was 
tested with multiplex ligation probe-dependent amplification (MLPA) for the 
detection of exon deletions or duplications.
In silico predictions
Variants were analyzed using the Alamut 2.0 software package (Interactive 
Biosoftware, Rouen, France), incorporating SIFT18, PolyPhen-219, Align GVGD20, 
dbSNP (build 135) and the splice site prediction algorithms SpliceSiteFinder-
like21, MaxEntScan22, NNSPLICE23 and Human Splicing Finder.24 The Exome 
Variant Server of the University of Washington25 that contains CDH1 sequencing 
data of approximately 6,500 individuals of European and African descent and 
our in-house exome sequencing database (accessed July 2014) that contains 
data of over 2,000 individuals, mainly of European descent, were used to assess 
whether variants were present in individuals without gastric cancer. Based on 
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these analyses, variants were classified into five classes according to the system 
introduced by Plon et al.26 
Data collection and analysis
For each family, the index case was defined as the youngest patient with gastric 
cancer or breast cancer tested, or the first relative tested if no affected cases 
were available for testing. The occurrence of cancer in the index and his/her first- 
and second-degree relatives had been documented by the genetic counselor. 
All available medical and pathology reports were reviewed. Whenever possible, 
gastric specimens were reviewed. Diagnoses were categorized according to 
the Laurén27 and WHO28 classifications into intestinal-type (papillary, tubular, 
mucinous-intestinal), diffuse-type (signet ring cell, poorly cohesive, mucinous-
diffuse), mixed-type or indeterminate gastric cancer (rare subtypes). All data 
were collected together with the mutation analysis results in an anonymized 
database. Subsequently, families were categorized into three categories: (a) 
index patients with a diagnosis of DGC or LBC or obligate carriers (concluded 
based on their position in the pedigree in relation to relatives with DGC) that 
fulfilled the HDGC criteria; (b) families that did not fulfill the HDGC criteria; and 
(c) families that could not be categorized either because the genetic test had 
been performed on DNA of an unaffected first-degree relative (FDR) of a gastric 
cancer patient (for cases where no DNA was available from an affected member) 
and/or because of missing pathology data. Sensitivity and specificity, as well as 
positive and negative predictive values were calculated combining test results 
(positive or negative) and categories ((a) fulfilling or (b&c) not-fulfilling criteria).
Statistical analysis
When possible, information on survival after diagnosis was retrieved, for 
histopathological confirmed gastric cancer cases, through municipal registries. 
Survival curves were generated using the method of Kaplan and Meier.29 For the 
univariate survival rate analysis, overall survival (OS) time (defined as the time 
between date of diagnosis and date of death by any cause) was used as follow-
up parameter. The survival curves include the first 120 months of follow-up, 
because of the rapidly declining number of patients thereafter. Cox univariate 
regression analysis was used in the analysis of the associations between the 
different variables and OS. Patients with and without germline CDH1 mutations 
were compared. All computations were done with the SPSS statistical package 
(IBM SPSS Statistics, Version 20, release 20.0.0.1). Two-sided P-values below 
0.05 were considered to be statistically significant. 
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RESULTS
Mutation detection and interpretation
CDH1 mutation analysis was performed in 578 individuals from 499 families. 
Fifteen different pathogenic CDH1 mutations were detected in 18 out of 499 
families. All 13 frameshift, nonsense and canonical splice site mutations, 
detected in 15 families, were considered pathogenic (Table 1). In the other three 
families a (likely) pathogenic missense mutation was detected. The missense 
mutation c.2195G>A; p.(Arg732Gln) was identified in two families. This mutation 
activates a cryptic acceptor splice site in exon 14, leading to a deletion of 32 
base pairs in exon 14.15 This mutation has also been shown to segregate with 
the occurrence of gastric cancer and is therefore considered pathogenic.15, 30 
The missense mutation c.1748T>G; p.(Leu583Arg) was classified as a likely 
pathogenic mutation based on data from functional assays and the presence 
of mucosal signet ring cell carcinomas in prophylactic gastrectomies of two 
asymptomatic carriers of this variant.31 
Eleven other silent, missense and near splice site CDH1 variants detected in 19 
families were considered less likely to be pathogenic based on their frequency in 
control populations, their putative effect on splicing, in silico predictions of their 
effect on protein function and/or data from functional analyses (see Table 1 and 
Supplementary Table 1).
Pathological review of gastric carcinomas
In 455 families at least one patient (index or first- or second-degree relative) had 
a diagnosis of gastric cancer. In total 1018 individuals were diagnosed with gastric 
cancer. Gastric specimens of 229 patients from 172 families were reviewed. In 181 
of 229 patients the Laurén and WHO classification could be obtained from the 
original pathology report. Histological review of gastric specimens confirmed 
the initial diagnosis in 175 patients (97%): 33 intestinal-type, 136 diffuse-type 
and eight mixed-type gastric carcinomas. In six patients the classification was 
altered: in two from DGC to mixed-type gastric cancer (MGC), in one from DGC 
into intestinal-type gastric cancer (IGC), and in three from IGC to DGC, MGC 
and indeterminate (medullary) gastric cancer, respectively. For 48 patients the 
histological classification could not be derived from original pathology reports 
(no classification other than “adenocarcinoma”) and was completely dependent 
on the review of the gastric specimen (18 intestinal-, 27 diffuse-, one mixed- 
and two indeterminate-type gastric carcinomas). Specimens of the remaining 
789 out of 1018 patients with a diagnosis of gastric cancer were not available 
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for review. The original pathology reports (when available) were used for 
categorization of the families.
Categorization of families and correlation with genotype data 
Based on the medical records and pathology data, all families were assigned 
into one of three categories (Table 2): (a) 118 families fulfilled the HDGC criteria; 
(b) 236 families did not fulfill the HDGC criteria; and (c) 145 families could not be 
categorized, either because the genetic test had been performed on DNA of an 
unaffected first-degree relative of a gastric cancer patient (because there was no 
DNA available from an affected member, n=25), because of missing pathology 
data (n=77) or both (n=43). A full description of the criteria and family history 
regarding cancer diagnoses of all families is available in Supplementary Table 2. 
Sixteen of 18 (89%) CDH1	 mutations	 were	 identified	 in	 index	 patients	 from	
families	 fulfilling	 the	 HDGC	 criteria	 defined	 in	 2010	 (Table	 1).	 Two	 families	 in	
whom	a	mutation	was	identified	did	not	meet	the	criteria.	The	first	family	did	not	
fulfill	the	criteria	as	the	mutation	was	found	in	a	patient	with	DGC	at	age	45	with	
a negative four-generation family history. The parents and two siblings of the 
patient were not tested, therefore a de novo mutation cannot be excluded. The 
other	family	could	not	be	formally	classified,	because	of	the	lack	of	medical	and	
pathological	data	to	confirm	the	gastric	cancer	diagnosed	at	age	32	in	the	parent	
of the index patient, who herself had been diagnosed with DGC at age 59 and with 
ductal	breast	cancer	at	age	56.	The	detailed	five-generation	family	pedigree	also	
mentioned a third-degree relative who died of gastric cancer at age 40. 
No pathogenic germline CDH1 mutations were found in 67 families with non-cardia 
IGC, nor in 31 families with a combination of relatives with IGC, DGC and/or MGC. 
Also, no CDH1 mutations were found in 22 families with exclusively LBC without 
DGC, nor in six families with young onset of signet ring cell colorectal cancer.
Survival rate analyses
Figure 1 shows the results of the univariate OS rate analyses for the total group 
(A) and for the group fulfilling HDGC criteria (B). Data could be retrieved from 
464 gastric cancer patients without and 35 patients with CDH1 mutations. The 
one- and five-year OS was 47% and 13% for the entire group tested without CDH1 
germline mutations and 38% and 4% for the CDH1 mutation group (P=.012 for 
comparative survival analysis), respectively. When performing Cox univariate 
regression analysis on the DGC cases (n=339), the Hazard ratio is 1.569 (95% 
confidence interval 1.058-2.327; P=.025) for DGC patients with a CDH1 mutation 
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compared to DGC patients without a CDH1 mutation. Taking into account only 
those patients fulfilling the HDGC criteria, the one- and five-year OS was 48% 
and 13% for the group without CDH1 mutations and, 36% and 4% for the CDH1 
mutation group (P=.014 for comparative survival analysis), respectively. The 
comparable one- and five-year OS ranges of all gastric cancer patients in the 
Netherlands (between 1989-2012) are 42-45% and 20-23%, respectively.9 
Table 2. Classification of families that had CDH1 mutation analysis
Criteria No. of families tested Mutations Mutation detection rate (%)
Meeting HDGC criteria 2010*      
Two or more gastric cancer cases, one DGC <50 years 53 8 15,1
Three or more DGC at any age 10 5 50,0
One DGC <40 years 41 2 4,9
Personal or family history of DGC and LBC, one <50 years 14 1 7,1
Not-meeting HDGC criteria 2010      
DGC and/or LBC, not meeting HDGC criteria* 38 1 2,6
Combined DGC, IGC and/or MGC** 31 0 0,0
(Familial) IGC** 67 0 0,0
Personal and/or family history of LBC*** 22 0 0,0
Other 78 0 0,0
Incomplete clinicopathological data for HDGC criteria 2010      
Index with DGC or LBC, incomplete pathology data of 
relatives
77 1 1,3
Index without gastric or breast cancer (FDR), family 
meets HDGC criteria
25 0 0,0
Index without gastric or breast cancer (FDR), incomplete 
pathology data of relatives
43 0 0,0
Total 499 18 3,6
*Index patients with a diagnosis of DGC or LBC and obligate carriers were included in this group
**Index patients with a diagnosis of gastric cancer (DGC, IGC or MGC) were included in this group
***Index patients with a diagnosis of LBC were included in this group
40
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Figure 1. Overall surivival of gastric cancer cases tested for (A) CDH1 mutations regardless of 
criteria and (B) patients who fulfilled HDGC criteria. For each data set the cases were divided into 2 
groups: with (CDH1 mutation) or without (CDH1 wild-type [WT]) mutations. 
DISCUSSION
Germline CDH1 mutations were detected in 4% of the 499 families that were 
referred for testing by a clinical geneticist based on the suspicion of gastric 
cancer predisposition. The CDH1 mutation detection rate in families that met 
the 2010 HDGC criteria was 14% (16 of 118 families). Our results are in agreement 
with recent reports on CDH1 mutation testing in a diagnostic setting, in which 
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a detection rate of 18% and 19% (11/61 and 34/183 families fulfilling the 2010 
HDGC criteria, respectively) was reported.13, 32 
The current HDGC criteria and accompanying mutation detection rates of 30-
50% are based on small, highly selected series of gastric cancer patients.15, 16, 
30, 33, 34 Most of these studies were published before 2010 and included families 
that fulfilled the original strict HDGC criteria: (i) two or more gastric carcinomas 
in first-degree relatives with at least one DGC diagnosed before age 50 or; (ii) 
three or more DGC in first-degree relatives diagnosed at any age. For these two 
criteria, the CDH1 mutation detection rate in our cohort is only 21% (13/63). This 
lower mutation detection rate might be due to lack of the founder mutation 
described in a previous report15, the diagnostic setting with a low bias towards 
highly suspected families, and a strict categorization of missense mutations 
leading to less variants being classified as pathogenic or likely pathogenic. In 
2010 two additional HDGC selection criteria were added: inclusion of individuals 
with DGC before the age of 40 without a family history, and inclusion of 
individuals and families with diagnoses of both DGC and LBC (one case below 
the age of 50).17 For these two additional criteria, when present without presence 
of the original criteria, our mutation detection rate was 5% (3/55). Therefore 
these criteria increased the sensitivity, but decreased the mutation detection 
ratio from 20% to 14%. The detection rate in families with sufficient histology 
data but not meeting the HDGC selection criteria was only 0.4% (1/236). 
In the new criteria that are established by the IGCLC in 2015, the two first criteria 
(“Two or more gastric cancer cases in a family, one DGC<50” and “Three or more 
DGC cases regardless of age”) were merged into a new criterion: “Two or more 
gastric cancer cases regardless of age, at least one confirmed DGC, in first 
and second degree relatives”.35 Because the age restriction is discarded, more 
families fulfill the criteria and become eligible for testing. Therefore, this new 
criterion implies a lower mutation detection rate. Nevertheless, it will lead to 
a higher sensitivity since more families will be identified. For our cohort, one 
additional mutation-positive and 58 additional mutation-negative families 
would fulfill the 2015 HDGC criteria (see column “New criterion: 2GC, 1 DGC” in 
Supplementary Table 2). 
In our cohort, almost all CDH1-mutation positive families (16/18) fulfilled the 
HDGC criteria as defined in 2010.17 In contrast, Benusiglio et al. found that 
39% of mutation carriers did not fulfill the HDGC criteria.32 They and other 
studies reported germline CDH1 mutations in families with exclusively lobular 
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breast cancer (LBC) without DGC.32, 36-38 Based on these data, Petridis et al. and 
Benusiglio et al. advise CDH1 mutation screening in women with bilateral LBC 
and/or lobular carcinoma in situ without a family history of gastric cancer.32, 
38 Schrader et al. screened 318 women with early-onset LBC or familial LBC 
for CDH1 mutations and found only four variants of uncertain significance. 
Therefore, they concluded that CDH1 mutations are at most infrequent in this 
group.39 In the current study, no pathogenic CDH1 mutations were detected in 
22 LBC families without DGC (four of them with two cases of LBC under the age 
of 50). This is most likely explained by the number of families with exclusively 
LBC, which is relatively low in our cohort.
The ability to apply the HDGC criteria largely depends on the histological 
diagnosis. In our setting, the original histological classification was concordant 
with that of the review in 97% (175/181). However, in 21% of the available 
pathology specimens the histological type of gastric cancer was missing in the 
original report. The introduction of fixed-format pathology reporting in the 
Netherlands, using pathology reports that strictly follow pre-defined protocols 
including the histological classification, will probably reduce this issue in the 
near future. No CDH1 mutations were detected in 98 families that presented 
with intestinal-type or combined histological diagnoses of gastric cancer and 
only one CDH1 mutation was detected in the 77 families that could not be 
classified because of lack of pathological data, demonstrating the merit of 
selecting patients with diffuse-type gastric cancer for mutation testing. 
Our study has a few limitations. First, the population studied consists of patients 
and relatives referred to a clinical geneticist by physicians who suspect genetic 
predisposition for gastric cancer. In the Netherlands, clinical geneticists, although 
affiliated to academic hospitals, counsel patients in outpatient clinics in many 
hospitals spread throughout the country. However, not all individuals at risk for 
CDH1 mutations are referred, and therefore, the sensitivity and specificity, as 
well as the positive- and negative-predictive values that were calculated may be 
overestimated. Second, we correlated the CDH1 mutation analysis results with 
clinicopathological data. Data were not complete for a relatively high number of 
individuals tested and were not available at all for relatives who did not consent 
to make medical reports available for genetic counseling. Therefore, shortage of 
data hampered categorization of a subset of families. Despite these limitations, 
our results are comparable to other recent studies who have performed similar 
analyses.13, 32 
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Our survival analysis showed that patients with DGC and germline CDH1 
mutations had shorter survival times compared to other HDGC patients 
tested and the overall Dutch gastric cancer population. However, it should be 
noted that these results depend on univariate analyses without correction for 
tumor stage and included a relatively small number of CDH1 patients. Also, 
approximately half of the gastric cancer patients’ data regarding survival were 
unavailable and could therefore not be included in the survival analysis. To the 
best of our knowledge, no other studies examined the overall survival in gastric 
cancer patients with CDH1 mutations. 
A positive family history is a strong and consistently reported risk factor for gastric 
cancer. CDH1 is the most important DGC susceptibility gene. Gastric cancer has 
also been associated with germline mutations in DNA mismatch repair genes, 
TP53, APC, BRCA1/2, STK11 and PTEN.40-45 Nonetheless, the molecular basis for 
familial aggregation of gastric cancer remains largely unknown. Endoscopic 
surveillance strategy for families that fulfill the HDGC criteria, but in whom no 
pathogenic mutation can be identified, is complicated. The IGCLC recommends 
annual endoscopic screening with extensive biopsy taking (>30) in an expert 
centre (Cambridge protocol).17, 35 However, early-stage signet ring cell carcinoma 
is difficult to visualize during gastroduodenoscopy with random biopsies. For 
CDH1 mutation carriers, Fujita et al. estimated a theoretical number of 3469 
biopsies to be needed to assure 90% detection rate of at least one neoplastic 
focus.46 Lim et al. showed that it is possible to increase the yield of signet ring cell 
carcinoma by adhering to the strict Cambridge protocol and found signet ring 
cell carcinomas in 14/22 patients with and 2/7 patients without CDH1 mutations 
fulfilling the 2010 HDGC criteria.47 A portion of the mutation-negative HDGC 
families described in the current study are followed by gastroduodenoscopy in a 
research setting of which results are not available yet. We think that endoscopic 
screening in a research setting is important to gather information on these 
families and detect cancer in early stage. Ultimately, endoscopic findings 
could also lead to the identification of new HDGC predisposing mutations as 
was demonstrated by Majewski and Kluijt et al., in which endoscopic screening 
led to the detection of intramucosal signet ring cells in four individuals from 
a large family without a pathogenic CDH1 mutation, eventually leading to the 
identification of a germline CTNNA1 mutation by exome sequencing.48 
Taken together, this study shows both the strengths and limitations of the 
current HDGC criteria. Despite the positive predictive value of only 14%, in 
our cohort of patients suspected for a gastric cancer predisposition the HDGC 
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criteria have a high sensitivity of 89% and a high negative predictive value of 
99% for finding a germline CDH1 mutation. When the histological gastric cancer 
subclassification is known, the HDGC criteria of 2010 seem to be an adequate 
tool for clinical geneticists to select patients for CDH1 mutation analysis. 
Although CDH1 mutations are exclusively found in patients with diffuse-type 
gastric cancer we feel that lack of data on pathological classification should not 
prohibit such testing.
Acknowledgments
The authors would like to thank all the technicians from the Laboratory of 
Tumor Genetics, Joanne Wes and Baukje Oosterhof for practical assistance with 
the data collection.
45
2
REFERENCES 
1. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in 
GLOBOCAN 2012. Int J Cancer 2015; 136:E359-86.
2. Jemal A, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
3. Han MA, et al. Association of family history with cancer recurrence and survival in patients with gastric 
cancer. J Clin Oncol 2012; 30:701-8.
4.	 Bernini	M,	et	al.	Family	history	of	gastric	cancer:	a	correlation	between	epidemiologic	findings	and	
clinical data. Gastric Cancer 2006; 9:9-13.
5. Kawasaki K, et al. Family history of cancer in Japanese gastric cancer patients. Gastric Cancer 2007; 
10:173-5.
6. La Vecchia C, et al. Family history and the risk of stomach and colorectal cancer. Cancer 1992; 70:50-5.
7. Roviello F, et al. High incidence of familial gastric cancer in Tuscany, a region in Italy. Oncology 2007; 
72:243-7.
8. Dassen AE, et al. Gastric cancer: decreasing incidence but stable survival in the Netherlands. Acta Oncol 
2014; 53:138-42.
9. http://www.cijfersoverkanker.nl/ Dutch cancer registry (IKNL) © April 2015.
10. Guilford P, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392:402-5.
11.	 Humar	B,	Guilford	P.	Hereditary	diffuse	gastric	cancer:	a	manifestation	of	lost	cell	polarity.	Cancer Sci 
2009; 100:1151-7.
12. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008; 65:3756-88.
13.	 Hansford	S,	et	al.	Hereditary	Diffuse	Gastric	Cancer	Syndrome:	CDH1	Mutations	and	Beyond.	JAMA 
Oncology 2015; 1:23-32.
14. Caldas C, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999; 
36:873-80.
15.	 Kaurah	 P,	 et	 al.	 Founder	 and	 recurrent	CDH1	mutations	 in	 families	with	 hereditary	 diffuse	 gastric	
cancer. JAMA 2007; 297:2360-72.
16. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg 
Pathol 2006; 14:21-33.
17.	 Fitzgerald	 RC,	 et	 al.	 Hereditary	 diffuse	 gastric	 cancer:	 updated	 consensus	 guidelines	 for	 clinical	
management and directions for future research. J Med Genet 2010; 47:436-44.
18.	 Kumar	P,	Henikoff	S,	Ng	PC.	Predicting	the	effects	of	coding	non-synonymous	variants	on	protein	
function using the SIFT algorithm. Nat Protoc 2009; 4:1073-81.
19. Adzhubei IA, et al. A method and server for predicting damaging missense mutations. Nat Methods 
2010; 7:248-9.
20. Tavtigian SV, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with 
classification	of	eight	recurrent	substitutions	as	neutral.	J Med Genet 2006; 43:295-305.
21.	 Shapiro	MB,	Senapathy	P.	RNA	splice	junctions	of	different	classes	of	eukaryotes:	sequence	statistics	
and functional implications in gene expression. Nucleic Acids Res 1987; 15:7155-74.
22. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA 
splicing signals. J Comput Biol 2004; 11:377-94.
23. Reese MG, et al. Improved splice site detection in Genie. J Comput Biol 1997; 4:311-23.
24. Desmet FO, et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. 
Nucleic Acids Res 2009; 37:e67.
25. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle, WA, July 2014.
26.	 Plon	SE,	 et	 al.	Sequence	 variant	 classification	 and	 reporting:	 recommendations	 for	 improving	 the	
interpretation of cancer susceptibility genetic test results. Hum Mutat 2008; 29:1282-91.
27.	 Lauren	P.	The	Two	Histological	Main	Types	of	Gastric	Carcinoma:	Diffuse	and	So-Called	Intestinal-Type	
Carcinoma.	An	Attempt	at	a	Histo-Clinical	Classification.	Acta Pathol Microbiol Scand 1965; 64:31-49.
46
Evaluation of CDH1 testing criteria
28.	 Bosman	FT,	et	al.	WHO	Classification	of	Tumours	of	the	Digestive	System.	IARC	Sci	Publ	2012;	
4th edition.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist 
Assn 1958; 53:457-481.
30.	 Brooks-Wilson	AR,	 et	 al.	Germline	 E-cadherin	mutations	 in	 hereditary	 diffuse	 gastric	 cancer:	
assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004; 
41:508-17.
31.	 Kluijt	 I,	 et	al.	CDH1-related	hereditary	diffuse	gastric	 cancer	 syndrome:	clinical	 variations	and	
implications for counseling. Int J Cancer 2012; 131:367-76.
32.	 Benusiglio	 PR,	 et	 al.	CDH1	germline	mutations	 and	 the	 hereditary	 diffuse	gastric	 and	 lobular	
breast cancer syndrome: a multicentre study. J Med Genet 2013; 50:486-9.
33.	 Gayther	SA,	et	al.	Identification	of	germ-line	E-cadherin	mutations	in	gastric	cancer	families	of	
European origin. Cancer Res 1998; 58:4086-9.
34. Molinaro V, et al. Complementary molecular approaches reveal heterogeneous CDH1 germline 
defects	 in	 Italian	 patients	 with	 hereditary	 diffuse	 gastric	 cancer	 (HDGC)	 syndrome.	 Genes 
Chromosomes Cancer 2014; 53:432-45.
35.	 van	 der	 Post	 RS,	 et	 al.	 Hereditary	 diffuse	 gastric	 cancer:	 updated	 clinical	 guidelines	 with	 an	
emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52:361-374.
36. Masciari S, et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 
2007; 44:726-31.
37. Xie ZM, et al. Germline mutations of the E-cadherin gene in families with inherited invasive 
lobular	breast	carcinoma	but	no	diffuse	gastric	cancer.	Cancer 2011; 117:3112-7.
38. Petridis C, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer 2014; 
110:1053-7.
39. Schrader KA, et al. Germline mutations in CDH1 are infrequent in women with early-onset or 
familial lobular breast cancers. J Med Genet 2011; 48:64-8.
40. Sereno M, et al. Gastric tumours in hereditary cancer syndromes: clinical features, molecular 
biology and strategies for prevention. Clin Transl Oncol 2011; 13:599-610.
41. Masciari S, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011; 
13:651-7.
42. van Lier MG, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers 
syndrome. Gut 2011; 60:141-7.
43. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. 
MedGenMed 2005; 7:60.
44. Shibata C, et al. Clinical characteristics of gastric cancer in patients with familial adenomatous 
polyposis. Tohoku J Exp Med 2013; 229:143-6.
45. Engel C, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J 
Clin Oncol 2012; 30:4409-15.
46.	 Fujita	H,	et	al.	Endoscopic	surveillance	of	patients	with	hereditary	diffuse	gastric	cancer:	biopsy	
recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated 
gastrectomies. Am J Surg Pathol 2012; 36:1709-17.
47.	 Lim	YC,	et	al.	Prospective	cohort	study	assessing	outcomes	of	patients	 from	families	 fulfilling	
criteria	 for	 hereditary	 diffuse	 gastric	 cancer	 undergoing	 endoscopic	 surveillance.	Gastrointest 
Endosc 2014; 80:78-87.
48.	 Majewski	IJ,	et	al.	An	alpha-E-catenin	(CTNNA1)	mutation	in	hereditary	diffuse	gastric	cancer.	J 
Pathol 2013; 229:621-9.
49. Suriano G, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: 
implications for genetic testing and clinical management. Clin Cancer Res 2005; 11:5401-9.
50. Jonsson BA, et al. Germline mutations in E-cadherin do not explain association of hereditary 
prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002; 98:838-43.
47
2
51.	 Lynch	HT,	et	al.	Hereditary	diffuse	gastric	cancer:	diagnosis,	genetic	counseling,	and	prophylactic	
total gastrectomy. Cancer 2008; 112:2655-63.
52.	 Kim	S,	et	al.	Searching	for	E-cadherin	gene	mutations	in	early	onset	diffuse	gastric	cancer	and	
hereditary	diffuse	gastric	cancer	in	Korean	patients.	Fam Cancer 2013; 12:503-7.
53. Rogers WM, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): 
pathologic	findings	with	clinical	implications.	Am	J	Surg	Pathol	2008;	32:799-809.
54.	 Suriano	 G,	 et	 al.	 A	 model	 to	 infer	 the	 pathogenic	 significance	 of	 CDH1	 germline	 missense	
variants. J Mol Med (Berl) 2006; 84:1023-31.
55. Chung DC, et al. Case records of the Massachusetts General Hospital. Case 22-2007. A woman 
with a family history of gastric and breast cancer. N Engl J Med 2007; 357:283-91.
56. Oliveira C, et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type 
allele in an HDGC tumour. Oncogene 2004; 23:2236-40.
57. Simoes-Correia J, et al. E-cadherin destabilization accounts for the pathogenicity of missense 
mutations	in	hereditary	diffuse	gastric	cancer.	PLoS One 2012; 7:e33783.
58.	 Keller	G,	 et	 al.	 Diffuse	 type	 gastric	 and	 lobular	 breast	 carcinoma	 in	 a	 familial	 gastric	 cancer	
patient with an E-cadherin germline mutation. Am J Pathol 1999; 155:337-42.
59.	 More	H,	et	al.	Identification	of	seven	novel	germline	mutations	in	the	human	E-cadherin	(CDH1)	
gene. Hum Mutat 2007; 28:203.
60. Johnston JJ, et al. Secondary variants in individuals undergoing exome sequencing: screening of 
572	 individuals	 identifies	high-penetrance	mutations	 in	cancer-susceptibility	genes.	Am J Hum 
Genet 2012; 91:97-108.
61.	 Garziera	M,	 et	 al.	 Identification	 and	Characterization	 of	CDH1	Germline	Variants	 in	 Sporadic	
Gastric Cancer Patients and in Individuals at Risk of Gastric Cancer. Plos One 2013; 8(10):e77035.
62. Keller G, et al. Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of 
RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med 
Genet 2004; 41:e89.
63. Salahshor S, et al. A germline E-cadherin mutation in a family with gastric and colon cancer. Int J 
Mol Med 2001; 8:439-43.
64.	 Vogelaar	IP,	et	al.	Identification	of	germline	mutations	in	the	cancer	predisposing	gene	CDH1	in	
patients with orofacial clefts. Hum Mol Genet 2013; 22:919-26.
65. Mateus AR, et al. E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp 
Cell Res 2009; 315:1393-402.
66. Oliveira C, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only 
in	hereditary	diffuse	gastric	cancer	kindred.	Hum Mutat 2002; 19:510-7.
67.	 Suriano	G,	et	al.	Identification	of	CDH1	germline	missense	mutations	associated	with	functional	
inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003; 
12:575-82.
68.	 Choi	HJ,	et	al.	Presymptomatic	 identification	of	CDH1	germline	mutation	 in	a	healthy	korean	
individual with family history of gastric cancer. Ann Lab Med 2014; 34:386-9.
69. Zhang Y, et al. Germline mutations and polymorphic variants in MMR, E-cadherin and MYH 
genes associated with familial gastric cancer in Jiangsu of China. Int J Cancer 2006; 119:2592-6.
70. Kim HC, et al. The E-cadherin gene (CDH1) variants T340A and L599V in gastric and colorectal 
cancer patients in Korea. Gut 2000; 47:262-7.
48
Evaluation of CDH1 testing criteria
S
U
P
P
L
E
M
E
N
T
A
R
Y
 F
IL
E
S
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
. D
et
ec
tio
n 
an
d 
in
te
rp
re
ta
tio
n 
of
 C
D
H
1 
va
ria
nt
s
Fa
m
ily
 
ID
CD
H1
 va
ria
nt
M
ut
at
io
n 
ty
pe
SI
FT
 sc
or
e
Po
ly
Ph
en
-2
 
sc
or
e
Al
ig
n 
GV
GD
 
sc
or
e
Gr
an
th
am
 
sc
or
e
Fr
eq
ue
nc
y i
n 
db
SN
P:
 M
AF
 in
 
pe
rc
en
t (
m
in
or
 
al
le
le
 co
un
t)
Al
le
le
 fr
eq
ue
nc
y i
n 
ES
P 
da
ta
ba
se
 (E
ur
op
ea
n 
Am
er
ica
n 
po
pu
la
tio
n)
Fr
eq
ue
nc
y i
n 
ou
r i
n-
ho
us
e 
da
ta
ba
se
 (p
er
ce
nt
)
Cl
as
sifi
ca
tio
n 
(P
lo
n)
Fu
lfi
lls
 20
10
 H
DG
C c
rit
er
ia
Ye
s
Un
kn
ow
n
No
Pa
th
og
en
ic 
m
ut
at
ion
s
10
02
a
c.1
87
C>
T; 
p.(
Ar
g6
3*
)
No
ns
en
se
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
07
a
c.4
89
C>
A;
 p.
(Cy
s1
63
*)
No
ns
en
se
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
06
c.1
00
3C
>
T; 
p.(
Ar
g3
35
*)
No
ns
en
se
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
19
c.1
40
4d
el;
 p.
(S
er
46
9f
s)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
12
a
c.1
56
5+
2d
up
Sp
lic
in
g
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
13
c.1
56
5+
2d
up
Sp
lic
in
g
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
08
c.2
06
4_
20
65
de
l; p
.(C
ys
68
8*
)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
03
a
c.2
19
5G
>
A;
 p.
(A
rg
73
2G
ln
)
M
iss
en
se
/ s
pl
ici
ng
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
17
a  
c.8
11
_8
12
de
lin
sT
TA
AG
GG
AT
AT
A;
 
p.(
Va
l27
1f
s)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
01
a,b
 
c.1
13
5_
11
37
+
5d
eli
ns
TT
AG
A
Sp
lic
in
g
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
09
a
c.1
40
4d
el;
 p.
(S
er
46
9f
s)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
04
a  
c.1
47
6_
14
77
de
l; p
.(A
rg
49
2f
s)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
18
a
c.1
74
8T
>
G;
 p.
(Le
u5
83
Ar
g)
M
iss
en
se
De
let
er
iou
s
Pr
ob
ab
ly 
da
m
ag
in
g
Cla
ss 
C0
10
2
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
4
x
 
 
10
14
a
c.5
5_
74
de
l; p
.(S
er
19
fs)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
11
c.3
77
de
l; p
.(P
ro
12
6f
s)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
10
05
c.9
71
de
l; p
.(G
ly3
24
fs)
Fra
m
es
hi
ft
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
x
 
 
49
2
10
15
c.2
43
9+
5_
24
39
+
8d
elG
TA
A
Sp
lic
in
g
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
 
x
 
10
10
c.2
19
5G
>
A;
 p.
(A
rg
73
2G
ln
)
M
iss
en
se
/ s
pl
ici
ng
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
5
 
 
x
Va
ria
nt
s o
f u
nc
er
ta
in
 si
gn
ifi
ca
nc
e
35
3
c.4
8+
5C
>
G 
ne
ar
 sp
lic
e s
ite
NA
NA
NA
NA
3.0
 (6
6)
0.0
3
No
t i
n i
n-
ho
us
e d
at
ab
as
e
2
x
 
15
2
c.1
27
2C
>
T; 
p.(
=
) 
Sy
no
ny
m
ou
s
NA
NA
NA
NA
0.2
 (4
)
0.1
0
0.2
9
2
x
 
 
23
c.1
74
4C
>
T; 
p.(
=
)
Sy
no
ny
m
ou
s
NA
NA
NA
NA
0.0
 (1
)
0.0
5
0.2
4
2
x
 
23
3
c.2
44
0-
6C
>
G
ne
ar
 sp
lic
e s
ite
NA
NA
NA
NA
0.1
 (3
)
0.3
0
0.1
9
2
x
 
 
28
0
c.1
77
4G
>
A;
 p.
(A
la5
92
Th
r)
M
iss
en
se
To
ler
at
ed
Po
ssi
bl
y 
da
m
ag
in
g
Cla
ss 
C0
58
0.1
 (3
)
0.6
3
1.2
4
3
x
 
27
0c
c.8
8C
>
A;
 p.
(P
ro
30
Th
r)
M
iss
en
se
To
ler
at
ed
Pr
ob
ab
ly 
da
m
ag
in
g
Cla
ss 
C0
38
0.2
 (4
)
0.1
6
0.4
8
3
 
x
 
34
5
c.8
8C
>
A;
 p.
(P
ro
30
Th
r)
M
iss
en
se
To
ler
at
ed
Pr
ob
ab
ly 
da
m
ag
in
g
Cla
ss 
C0
38
0.2
 (4
)
0.1
6
0.4
8
3
 
x
 
48
0
c.8
8C
>
A;
 p.
(P
ro
30
Th
r)
M
iss
en
se
To
ler
at
ed
Pr
ob
ab
ly 
da
m
ag
in
g
Cla
ss 
C0
38
0.2
 (4
)
0.1
6
0.4
8
3
 
x
34
9
c.1
74
4C
>
T; 
p.(
=
)
Sy
no
ny
m
ou
s
NA
NA
NA
NA
0.0
 (1
)
0.0
5
0.2
4
2
 
x
28
9
c.1
77
4G
>
A;
 p.
(A
la5
92
Th
r)
M
iss
en
se
To
ler
at
ed
Po
ssi
bl
y 
da
m
ag
in
g
Cla
ss 
C0
58
0.1
 (3
)
0.6
3
1.2
4
3
 
x
10
15
c.1
77
4G
>
A;
 p.
(A
la5
92
Th
r)
M
iss
en
se
To
ler
at
ed
Po
ssi
bl
y 
da
m
ag
in
g
Cla
ss 
C0
58
0.1
 (3
)
0.6
3
0.7
2
3
 
x
 
95
c.2
09
1G
>
A;
 p.
(=
) 
Sy
no
ny
m
ou
s
NA
NA
NA
NA
No
t i
n d
bS
NP
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
2
 
x
10
16
c.8
92
G>
A;
 p.
(A
la2
98
Th
r)
M
iss
en
se
De
let
er
iou
s
Pr
ob
ab
ly 
da
m
ag
in
g
Cla
ss 
C5
5
58
0.1
 (2
)
0.0
2
0.0
5
3
 
 
x
25
2
c.1
01
8A
>
G;
 p.
(T
hr
34
0A
la)
M
iss
en
se
To
ler
at
ed
Be
ni
gn
Cla
ss 
C0
58
0.0
 (1
)
No
t i
n E
SP
 da
ta
ba
se
No
t i
n i
n-
ho
us
e d
at
ab
as
e
3
 
 
x
21
0
c.1
02
0G
>
A;
 p.
(=
) 
Sy
no
ny
m
ou
s
NA
NA
NA
NA
No
t i
n d
bS
NP
0.0
0.1
2
 
 
x
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
. C
on
tin
ue
d
50
Evaluation of CDH1 testing criteria
49
c.1
77
4G
>
A;
 p.
(A
la5
92
Th
r)
M
iss
en
se
To
ler
at
ed
Po
ssi
bl
y 
da
m
ag
in
g
Cla
ss 
C0
58
0.1
 (3
)
0.6
3
1.2
4
3
 
 
x 
30
c.2
39
9G
>
A;
 p.
(A
rg
80
0H
is)
M
iss
en
se
De
let
er
iou
s
Pr
ob
ab
ly 
da
m
ag
in
g
Cla
ss 
C2
5
29
No
t i
n d
bS
NP
0.0
1
No
t i
n i
n-
ho
us
e d
at
ab
as
e
3
 
 
x
13
8
c.2
44
0-
6C
>
G
ne
ar
 sp
lic
e s
ite
NA
NA
NA
NA
0.1
 (3
)
0.3
0
0.1
9
2
 
 
x 
46
5
c.2
44
0-
6C
>
G
ne
ar
 sp
lic
e s
ite
NA
NA
NA
NA
0.1
 (3
)
0.3
0
0.1
9
2
 
 
x
Fa
m
ily
 re
po
rt
ed
 b
ef
or
e 
by
 a K
lu
ijt
 e
t a
l.1
, b
O
liv
ei
ra
 e
t a
l.2
 c F
am
ily
 w
ith
 m
ut
at
io
n 
in
 C
TN
N
A
1 
re
po
rt
ed
 b
y 
M
aj
ew
sk
i e
t a
l.3
 
R
E
FE
R
E
N
C
E
S
1.
	
K
lu
ijt
	I,
	e
t	a
l.	
C
D
H
1-
re
la
te
d	
he
re
di
ta
ry
	d
iff
us
e	
ga
st
ri
c	
ca
nc
er
	s
yn
dr
om
e:
	c
lin
ic
al
	v
ar
ia
ti
on
s	
an
d	
im
pl
ic
at
io
ns
	fo
r	c
ou
ns
el
in
g.
	In
t	J
	C
an
ce
r	2
01
2;
	1
31
:3
67
-7
6.
2.
 
O
liv
ei
ra
 C
, e
t a
l. 
In
tr
ag
en
ic
 d
el
et
io
n 
of
 C
D
H
1 
as
 th
e 
in
ac
tiv
at
in
g 
m
ec
ha
ni
sm
 o
f t
he
 w
ild
-t
yp
e 
al
le
le
 in
 a
n 
H
D
G
C
 tu
m
ou
r. 
O
nc
og
en
e 
20
04
; 2
3:
22
36
-4
0.
3.
	
M
aj
ew
sk
i	I
J,
	e
t	a
l.	
A
n	
al
ph
a-
E-
ca
te
ni
n	
(C
T
N
N
A
1)
	m
ut
at
io
n	
in
	h
er
ed
it
ar
y	
di
ff
us
e	
ga
st
ri
c	
ca
nc
er
.	J
	P
at
ho
l	2
01
3;
	2
29
:6
21
-9
.
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
. C
on
tin
ue
d
51
2
Supplementary Table 2. Characteristics of all families tested for CDH1 mutations
Family 
no.
Gender 
index
Diagnosis index 
(age)
Frequency of gastric or 
breast cancer in first 
degree relatives (age)
Frequency of gastric or 
breast cancer in second 
degree relatives (age)
Other cancer diagnoses 
in first and second 
degree relatives (age)
New criterion: 
2 gastric 
cancer cases, 
1 confirmed 
DGC*
Criterion: Two or more gastric cancer cases, one DGC<50*
18 F DGC (26)   sGC: 1 (27); sBC: 1 (56) OC: 1 (33); PCa: 3 (57, 70, ?) Yes
23 F DGC (43) DGC:1 (58); LBC: 1 (43) sBC: 1 (49) PCa: 1 (82) Yes
27 F DGC (55) DGC: 1 (37) sGC: 1 (67) CC: 1 (66); CRC: 1 (66); 
LC: 1 (57) 
Yes
31 F DGC (42) sGC: 1 (69); sBC: 1 (47)   DCIS: 1 (53) Yes
33 F DGC (47) DGC: 1 (84); DBC: 1 (50)     Yes
40 M DGC (43) DGC: 1 (67)   OC: 2 (36, 45) Yes
42 F DGC (35) sGC: 1 (50)     Yes
45 M DGC (42) sGC: 1 (23) sGC: 2 (30, 50)   Yes
46 F DGC (74), ThC (69) DGC: 1 (46)   CRC: 1 (50); ThC: 1 (57) Yes
57 M DGC (41)   sGC: 1 (57) ES: 1 (70) Yes
59 F DGC (35) DGC: 1 (51); sGC: 2 (22, 42)   Thymoma: 1 (37) Yes
125 M DGC (33) DGC: 1 (56) sBC: 1 (50) CRC: 2 (48, 60); CUP: 1 (50) Yes
128 F DGC (48) DGC: 1 (75)   HNC: 1 (75) Yes
132 F DGC (44) DGC: 1 (34)   Leu: 1 (62) Yes
133 M DGC (20) DGC: 1 (50)   CRC: 1 (70) Yes
135 F DGC (46), DBC (51) sGC: 1 (52)     Yes
146 M DGC (44)   UGC: 1 (75)   Yes
152 F DGC (48) sGC: 1 (60)   EC: 1 (52); LC: 3 (75, ?) Yes
153 M DGC (48), DBC (78) sBC: 1 (48) sBC: 4 (38, 49, ?); sGC: 2 (?)   Yes
177 F DGC (35)   sGC: 1 (80) CRC: 1 (70) Yes
179 F DGC (34)   sGC: 1 (72) RC: 1 (50) Yes
180 F DGC (34)   sGC: 2 (59, 65); DBC: 1 (53)   Yes
194 M DGC (48)   sGC: 1 (50)   Yes
213 F DGC (26)   sGC: 1 (72); sBC: 1 (72)   Yes
233 F DGC (41) sGC: 1 (?)     Yes
241 F DGC (33)   UGC: 1 (35) UTC: 1 (62) Yes
249 F DGC (45) sGC: 1 (87)   Leu: 1 (13); PC: 1 (60) Yes
285 F DGC (26)   sGC: 1 (63); sBC: 1 (49) EC: 1 (?); Yes
287 M DGC (36)   sGC: 1 (60) CRC: 1 (?); RC (63) Yes
293 F DGC (47)   sGC: 2 (?)   Yes
296 F DGC (36)   sGC: 1 (52)   Yes
308 M DGC (38) sGC: 2 (33, 34)   BRAT: 1 (46) Yes
330 M DGC (74) sGC: 2 (57, 64); DBC: 1 (65) DGC: 1 (33) EC: 1 (?); MM: 1 (?) Yes
353 M DGC (42) DGC: 1 (38)     Yes
360 F DGC (45)   DGC: 1 (53) ES: 1 (75) Yes
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362 M DGC (43)   sGC: 2 (87, 87)   Yes
364 F DGC (42)   sGC: 1 (87) MM: 1 (45) Yes
373 F DGC (65) DGC: 1 (46)   LC: 1 (70); PCa: 1 (67) Yes
392 F DGC (46) UGC: 1 (74)     Yes
404 M DGC (47)   sGC: 1 (62) OC: 1 (20); UTC: 1 (61) Yes
432 F DGC (40)   sGC: 1 (56)   Yes
478 F DGC (39) sGC: 1 (46)   LC: 1 (75) Yes
487 F DGC (38) sGC: 1 (60)   GCC appendix (27) Yes
489 F DGC (38) sGC: 1 (58)   ES: 1 (?); LiC: 1 (41) Yes
1002 F DGC (41) sGC: 1 (28) sGC: 1 (?)   Yes
1003 F DGC (39) sGC: 1 (37)   HNC: 1 (60); LC: 1 (60) Yes
1006 F DGC (40) DBC: 1 (51) sGC: 1 (41)   Yes
1007 F DGC (45), LBC 
(44), LCIS (45) 
DGC: 1 (41); sGC: 1 (35)   GIST: 1 (43) Yes
1008 F Obligate carrier DGC: 2 (24, 48); sGC: 1 (52) sGC: 1 (44); sBC: 1 (63) CRC: 2 (33, 67); LC: 1 (61) Yes
1012 F DGC (43) UGC: 1 (55); sGC: 1 (43) sGC: 1 (47) EC: 1 (47); MM: 1 (47); 
PC:1 (47) 
Yes
1013 F DGC (40) sGC: 1 (33)     Yes
1019 F DGC (31) sGC: 1 (38) sGC: 1 (77)   Yes
1201 M DGC (36) sGC: 2 (50, 61); LBC: 1 (33)     Yes
Criterion: Three or more DGC at any age*
24 M DGC (71) DGC: 2 (59, 65)   CRC: 2 (63, 65); RC: 1 (64) Yes
122 M DGC (46) DGC: 3 (26, 45, 51)   CRC: 1 (45); TC: 1 (?) Yes
216 F DGC (56) DGC: 3 (39, 41, 64); sGC: 
1 (54)
    Yes
301 M DGC (52) DGC: 1 (58) DGC: 1 (85); sGC: 1 (75) CUP: 1 (82); RC: 1 (63) Yes
398 F DGC (47) DGC: 1 (69) DGC: 1 (75) LC: 1 (60) Yes
1001 F DGC (30) DGC: 2 (26, 52)     Yes
1004 M DGC (42) DGC: 2 (26, 43) sGC: 1 (37)   Yes
1009 F DGC (65) DGC: 2 (23, 44); DGC: 1 (34); sGC: 3 (25, 
39, 65)
  Yes
1017 M DGC (55) DGC: 1 (36); MGC: 1 (20) DGC: 1 (26); sBC: 1 (50)   Yes
1018 F DGC (41) DGC: 2 (22, 32); UGC: 
1 (21)
    Yes
Criterion: One DGC <40 years*
6 F DGC (36) sBC: 1 (52)   HL: 1 (18) No
25 F DGC (32)       No
36 F DGC (23)   sBC: 2 (45, 45) EC: 1 (70) No
37 F DGC (34)       No
112 F DGC (34) sBC: 1 (65)   LC: 1 (53) No
117 F DGC (17)       No
121 M DGC (27)     CRC: 3 (55, 57, 70) No
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126 F DGC (32)     CC: 1 (41) No
140 M DGC (23)       No
148 F DGC (37)     LC: 1 (56) No
150 F DGC (28)       No
156 M DGC (38) sBC: 1 (65)   CC: 1 (?); CUP: 1 (?) No
162 M DGC (33) IGC :1 (42)   ES: 1 (69) No
163 F DGC (39)       No
164 M DGC (36)     ES: 1 (65) No
167 F DGC (31)   sBC: 1 (59) MM: 1 (60) No
198 F DGC (31)       No
199 F DGC (32)     CRC: 1 (48) No
200 F DGC (28), RC (11), 
DCIS&LCIS (44)
  sBC: 1 (35); sGC: 1 (45) LC: 2 (63, ?) No
214 F DGC (36)     NHL: 1 (68) No
220 F DGC (25)       No
235 M DGC (34)       No
257 M DGC (39)     CRC: 1 (60) No
269 M DGC (33)       No
275 F DGC (35)     LC: 1 (55) No
276 M DGC (38)     PC: 1 (51) No
280 M DGC (36)     BRAT: 1 (41); CUP: 1 (14); 
ES: 1 (52)
No
290 F DGC (36)     CRC: 1 (57); HNC: 1 (?) No
310 F DGC (36)     CUP: 1 (70) No
312 F DGC (35)     Leu: 1 (83) No
337 F DGC (26)       No
340 F DGC (28)     BRAT: 1 (?) No
342 F DGC (26)   DBC bilateral: 1 (37, 68)   No
367 F DGC (28) sBC: 1 (70)   BRAT: 1 (50); CC: 1 (34); 
EC: 1 (60)
No
377 F DGC (25)       No
380 F DGC (36)     Leu: 1 (37) No
386 F DGC (36)       No
393 M DGC (31)       No
481 F DGC (39)     CUP: 3 (61, ?); ES: 1 (63) No
1011 M DGC (39)     UTC: 1 (77) No
1014 M DGC (27)       No
Criterion: Personal or family history of DGC and LBC, one <50 years**
90 F LBC (49) DGC: 1 (34); sBC: 1 (55)   CRC: 1 (?); Leu: 1 (48) No
96 F LBC (45) DGC: 1 (53)   PC: 1 (70) No
103 F LBC (56) DGC: 1 (43); sGC: 1 (70); 
DBC: 2 (45, 55)
sGC: 1 (64) HNC: 1 (42) No
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154 F LBC (49) DGC: 1 (67) sGC: 1 (68) LiC: 1 (62) No
229 F LBC (51), DBC (51) DGC: 1 (41) sBC: 1 (60) MM: 2 (48, 60) No
303 F LBC Ri (45), DBC 
Le (63)
  DGC: 1 (43)   No
307 F LBC (43)   DGC: 1 (70); sGC: 1 (52); 
sBC: 2 (67, 74)
CRC: 3 (48, 67, 73); EC: 
1 (57)
No
320 M DGC (48) LBC: 1 (51)   CRC: 1 (49); CUP: 1 (25); LC: 
1 (49); PC: 1 (64); PCa: 1 
(69); UTC: 1 (85)
No
401 F LBC (51) DGC: 1 (28); IGC: 1 (73) sGC: 1 (46)   No
410 F LBC Le (43), DBC 
Le (54), LBC Ri 
(62)
DGC: 1 (86)   PCa: 2 (68, 85) No
444 F LBC (47)   DGC: 3 (61, 73, 74); sGC: 
1 (80)
BRAT: 1 (71) No
472 F LBC (49) DGC: 1 (75)   CRC: 1 (90); Leu: 1 (19) No
494 F DGC (44) LBC: 1 (84)   PCa: 1 (70) No
1005 F LBC (59), MM (58) DGC: 1 (61); LBC: 1 (49) sGC: 1 (38) UTC: 1 (55) No
Criterion: Personal or family history of DGC and/or LBC, not meeting HDGC criteria**
51 F DGC (56), OC (66)     OC: 1 (46) No
52 M DGC (67)     PC: 2 (50, 86) No
58 F DGC (40), DBC (33)       No
66 F DGC (43)       No
67 F DGC (51)     CRC: 2 (59, 61) No
71 M DGC (68) sGC: 1 (61)   CRC: 4 (52, 52, 65, 70) No
80 F DGC (41)       No
93 F DGC (45)     BRAT: 1 (64); ES AC: 1 (68); 
TC: 1 (64)
No
130 F DGC (54)       No
136 M DGC (41)     Leu: 1 (80) No
159 F DGC (46)       No
160 F DGC (40)   sBC: 1 (38)   No
169 M DGC (42)     Leu: 1 (80) No
205 F DGC (45)       No
206 F DGC (50) UGC: 1 (56)     Yes
210 F DGC (40)       No
215 M DGC (46) sBC: 2 (48, 74) sBC: 2 (?) CRC: 3 (50, 52, ?) No
218 F DGC (40)     CRC: 1 (56) No
219 M DGC (40)       No
222 F DGC (79) DBC: 1 (57); sBC: 3 (51, 
55, 92)
  BO: 1 (41); PCa: 1 (?); 
UTC: 1 (?)
No
274 M DGC (40)     CRC: 2 (49, 71); HNC: 1 (70); 
Leu: 1 (85)
No
284 F DGC (48)       No
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286 M DGC (58) sBC: 1 (?) sBC: 2 (?)   No
309 M DGC (46)     LiC: 1 (75) No
318 M DGC (43)       No
334 F DGC (43) DBC: 1 (82)     No
351 F DGC (70), LBC 
bilateral (64, 66) 
sGC: 1 (60); sBC: 2 (57, 59)   CRC: 2 (50, 65); CUP: 2 (50, 
64); NHL: 1 (84); LC: 1 (65)
Yes
359 F DGC (42)   sBC: 1 (72) ES: 1 (52); LC: 3 (50, 60, 62) No
365 F DGC (53) sBC: 1 (67)   Leu: 1 (55); CUP: 1 (?) No
389 M DGC: 1 (69)     CRC: 1 (68) No
409 M DGC (40)       No
413 F DGC (41)     PC: 1 (86) No
419 M DGC (80) sGC: 1 (74); sBC: 1 (60)   CUP: 2 (?) Yes
476 F LBC (51) sBC: 2 (47, 62) UGC: 1 (73); sBC: 1 (55)   No
479 M DGC (57), 
Polyposis colon, 
NET duodenum
sBC: 1 (79)     No
495 F DGC (45)     CUP: 1 (70) No
499 F LBC bilateral 
(52, 57)
DGC: 1 (72) sGC: 1 (70)   No
1010 M DGC (45)     LC: 1 (60) No
Criterion: Personal or family history of diagnoses of DGC, MGC and/or IGC*
13 F DGC (63) IGC: 2 (69, 74) sGC: 2 (35, 60)   Yes
14 M IGC (41) DGC: 1 (63)     No
17 F MGC (41)   sBC: 1 (60) LC: 1 (60) No
26 M MGC (54) IGC: 1 (79); sGC: 2 (40, 79)   LC: 1 (50) Yes
43 M DGC (50) DGC: 1 (79); IGC: 2 (67, 
70); sGC: 2 (79, 83)
    Yes
77 F DGG (59) MGC: 1 (71)     Yes
108 M IGC (68) DGC: 1 (22); sGC: 1 (78)   CRC: 2 (50, 59) No
129 M IGC (59) DGC: 2 (56, 58); sGC: 
1 (59);
  CRC: 1 (73); LiC: 1 (54); 
PCa: 1 (59)
No
141 F DGC (66), OC (67), 
LBC (76)
IGC: 1 (60); sBC: 2 (60, 82) sGC: 1 (70) CUP: 1 (70) Yes
145 M MGC (37)       No
158 F UGC (59) sGC: 1 (73)     No
165 F DGC (45) IGC: 1 (77) sGC: 1 (70) RC:1 (60) Yes
172 M MGC (38)   sBC: 1 (64) NHL: 1 (71) No
173 F DGC (78) DGC: 1 (57); IGC: 1 (69)   Leu: 1 (14) Yes
254 F IGC (53), ES SCC 
(53)
DGC: 1 (34)   CRC: 1 (80), LC: 1 (53) No
271 M MGC (69)     CRC: 2 (75, 78); UTC: 1 (80) No
297 F DGC (47) IGC: 1 (76)   PCa: 1 (73) No
299 F UGC (57) MGC: 1 (68) sGC: 1 (67) CRC: 1 (80); LiC: 1 (57) No
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313 F MGC (61) IGC: 1 (83) sGC: 1 (92) CUP: 2 (50, 72) No
356 M DGC (71) IGC: 1 (69) sGC: 1 (76); sBC: 2 (30, 46) CRC: 1 (60); Leu: 1 (23) No
384 F MGC (55)     PC: 1 (81) No
388 F MGC: 1 (41)     CRC: 2 (46, 70) No
394 F DGC (49)   IGC: 1 (71); sGC: 2 (49, ?); 
sBC: 1 (70)
CRC: 1 (65) No
395 F MGC (35) MGC: 1 (42)     No
407 F DGC (63) DGC: 1 (59); IGC: 1 (59)   LC: 1 (?) Yes
450 F DGC (56) MGC: 1 (73)     Yes
452 M IGC (72) MGC: 1 (73); sGC: 1 (45) sGC: 3 (?)   No
460 F MGC (49), EC (70)   sGC: 1 (66) LC: 1 (69); UTC: 1 (77) Yes
474 M IGC (65) DGC: 1 (72); sGC: 1 (77) sGC: 1 (63) CUP: 2 (69, 73); PCa: 1 (62) No
1016 M MGC (32)       No
1106 F DGC (67), CRC (42) DGC: 1 (66); sGC: 1 (44); 
DBC: 1 (71); sBC: 1 (78)
IGC: 1 (48); sGC: 3 (26, 
30, 39)
CRC: 4 (26, 30, 44, 56); 
OC: 1 (46)
Yes
Criterion: Personal or family history of IGC*
9 M IGC (39) sBC:1 (48) sGC: 1 (39)   No
30 F IGC (32) sGC: 1 (46)   LC: 1 (46) No
47 M IGC (46) sGC: 1 (60); DBC: 1 (22)     No
49 M IGC (66) IGC: 1 (54); sGC: 1 (60) sGC: 4 (50, 58, 60, 83) OC: 1 (75); RC: 1 (70) No
56 M IGC (38) IGC: 1 (74); sBC: 1 (69)   HNC: 1 (76); LC: 2 (70, 86) No
60 M IGC (30)   DBC: 1 (68) MM: 1 (50) No
64 F IGC (23)     CRC: 1 (57) No
69 F IGC (45) sGC: 1 (63)   CRC: 1 (78); LC: 1 (61); LiC: 1 
(41); UTC: 1 (78)
No
91 F IGC (53), CRC (63), 
MM (23)
      No
101 F IGC (70) sGC: 1 (67) sGC: 2 (59, ?) CC: 1 (37); LC: 1 (65) No
106 M IGC (73) IGC: 1 (78); sGC: 3 (35, 
48, 63)
  CUP: 1 (42); LC: 1 (?) No
107 F IGC (69) sGC: 4 (57, 66, 72, 81)   PCa: 1 (64) No
109 M IGC (60) IGC: 1 (65); sGC: 1 (64)   CUP: 1 (60); LiC: 1 (71) No
113 F IGC (72) IGC: 1 (82); sGC: 3 (63, 
66, 82)
  HL: 1 (72) No
116 F IGC (73) IGC: 1 (72); sGC: 1 (70)     No
118 F IGC (32)     CRC: 1 (79); UTC: 1 (77) No
119 M IGC (31)     LC: 1 (72) No
120 F IGC (31)     CRC: 1 (60) No
123 M IGC (56) LBC: 1 (74) LBC: 1 (80)   No
124 M IGC (55) UGC: 1 (35)   LC: 1 (63); LiC: 1 (77) No
134 F IGC (40) sGC: 2 (37, 53) sGC: 3 (46, 64, ?) CRC: 1 (?); CUP: 1 (?) No
138 M IGC (70) sGC: 1 (80); sBC: 1 (47)   ES AC: 1 (44); PCa:1 (70) No
149 F IGC (65), MM (46) sGC: 1 (72) sGC: 1 (76) BO: 1 (?) No
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151 M IGC (66) sGC: 1 (59) sGC: 1 (54) CRC: 1 (59) No
155 M IGC (78) sGC: 2 (61, ?)   BRAT: 1 (82) No
157 M IGC (55) sGC: 2 (64, 80) sGC: 5 (56, 74, 78, 86, 88) CUP: 1 (53) No
168 M IGC (54) IGC: 1 (56)   MM: 1 (32); PC: 1 (82) No
175 F IGC (57) IGC: 1 (60)   CRC: 2 (56, 60) No
187 M IGC (59) sGC: 1 (82); LBC: 1 (56) sBC: 1 (83) CC: 1 (30); Sarcoma: 1 (41) No
193 M IGC (55), MM (46), 
NET Pancreas (46)
sGC: 1 (62) sGC: 1 (78); sBC: 1 (60) Leu: 1 (81) No
196 M IGC (65) sGC: 1 (46)     No
201 M IGC (55)   MGC: 1 (60)   No
203 M IGC (21)     PC: 1 (72); PCa: 1 (52) No
238 F IGC (64), DBC (54) sGC: 3 (55, 60, 60)     No
242 F IGC (31)     CRC: 2 (42, 45) No
250 M IGC (62) IGC: 1 (54); sGC: 1 (48) sGC: 1 (80)   No
258 M IGC (48) UGC: 1 (70)   PCa: 1 (55) No
267 M IGC (61), HNC (59) sGC: 2 (63, 70)     No
273 M IGC (52) UGC: 1 (49); sGC: 1 (74)     No
282 M IGC (69) sGC: 1 (35) sGC: 3 (50, 73, 80) CUP: 1 (28); EC: 1 (40); LC: 
2 (60, 73)
No
283 M IGC (39) IGC: 1 (70); IGC: 1 (63); sGC: 1 (66) BRAT: 2 (50, 56); LiC: 1 (49) No
288 M IGC (65) sGC: 2 (47, 63) sGC: 1 (?)   No
294 M IGC (33)       No
295 M IGC (62) sGC: 1 (61) sGC: 1 (78) BRAT: 1 (85); CRC: 2 (77, 
84); CUP: 4 (60, 75)
No
298 M IGC (46) IGC: 1 (39); sGC: 1 (49) sGC: 1 (70)   No
306 F IGC (56)   sGC: 2 (65, 90) CRC: 1 (64); MM: 1 (50); 
PC: 1 (65) 
No
317 M IGC (47), NHL (41)     CUP: 2 (70, ?); ES: 1 (70) No
328 F IGC (37) sGC: 1 (46) sGC: 2 (30, 71)   No
329 M IGC (60) IGC: 1 (58); sGC: 1 (60)     No
332 M IGC (56), UCC (63)   IGC: 1 (72) CC: 1 (72); CRC: 2 (66, 80); 
HNC: 1 (61); LC: 2 (70, 73); 
UTC: 1 (63)
No
338 F IGC (43)       No
361 M UGC (55) IGC: 1 (52); sGC: 1 (59)   LC: 1 (58); UTC: 2 (56, 65) No
368 M IGC (69), PCa (64) sGC: 1 (42) sGC: 5 (50, 52, 57, 67, ?) CRC: 1 (59); LC: 1 (62) No
374 F IGC (87) UGC: 1 (73); sGC: 4 (48, 
57, 65, 73)
sBC: 1 (66) MM: 1 (70) No
383 M IGC (77) sGC: 1 (56) DGC: 1 (78); sGC: 2 (68, 78) CUP: 1 (76) No
403 M UGC (63) IGC: 1 (58)   NHL: 1 (34) No
416 M IGC (73), CRC (72) UGC: 1 (78); sGC: 1 (41)   Leu: 1 (17) No
430 M IGC (63) IGC: 1 (73); sGC: 1 (65)     No
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438 M IGC (78) sGC: 2 (36, 70); sBC: 1 (70)   HNC: 1 (62); Leu: 1 (?); PCa: 
2 (73, 75)
No
465 F IGC (35)       No
483 F IGC (68) sGC: 2 (25, 75)     No
497 F IGC (40)       No
498 M IGC (50) sBC: 1 (60)     No
500 F IGC (60) IGC: 2 (56, 78); sGC: 2 
(68, 70)
  CUP: 1 (?); Leu: 1 (50); 
PCa: 1 (?)
No
1105 M IGC (66), CRC (66) sGC: 1 (48) sGC: 2 (41, 46) CRC: 1 (34); EC: 1 (41) No
1203 F IGC (52) sGC: 1 (58) sGC: 2 (?) CRC: 1 (?); CUP: 1 (?); ES: 
1 (64)
No
1204 M IGC (42) IGC: 1 (61) sBC: 2 (44, ?) HL: 1 (32); PC: 1 (62) No
Criterion: Personal or family history of ≥2 LBC < 50 years***
176 F LBC (36) LBC: 2 (46, 47); sBC: 1 (82)   OC: 1 (71) No
217 F LBC bilateral 
(40, 42)
IGC: 1 (70)     No
239 F LBC bilateral 
(44, 49)
    LC: 1 (63); Leu: 1 (68) No
376 F LBC (41) LBC: 1 (49) sBC: 2 (44, 58) Leu: 1 (62); UTC: 1 (79) No
Criterion: Personal or family history of LBC at any age***
99 F LBC (47)     BRAT: 1 (71); CUP: 1 (34); 
LC: 1 (69)
No
115 F LBC (48)     BO: 1 (49); LC: 1 (?); Leu: 1 
(?); LiC: 1 (?) 
No
188 F LBC (27) LBC: 1 (56); sBC: 1 (26)   ES: 1 (74) No
230 F LBC (43) LBC: 1 (80) sBC: 2 (85, 87) Leu: 2 (?) No
259 F LBC (45) sBC: 1 (52)   CRC: 1 (52) No
265 F LBC (65) sBC: 2 (48, 49) sBC: 2 (47, 70)   No
331 F LBC (41) LBC: 1 (65); sBC: 3 (44, 
48, 65)
sBC: 1 (50) PC: 1 (83) No
344 F LBC (45)     OC: 1 (54) No
347 F LBC (70)     CRC: 1 (79); PCa: 1 (50) No
348 F LBC (63) LBC: 2 (68, 73) sBC: 1 (59) CRC: 1 (68); CUP: 1 (53); 
NHL: 1 (67); OC: 1 (59)
No
355 F LBC (50), MM (62) DBC bilateral: 1 (55)   BRAT: 1 (79); CRC: 1 (50); 
LC: 2 (43, 64); MM: 2 (55, 
62); PC: 1 (81); RC: 1 (43)
No
358 F LBC (51) sBC: 1 (44) sBC: 1 (90) EC: 1 (65) No
366 F LBC bilateral 
(65, 67)
    CUP: 2 (73, 74); Leu: 1 (32); 
MM: 1 (25); PC: 1 (?)
No
391 F LBC (51) LBC: 1 (73) sBC: 1 (40) Leiomyosarcoma uterus: 
1 (68)
No
397 F LBC (33)     LC: 1 (65); PCa: 1 (79); UTC: 
1 (78) 
No
399 F LBC bilateral (58) sBC: 2 (29, 76)     No
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435 F LBC Le (45), DBC 
Ri (45)
IGC: 1 (66)   CRC: 1 (65) No
447 F LBC (60) LBC: 1 (46) DBC: 1 (67); sBC 1 (69) CRC: 2 (73, 80) No
Criterion: Index with unknown primary cancer <40 years
74 F CUP (39) sBC: 1 (66) sGC: 1 (50) OC: 1 (?) No
184 F CUP (39) sGC: 1 (59) sGC: 1 (74) ES: 1 (?) No
244 M CUP SRCC (26)     LiC: 1 (55) No
252 F CUP SRCC (19)       No
300 F CUP (28)     CUP: 1 (74) No
402 M CUP (35)     CC: 1 (?); LC: 1 (55); Leu: 
1 (54)
No
471 F CUP SRCC (36)       No
Criterion: Index with signet ring cell colorectal cancer <40 years
81 F CRC (32)     BRAT: 1 (30); PC: 1 (59) No
82 M CRC (23)       No
181 F CRC (14)     MM: 1 (69) No
335 F CRC (24)       No
387 F CRC (25)     ES: 1 (50) No
400 M CRC (29)   sGC: 1 (56); sBC: 1 (46) CRC: 1 (53) No
Criterion: Index with intestinal-type adenocarcinoma esophagus ≤40 years
89 M ES AC (24)     CRC: 1 (77); OC: 1 (68); 
UTC: 1 (60)
No
92 M ES AC (28)       No
186 M ES AC (36)     CRC: 1 (58); ES AC: 1 (48); 
PCa: 1 (71); RC: 1 (56); 
TC: 1 (39)
No
212 M ES AC (37)       No
439 M ES AC (39)     CUP: 1 (?); PC: 1 (65) No
459 M ES AC (40)     LC: 1 (69) No
Criterion: Personal or family history of gastric cancer and DBC**
1 F DBC (32) DGC: 1 (33); DBC: 1 (43)   HL: 1 (17); HNC: 1 (46) No
12 F DGC (53), DBC (43)   IGC: 1 (68) LC: 1 (67); PCa: 1 (?) No
16 F DBC (33)   MGC: 1 (49); sGC: 1 (46)   No
54 F DGC (61), DBC (69) sBC: 3 (57, 62, 82)   Leu: 1 (64); PCa: 1 (64) No
104 F DBC (50)   sGC: 3 (60, 67, 68); sBC: 
1 (50)
CRC: 1 (68); LC: 1 (70) No
131 F DGC (58), DBC (41) sGC: 1 (75)   CUP: 1 (47) Yes
195 F DBC (43) DGC: 1 (48) sGC: 1 (46) CRC: 1 (66); PCa: 1 (66) No
202 F DGC (59), DBC 
(50), rectal 
carcinoid (57)
    CRC: 2 (62, 70); RC: 1 (50); 
TC: 1 (24)
No
237 F DBC (50)   sGC: 1 (52)   No
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253 F DBC (47)   sGC: 1 (39) ES: 2 (69, 71); LC: 2 (75, ?); 
MM: 1 (47)
No
256 M DGC (49) DBC: 1 (44)   CUP: 1 (63); LC: 1 (54); 
PC: 1 (57)
No
272 F DBC (55), NHL (45) UGC: 1 (39) sGC: 1 (60) Leu: 1 (54) No
292 F DBC (63) UGC: 1 (44); sGC: 1 (48)     No
305 F DBC (20) DGC: 1 (55)     No
314 F DBC (42) sBC: 1 (44) sGC: 1 (35)   No
372 F DBC (63) sGC: 1 (56) sGC: 7 (42, 48, 51, 52, 
59, 80, ?)
CRC: 1 (70) No
421 F DGC (56), DBC (44) UGC: 1 (76) sGC: 1 (?)   Yes
446 F CRC (41), DBC (49) DGC: 1 (28)   CRC: 1 (38); ES AC (63); LC: 2 
(60, 62); OC: 1 (34) 
No
448 F DBC (39), CUP (58) sGC: 4 (55, 66, 73, 76); 
sBC:1 (68)
sGC: 1 (?) LC: 2 (60, 64); LiC: 1 (76) No
462 F DGC (62), DBC (48) sBC: 1 (85)     No
463 F DBC (47) DGC: 1 (53); sBC: 2 (59, 80) sBC: 1 (60) LC: 1 (43); Leu: 1 (46); MM: 
1 (80); OC: 1 (66)
No
485 F DBC (62) DGC: 1 (47); sGC: 1 (47)   LC: 1 (72) No
492 F DBC (65) sBC: 1 (85) sGC: 1 (76); sBC: 1 (55)   No
Criterion: Other, not meeting the criteria
3 F DCIS (44)   IGC: 1 (63); sGC: 1 (78) CUP: 4 (51, 70, ?); HNC:1 
(?); LC: 2 (58, 68)
No
28 F - DGC: 1 (54); sGC: 1 (56) MGC: 1 (82) CRC: 1 (74) No
29 F - DGC: 1 (56)   NHL: 1 (69) No
32 M CRC (51) IGC: 1 (69) sGC: 3 (48, 63, 70); sBC: 
1 (73)
  No
105 M - DGC: 1 (42)   CRC: 1 (46); LC: 3 (60, 
60, 65)
No
178 F - DGC: 1 (48)   CC: 1 (40) No
182 M - DGC: 1 (48); DBC: 1 (48)   CRC: 1 (65); CUP: 1 (43) No
204 M CUP (41) IGC: 1 (68)   LC: 1 (70); NHL: 1 (70); 
RC: 1 (77) 
No
228 M CUP (54) sGC: 1 (70) sGC: 1 (50)   No
234 M - DBC: 1 (47) IGC: 1 (76) PCa: 1 (60) No
243 F - DGC: 1 (40)     No
248 M - DGC: 1 (49)   CC: 1 (48); CRC: 1 (54); 
EC: 1 (40)
No
251 F - sGC: 1 (60)   ES: 1 (88) No
255 F - DGC: 1 (42)   LC: 2 (33, 52); PC: 1 (67) No
264 F - DGC: 1 (42); DBC: 1 (47)   LC: 1 (42); PC: 1 (65) No
323 M ES AC (52)   sBC: 2 (44, 50) CRC: 2 (67, 75); CUP: 2 (43, 
65); LC: 1 (63); PCa (82)
No
327 F - DGC: 1 (40)   CRC: 1 (58); CUP 2 (65, 67); 
LC: 1 (66); TC: 1 (32)
No
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336 F - IGC: 1 (61) IGC: 1 (67); sGC: 1 (55); 
sBC: 1 (68)
NHL: 1 (53) No
354 F - IGC: 1 (33); sGC: 1 (40)     No
363 F - DGC: 1 (73) sGC: 1 (68)   No
371 F - sGC: 1 (67) IGC: 2 (72, 81); sGC: 1 (70) CUP: 1 (44) No
390 M CRC (54)       No
396 F - IGC: 1 (75) UGC: 1 (58); sGC: 1 (66)   No
405 M - UGC: 1 (59); sGC: 1 (68); 
sBC: 2 (40, 60)
  CUP: 1 (39) No
412 F DBC (18), CUP (48)       No
417 M - DGC: 1 (71) DGC: 1 (88)   No
420 M CRC (69), IGC (75)   sBC: 1 (57)   No
423 F - DGC: 1 (65)     No
433 F - MGC: 1 (70); UGC: 1 (64) sGC: 1 (50)   No
440 M CRC (47)     CRC: 1 (82); ES AC: 2 
(42, 57)
No
442 F - DGC: 1 (49)   CUP: 1 (43) No
449 F DBC Ri (32), 
DCIS&LCIS Le (40)
LBC: 1 (47)   RC: 1 (59) No
451 F - MGC: 1 (60)     No
454 F -     ES AC: 1 (27); LC: 1 (53); 
MM: 1 (33)
No
456 F - LBC: 2 (43, 47); sBC: 1 (58)   LC: 2 (78, 80) No
467 F MM (46), CRC (66)   sBC: 2 (51, 86) UTC: 1 (68) No
Criterion: Index with gastric or breast cancer, incomplete pathology data to meet HDGC criteria
5 F DGC (50) DGC: 1 (50); sGC: 1 (48)   ThC: 1 (48) Yes
34 F DGC (77) sGC: 1 (72) sGC: 5 (?)   Yes
55 M DGC (67) DGC: 1 (70); sGC: 1 (78)   Thymoma: 1 (?) Yes
61 M sGC (50) DGC: 2 (67, 77); sGC: 2 (53, 
60); LBC: 1 (62)
sGC: 2 (?); sBC: 2 (?) CRC: 1 (45); HNC: 1 (55); 
LC: 1 (59)
Yes
63 F DGC (64) sGC: 1 (52) sGC: 3 (62, 64, 82) CRC: 4 (62, 74, 82, 83) Yes
70 M DGC (52) IGC: 1 (53); sBC: 1 (25)   GIST: 1 (68); LC: 1 (62) No
75 F LBC (63) sGC: 1 (49)     No
76 F UGC (75) DBC: 1 (77); sBC: 2 (50, 83) sGC: 1 (?); sBC: 1 (52) CRC: 1 (46) No
78 M DGC (58) sGC: 1 (68) sGC: 1 (74) BO: 1 (39) Yes
79 M sGC (23), IGC (57) sBC: 1 (52) sGC: 1 (50) BO: 1 (23); LC: 1 (79) No
83 F LBC (44) DBC: 1 (39); sBC: 1 (60) sGC: 3 (48, 63, 73); sBC: 
1 (76)
ES: 1 (78); RC (63) No
84 F LBC (40) LBC: 1 (58) sGC: 1 (63) PCa: 1 (?) No
94 M DGC (58) sGC: 1 (45) sGC: 1 (43)   Yes
95 M DGC (56) sGC: 1 (66) sGC: 3 (53, 69, 73) BO: 2 (57, 80); CRC: 1 (66) Yes
97 F LBC (54)   sGC: 1 (58) LC: 2 (58, 70) No
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102 M DGC (58) sGC: 1 (34); LBC: 1 (72); 
sBC: 1 (58)
sGC: 3 (64, 64, 68) CC: 1 (73); CRC: 1 (57); UTC: 
1 (49) 
Yes
111 M DGC (72) sGC: 1 (63)     Yes
127 M DGC (50) sGC: 1 (56)   CRC: 1 (75); NHL: 1 (65) Yes
137 F DGC (55) DGC: 1 (83) sGC: 1 (62)   Yes
139 F DGC (77) DGC: 1 (54); sGC: 1 (68); 
DBC: 1 (53); sBC: 1 (45)
sGC: 4 (?); sBC: 3 (38, 
40, 70)
ES: 1 (?) Yes
161 M DGC (63), MM (60) sGC: 1 (61) sGC: 1 (72) PCa: 1 (88) Yes
166 F DGC (66) sGC: 1 (48) sGC: 1 (60); sBC: 1 (60) CRC: 1 (?); LC: 2 (53, 55); 
PC: 2 (48, 60); PCa: 1 (71); 
RC: 1 (53)
Yes
170 M DGC (78) sGC: 1 (74) sGC: 1 (74)   Yes
171 F DGC (57) sGC: 1 (51) sGC: 1 (80)   Yes
183 F sGC (39)       No
185 M DGC (55) sGC: 1 (55)     Yes
207 F LBC (40) sGC: 1 (49)   CRC: 1 (60); LC: 1 (67); MM: 
1 (38)
No
211 F sGC (62) sGC: 3 (50, 66, 67)     No
221 M DGC (42), Fundic 
gland polyposis
  sBC: 1 (50)   No
236 M DGC (55) sGC: 1 (48) sGC: 1 (48)   Yes
240 F DGC (54) IGC: 1 (80) sGC: 2 (73, 81) CRC: 1 (78); PCa: 1 (71) Yes
246 F LBC (44), 
DCIS (43), 
Schwannoma (18)
sGC: 1 (49)   LC: 1 (65) No
260 F DGC (74)   sGC: 3 (63, 67, 80) LC: 1 (75) Yes
262 F LBC (48)   sGC: 3 (50, 50, 50)   No
266 F LBC bilateral (47)   sGC: 1 (59) LC: 1 (76) No
268 F DGC (54), CRC (55) DGC: 1 (65); LBC: 1 (62); 
sGC: 1 (45)
sGC: 3 (48, 68, 79); sBC: 
1 (60)
LC: 1 (48) Yes
270 M DGC (62) DGC: 1 (63); sGC: 2 (54, 71) sGC: 4 (45, 51, 57, 72) BRAT: 1 (49) Yes
278 M DGC (76) IGC: 1 (73); UGC: 1 (51); 
sGC: 2 (51, 69)
sGC: 5 (60, 68, 70, 70, 74) CRC: 1 (39); CUP: 1 (79) Yes
279 F DGC (69) DGC: 1 (68) sGC: 1 (43) CRC: 1 (43) Yes
281 M sGC (42), TC 
(24, 42)
sBC: 1 (33)     No
289 M DGC (42) sBC: 1 (51)   BDC: 1 (71); CUP (61); MM: 
1 (67)
No
302 M DGC (60), HNC 
(60)
UGC: 1 (73) sGC: 1 (73) CRC: 1 (70); LC: 1 (?) Yes
304 F DGC (65), DBC (60) DGC: 1 (57); sGC: 1 (53) sGC: 1 (55) BRAT: 1 (2); HL: 1 (46); 
UTC: 1 (51)
Yes
316 F DGC (54) sGC: 1 (67) sGC: 1 (?) CRC: 1 (50) Yes
321 F DGC (53) sGC: 1 (58) sGC: 1 (60)   Yes
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324 F LBC (65) sBC: 1 (54) sGC: 1 (39) CRC: 3 (63, 81, 93); LC: 
1 (65)
No
325 M DGC (62) sGC: 2 (?)   CRC: 2 (52, ?); ThC: 2 (53, ?) Yes
326 F LBC (46), RC (46)   sGC: 1 (67) HNC: 1 (60); Leu: 1 (72); 
PCa: 3 (57, 64, 80) 
No
341 F LBC bilateral 
(63, 65)
sGC: 1 (?)   CRC: 1 (59); PCa: 1 (54) No
346 F LBC (54) sBC bilateral: 2 (41&44, 
42&47)
sGC: 1 (78); sBC: 1 (75) CC: 1 (41); EC: 2 (20, 25) No
349 M DGC (57)   DGC: 1 (69); sGC: 1 (85)   Yes
350 F LBC (48) LBC bilateral: 1 (40&45) sGC: 1 (60)   No
352 F LBC Le (39), DBC 
Ri (39)
  IGC: 1 (59); sGC: 3 (64, 
65, 66); DBC: 1 (65); sBC: 
1 (34)
ES AC: 2 (60, 71); OC: 1 (49); 
PCa (79)
No
357 M UGC (43)   DGC: 1 (53) CRC: 4 (52, 56, 64, 70); 
LiC: 1 (52); OC: 1 (35); PCa: 
2 (76, ?) 
No
370 F LBC (44)   sGC: 1 (42) CRC: 1 (37) No
375 F LBC bilateral 
(48, 60)
sGC: 1 (89)     No
382 F UGC (80) UGC: 1 (42)     Yes
406 F DGC (45)   sBC: 1 (77) RC: 1 (74) No
408 M DGC (72) DGC: 1 (73); UGC: 2 (69, 
80); sGC: 1 (70)
    Yes
411 M DGC (56) sGC: 1 (42)     Yes
415 F LBC Ri (50), LBC 
Le (67)
sGC: 1 (?) sGC: 1 (46)   No
418 F LBC (48) sGC: 1 (65)   PC: 1 (55) No
425 F sBC (53)   sGC: 3 (68, 71, 76) HNC: 1 (79) No
426 F LBC (48) sGC: 1 (40) sGC: 1 (70); sBC 1 (75) BRAT 1 (40); CC: 1 (45); 
HNC: 1 (61); LC: 4 (40, 44, 
54, 54) 
No
428 F LBC Le (34), DBC 
Ri (32)
  sGC: 4 (59, 60, 67, 70); 
sBC: 1 (72)
CRC: 1 (62) No
429 F DGC (57) UGC: 1 (38)   CRC: 1 (39); CUP: 1 (49) Yes
434 F LBC (55) sGC: 1 (73); sBC: 1 (46)   BRAT: 1 (56); LC: 1 (62) No
436 M DGC (76) sGC: 3 (65, 82, 83) sGC: 1 (83) CC: 1 (27), CRC: 1 (42, 54) Yes
437 F LBC (60) DBC: 1 (86), sBC: 1 (32) sGC: 3 (50, 50, 55); sBC: 
1 (35)
  No
455 F LBC bilateral (50)   sGC: 1 (62)   No
464 F DGC (55) sGC: 1 (44)   CRC: 1 (57); LC: 2 (53, ?); 
LiC: 1 (?); PC: 1 (?)
Yes
470 F DGC (80) sGC: 1 (80) sGC: 2 (77, ?)   Yes
480 F LBC (52), DBC (52) sGC: 1 (39); DBC: 1 (58); 
LBC: 1 (63)
sGC: 1 (43)   No
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484 M DGC (42)   sBC: 1 (36)   No
490 F UGC (41), DBC (54) DGC: 1 (71); sGC: 1 (60)   TC: 1 (?) Yes
1015 F DGC (59), LBC (56) sGC: 1 (32)     Yes
1101 F DGC (54) DBC: 1 (48) sGC: 1 (60) CRC: 5 (46, 46, 48, 60, 62); 
OC: 1 (56)
Yes
Criterion: Index without gastric or breast cancer (FDR), family meets HDGC criteria
4 F HNC (45), ES SCC 
(65)
DGC: 2 (34, 63) IGC: 1 (61) CUP: 1 (49) No
10 F - DGC: 1 (34); DBC: 1 (43) sBC:1 (40) Leu: 1 (80) No
15 F - DGC: 1 (34) sGC: 1 (56) CRC: 1 (60) No
19 F - DGC: 1 (28)   LC: 1 (49) No
21 F - DGC: 2 (31, 42)     No
86 M - DGC: 1 (41); sGC: 1 (44)     No
88 F - DGC: 1 (30) sBC: 2 (33, 42)   No
110 F - DGC: 1 (38) DGC: 1 (47)   No
114 M - DGC: 2 (36, 61) sGC: 5 (57, 65, 68, 75, 83) CRC: 3 (68, 70, 74); HL: 
1 (18)
No
190 F - DGC: 1 (40); sGC: 1 (48)   GIST: 1 (64) Yes
223 F - sGC: 1 (31) DGC: 1 (46); sGC: 1 (46)   No
225 F - DGC: 1 (40) DGC: 1 (86)   No
245 F - DGC: 1 (31)     No
261 F CC (27) DGC: 1 (37); CRC: 1 (37)   CC: 3 (40, 45, 48) No
263 F - DGC: 1 (30)   LC: 1 (52) No
277 M - DGC: 1 (32)   CRC: 1 (72) No
291 F - DGC: 2 (42, 67)   CRC: 1 (49); CUP: 1 (?); ES: 1 
(70); NHL: 1 (?)
No
422 F - DGC: 2 (47, 55)     No
431 F - DGC: 1 (39) sBC: 1 (60)   No
441 F - DGC: 1 (34)   CUP: 1 (30) No
445 M - DGC: 1 (34)   CUP: 1 (?) No
458 M HNC (71), CRC (77) DGC: 1 (26); sGC: 1 (75)   CRC: 2 (41, 48) No
468 F - DGC: 1 (28) sBC: 1 (76) Leu: 1 (70) No
475 F - DGC: 1 (31)     No
1205 F - DGC: 1 (28) DBC: 1 (49)   No
Criterion: Index without invasive gastric or breast cancer (FDR), incomplete pathology data for HDGC criteria
48 M -   sGC: 1 (42); sBC: 1 (75) LiC: 1 (70); PC: 1 (53); ThC: 
1 (74)
No
62 F ES AC (54) sGC: 1 (28)     No
65 M - sGC: 2 (40, 53) sGC: 2 (?)   No
68 F - sGC: 1 (77) sGC: 2 (45, 65) CRC: 2 (70, 80); LC: 1 (60) No
73 F - sGC: 1 (32)     No
87 F DCIS (50) DGC: 1 (76) sGC: 5 (57, 72, 76, 77, 81) BDC: 1 (77) No
98 F - sGC: 1 (47) sGC: 1 (47) LC: 1 (60) No
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174 M CRC (44) DGC: 1 (40); IGC: 1 (68) sGC: 1 (?) CRC: 1 (67); OC: 1 (64) No
189 F OC (44)   sGC: 2 (40, 44) Leu: 1 (64) No
191 F OC (22) DGC: 1 (58) sGC: 2 (59, 64) PCa: 1 (61) No
192 F - sGC: 1 (29) sGC: 2 (40, 60); sBC: 1 (30)   No
197 M - sGC: 2 (40, 48)     No
208 M - sGC: 2 (26, 80); sBC: 1 (29)   CUP: 1 (37) No
209 F - sGC: 1 (38)   CUP: 1 (51) No
224 F - DGC: 2 (66, 69); sGC: 2 
(61, 68)
    No
226 M - sGC: 2 (?) sGC: 1 (52)   No
227 F - DGC: 1 (?) DGC: 1 (?)   No
231 M - sGC: 1 (44) sGC: 1 (60)   No
232 M - sGC: 1 (32)     No
247 F - DGC: 1 (50); DBC: 1 (53) sGC: 2 (65, 75) CRC: 2 (68, 70) No
311 F - sGC: 1 (61) sGC: 2 (68, 72)   No
315 M - sGC: 1 (48) sGC: 1 (53)   No
319 M - DGC: 1 (43) sBC: 1 (?) CUP: 2 (55, 63) No
322 M Polyposis colon 
(68)
sGC: 2 (36, 66)   CUP SRCC: 1 (60) No
333 F - sBC: 2 (43, 62) sGC: 2 (52, 64); sBC: 2 (?) LC: 1 (66) No
339 F - LBC: 1 (38) sGC: 2 (50, 70); DBC: 1 
(63); sBC: 1 (71)
EC: 1 (78); LC: 1 (59); UTC: 
1 (84)
No
345 F - DGC: 1 (42) sBC: 1 (?)   No
369 F DCIS Ri (53), DCIS 
Le (66)
sGC: 1 (72); LBC: 1 (55) sGC: 2 (66, 68)   No
379 F - DGC: 1 (61) sGC: 1 (83)   No
381 F - sGC:1 (52); sBC: 1 (45) sGC: 4 (59, 61, 62, 67) LC: 1 (62); MM: 1 (60) No
385 M - UGC: 1 (54); sGC: 1 (40) sGC: 1 (41)   No
414 M - DGC: 1 (90); sGC: 1 (72) sGC: 1 (60)   No
424 F LCIS (45) sGC: 1 (?) LBC: 1 (77) CRC: 1 (44) No
427 M - DGC: 1 (72); DBC: 1 (50); 
sBC: 2 (50, 53)
sGC: 2 (71 ,77); sBC: 1 (45)   No
443 M - DGC: 1 (90) sGC: 3 (50, 50, 60)   No
453 M - sGC: 3 (54, 57, 77); DBC: 
1 (66)
  LiC: 1 (64) No
457 F LCIS (44), DCIS 
(44)
DGC: 1 (66); sGC: 1 (43)   PC: 1 (52) No
466 F - sGC: 1 (55) sGC: 2 (46, 60) LC: 1 (57) No
469 F GCC appendix (49) sBC bilateral: 1 (57, 62) sGC: 1 (44) CRC: 1 (73) No
473 F - sGC: 1 (30)   CUP: 1 (30); PC: 1 (?) No
486 F - sGC: 1 (70); sBC: 1 (35)     No
491 F CRC (77) sGC: 2 (27, 40)   ES SCC: 1 (68); Leu: 1 (46) No
1202 F OC (56) sGC: 1 (36); DBC: 1 (45) sBC: 1 (70)   No
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Abbreviations: BDC= bile duct cancer; BO= bone cancer; BRAT= brain tumor; CC= cervical cancer; 
CRC= colorectal cancer; CUP= cancer of unknown primary; DBC= ductal breast cancer; DCIS= ductal 
carcinoma in situ; DGC= diffuse-type gastric cancer; EC= endometrial cancer; ES= esophageal 
cancer; ES AC= esophageal adenocarcinoma; ES SCC= esophageal squamous cell carcinoma; GCC 
appendix= goblet-cell carcinoma appendix; GIST= gastrointestinal stromal tumor; HL= Hodgkin 
lymphoma; HNC= head and neck cancer; IGC= intestinal-type gastric cancer; LBC= lobular breast 
cancer; LCIS= lobular carcinoma in situ; LC= lung cancer; Le= left-sided; Leu= leukemia; LiC= 
liver cancer; MGC= mixed-type gastric cancer; MM= malignant melanoma; NHL= non-Hodgkin 
lymphoma; OC= ovarian cancer; PC= pancreatic cancer; PCa= prostate cancer; RC= renal cancer; 
Ri= right-sided; sBC= self-reported breast cancer; sGC= self-reported gastric cancer; SRCC= signet 
ring cell carcinoma; TC= testicular cancer; ThC= Thyroid cancer; UGC= unclassified gastric cancer; 
UTC= urinary tract cancer
*Index patients with a diagnosis of gastric cancer (DGC, IGC or MGC) were included in this group 
**Index patients with a diagnosis of gastric cancer or LBC and obligate carriers were included in 
this group
***Index patients with a diagnosis of breast cancer were included in this group
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ABSTRACT
Germline CDH1 mutations confer a high lifetime risk of developing diffuse 
gastric (DGC) and lobular breast cancer (LBC). A multidisciplinary workshop was 
organized to discuss genetic testing, surgery, surveillance strategies, pathology 
reporting and the patient’s perspective on multiple aspects, including diet 
post-gastrectomy. The updated guidelines include revised CDH1 testing criteria 
(taking into account first- and second-degree relatives): (1) families with two 
or more gastric cancer patients at any age, one confirmed DGC; (2) individuals 
with DGC before the age of 40 and (3) families with diagnoses of both DGC 
and LBC (one diagnosis before the age of 50). Additionally, CDH1 testing could 
be considered in: patients with bilateral or familial LBC before the age of 50; 
patients with DGC and cleft lip/palate; and those with precursor lesions for 
signet ring cell carcinoma. Given the high mortality associated with invasive 
disease, prophylactic total gastrectomy at a centre of expertise is advised 
for individuals with pathogenic CDH1 mutations. Breast cancer surveillance 
with annual breast MRI starting at age 30 for women with a CDH1 mutation is 
recommended. Standardized endoscopic surveillance in experienced centres 
is recommended for those opting not to have gastrectomy at the current 
time, those with CDH1 variants of uncertain significance and those that fulfil 
HDGC criteria without germline CDH1 mutations. Expert histopathological 
confirmation of (early) signet ring cell carcinoma is recommended. The impact 
of gastrectomy and mastectomy should not be underestimated; these can have 
severe consequences on a psychological, physiological and metabolic levels. 
Nutritional problems should be carefully monitored. 
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INTRODUCTION
Worldwide, gastric cancer (GC) is the fifth leading cause of cancer and the 
third most common cause of death from cancer, with an estimated number 
of 723,000 deaths annually.1 The vast majority of GCs are sporadic, but it has 
now been established that 1-3% of GCs arise as a result of inherited cancer 
predisposition syndromes. These syndromes include Li-Fraumeni syndrome,2-4 
Lynch syndrome,5-7 Peutz-Jeghers syndrome,8-10 hereditary breast and ovarian 
cancer,11, 12 MUTYH-associated adenomatous polyposis (MAP),13 familial 
adenomatous polyposis (FAP),14-16 juvenile polyposis syndrome,17, 18 and PTEN 
hamartoma tumour syndrome (Cowden syndrome).19 The lifetime risk of GC 
in these syndromes varies substantially between populations studied, but is 
generally low. 
Over 15 years ago, linkage analysis implicated germline mutations in the CDH1 
gene, encoding the tumour-suppressor protein E-cadherin, as the genetic cause 
of hereditary diffuse gastric cancer (HDGC).20 Heterozygous germline CDH1 
mutations increase lifetime risk of developing diffuse gastric cancer (DGC) and 
lobular breast cancer (LBC). Criteria have been set to select families eligible 
for screening of germline CDH1 mutations and they were updated in 2010.21, 22 
Not all families fulfilling these criteria have mutations in CDH1, indicating that 
other genes may also be involved in DGC predisposition. Germline mutations in 
CTNNA1 were described in three families that presented with DGC, one of them 
fulfilled the 2010 HDGC criteria.23, 24 
Increasing awareness of HDGC and the rapid advances in genetic diagnostic tools, 
endoscopic modalities and the increasing use of laparoscopic surgery led a group 
of clinical geneticists, gastroenterologists, surgeons, oncologists, pathologists, 
molecular	biologists,	dieticians	and	patient’s	representatives	from	nine	different	
countries to convene a workshop in order to update the management guidelines 
for this condition set in 2010 and to propose directions for future research. The 
workshop	discussions	were	focused	on	five	major	topics:	(1)	genetic	counselling	
and mutation analysis; (2) endoscopic surveillance and screening of cancer; (3) 
risk-reduction surgery of the stomach and breasts; (4) pathological specimen 
processing and diagnosis; and (5) patient’s and dietician’s perspective.
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GENETIC COUNSELLING AND MUTATION ANALYSIS
Genetic evaluation of HDGC patients
Genetic counselling is an essential component of the evaluation and 
management of HDGC. The counselling process should include a formal 
genetics evaluation by a cancer genetics professional with expertise in the field. 
The evaluation should include a detailed three-generation family pedigree, 
histopathological confirmation of DGC diagnoses and/or precursor lesions 
(in situ or pagetoid spreading of signet ring cells) and a discussion on lifetime risks 
of developing DGC and LBC. Informed consent for genetic testing is required. In 
the management of individuals with a CDH1 mutation, a full multidisciplinary 
team (MDT) should be involved comprising those with relevant expertise in 
gastric surgery, gastroenterology, breast oncology, pathology, psychosocial 
support and nutrition. Genetic testing can be offered from the age of consent 
(and therefore will vary between countries, but will generally be around 16-18 
years). Testing of younger unaffected family members can be considered on a 
case-by-case basis. Rare cases of clinically significant DGC have been reported 
in affected families before the age of 18,25 but the overall risk of this disease 
before the age of 20 is low.26, 27 
Cancer risks in CDH1 mutation carriers
In a recent study, penetrance data for CDH1 mutation carriers has been updated 
based on affected individuals, who presented clinically with DGC or LBC, from 
75 families with pathogenic CDH1 mutations. Families with CDH1 missense 
mutations and families of which no carrier test information was available were 
excluded from this analysis. The cumulative risk of DGC for CDH1 mutation 
carriers by age 80 years is reported to be 70% for men (95% confidence interval 
[95% CI], 59-80%) and 56% for women (95% CI, 44-69%). Furthermore, the 
cumulative risk of LBC for women with a CDH1 mutation is estimated to be 42% 
(95% CI, 23-68%) by 80 years. There is currently no evidence that the risk of other 
cancer types in individuals with a CDH1 mutation is significantly increased.24 
Implications of counselling
Clinical geneticists (or other members of the multidisciplinary team) should 
inform the counselee about gastric surgery and options of surveillance. Proven 
pathogenic CDH1 germline mutation carriers should be advised to undergo 
prophylactic gastrectomy (for more details see ‘Surgery’ section). Some patients 
may want to delay prophylactic gastrectomy for personal and/or work-related 
reasons. In these individuals endoscopic surveillance, described in detail under 
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´Endoscopic surveillance´, should be considered in the interim. The management 
of patients and families with clinical features suggestive of HDGC, but without a 
germline CDH1 mutation, is not straightforward. We advise intensive endoscopic 
surveillance in an expert centre for first-degree relatives of patients meeting 
criteria mentioned in Figure 1. This is also the case for patients and families who 
carry a CDH1 variant with unproven deleterious effect. Recommendations on 
breast cancer surveillance and therapy in CDH1 mutation carriers can be found 
below. 
Figure 1. Algorithm for management starting from clinical HDGC testing criteria, genetic testing, 
role of endoscopy and gastrectomy. Abbreviations: GC: gastric cancer; DGC: diffuse gastric cancer; 
LBC: lobular breast cancer; MLPA: multiplex-ligation probe amplification
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Criteria for germline CDH1 mutation testing
The last guideline in 2010 broadened the clinical criteria to select patients eligible 
for CDH1 mutation analysis. The detection rate of CDH1 mutations before 2010, 
using the guidelines established in 1999,21 was reported to be 25-50%.27, 28 Using 
the new criteria, the CDH1 detection rate in countries with a low incidence of 
GC has decreased to 10-18% (van der Post et al. 2014 under revision).24, 29 This 
decrease may also be explained partly by the enrichment of large and highly 
suspected families in studies published before 2010 (i.e. ascertainment bias). 
The detection rate is considerably higher in the New Zealand Maori population 
and is likely higher in the Newfoundland population, where a founder mutation 
has been described.27 It should be noted that these criteria are designed for 
countries with a low incidence of sporadic GC. Few small series and case reports 
of individuals with CDH1 mutations have been described in countries with a 
high incidence of sporadic GC; no large cohorts were examined systematically. 
In small series of South-Korea, Japan and Portugal, mutation detection rates 
of pathogenic germline CDH1 mutations in HDGC and early-onset GC range 
between 8-15%.2, 30-33 
During the workshop, it was decided to merge the first (“Two or more GC cases 
in a family, one DGC <50”) and second (“Three or more DGC cases regardless 
of age”) testing criteria from the previous guideline22 into a new criterion: “Two 
or more GC cases regardless of age, at least one confirmed DGC”, in first- and 
second-degree relatives. The two other testing criteria have not been changed. 
The revised criteria are depicted in the upper panel of the box in Figure 1. The 
revised criterion now covers families for whom detailed pathology is incomplete. 
However, as in the earlier criteria, confirmed intestinal-type GC cases are not part 
of HDGC and in these families no CDH1 mutation analysis should be performed. 
To properly assess whether a family meets the HDGC criteria, pathology reports 
and preferably review of gastric specimens by a pathologist dedicated to GC, 
are essential. 
There are other families in which genetic testing may also be considered 
(Figure 1, lower panel). The presence of bilateral LBC at young age (under the 
age of 50 years) or the presence of multiple close relatives with LBC (at least two 
under the age of 50 years) may direct towards testing for CDH1 mutations.29, 34 
Testing should also be considered in individuals with a personal or family history 
of cleft lip/cleft palate (CL/P) and DGC.35, 36 Furthermore, in cases where expert 
pathologists detect in situ signet ring cells and/or pagetoid spread of signet ring 
cells in the stomach, genetic testing should be considered since this is rarely 
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(if ever) seen in sporadic cases. Genetic testing should, whenever possible, be 
initiated in an affected proband. If the affected proband is deceased, frozen- 
or formalin-fixed, paraffin-embedded tissue (preferably normal, non-malignant 
tissue) still may be available for CDH1 germline mutation testing. In case tissue 
of an affected individual is not available or of insufficient quality to perform the 
test, testing of unaffected relatives is acceptable. This should be performed 
preferably in at least three first-degree relatives simultaneously, increasing 
likelihood of detecting a CDH1 mutation. However, it has to be made clear to 
the counselee that unaffected individuals have only a 50% chance of having 
inherited a mutated CDH1 allele. The testing criteria still have to be met by the 
counselee’s family. If no mutation is found in these cases, endoscopic screening 
should be discussed with an expert gastroenterologist on a case-by-case 
basis. Similarly, in small families with DGC or families where family history is 
unavailable, CDH1 mutation screening should also be considered on a case-by-
case basis.
Genetic testing: lab perspective
Genetic testing on blood or tissue for germline mutations should be performed 
in certified molecular diagnostic laboratories, e.g. Clinical Laboratory 
Improvement Amendments (CLIA) approved, ISO 15189 accredited or equivalent. 
CDH1 analysis should include mutation analysis of the entire open reading 
frame, including intron-exon boundaries, as well as copy number analysis of 
individual exons to detect intragenic exon deletions or duplications. At present, 
analyses are mostly performed by a combination of Sanger sequencing and 
Multiplex Ligation-dependent Probe Amplification (MLPA). These techniques 
can be replaced by next generation sequencing if the approach used fulfils the 
requirement of similar sensitivity.
To date, over 155 different germline CDH1 mutations have been described, 
the majority pathogenic mutations and a number of variants of uncertain 
significance (van der Post et al. under revision).24 The majority of the pathogenic 
mutations are truncating and thus do not lead to a functional protein. Large 
exonic deletions are relatively rare, with a frequency of about 5%.37, 38 CDH1 is 
a tumour suppressor gene and therefore a somatic second hit is required for 
initiation of tumour formation. The trigger and molecular mechanism by which 
the second allele of CDH1 is inactivated appears to be diverse and includes 
methylation, somatic mutation and loss of heterozygosity (LOH).39-42
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The identification of germline CDH1 missense variants requires additional studies 
to assess their putative pathogenicity. A multidisciplinary approach combining 
familial and population data, in silico analysis and in vitro analysis is currently 
used to classify the variants as neutral or pathogenic.43-47 Genetic parameters 
such as mutation frequency in healthy control populations, co-segregation of 
the mutation within the pedigree and recurrence of the mutation in independent 
families should be considered as a first approach.43, 45 However, the low number of 
individuals affected by the disease, the small size of the pedigrees and the absence 
of mutation hotspots (which prevents the establishment of any correlation 
between the mutation site and its functional consequence) are limitations of this 
approach. In silico experiments predict the degree of conservation of a specific 
nucleotide within species, the effect of missense variants on splicing and also 
the putative impact of the variants on protein structure.45, 47 Still, in silico results 
should be carefully interpreted, because the degree of conservation among 
species of each amino acid position is considered separately and do not take 
into account possible compensatory effects of neighbouring amino acids.45, 47 
Functional in vitro assays should be performed in order to evaluate the impact 
of CDH1 missense alterations in protein structure, trafficking, signalling and, 
consequently, in E-cadherin function.44, 46 Compared to the cells expressing 
wild-type E-cadherin, pathogenic missense mutants impair the correct binding 
of key adhesion-complex regulators and likely compromise normal E-cadherin 
localization and stability at the plasma membrane.46, 48 As a consequence, 
disruption of cell-cell adhesion and increased invasive behaviour may be 
observed in the presence of pathogenic variants.44, 46 To date, 49 germline 
CDH1 missense variants were reported for functional evaluation to IPATIMUP 
(Portugal, reference laboratory for functional characterization of CDH1 missense 
variants for the IGCLC), the majority being classified as deleterious and thus 
possibly pathogenic (R. Seruca, personal communication 2014).
Panel sequencing
Penetrance estimates for CDH1 mutation carriers have been derived from the 
study of highly ascertained HDGC families and it is likely that the penetrance for 
mutations detected in non-HDGC families will be lower. With the introduction of 
next generation sequencing based gene panels, both in research and diagnostic 
settings, CDH1 alterations may be found in patients without a personal 
or family history of GC.49, 50 In our opinion, one should be very cautious in 
the interpretation of coding variants identified in non-HGDC families, especially 
if the alterations do not lead to a premature stop codon.
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CDH1 mutation database
Currently, there is no international database containing all germline CDH1 
mutations and variants identified to date. A database has been designed and is 
currently under construction. This database can be consulted to assess whether 
a given CDH1 mutation has been found by others, and whether it has been 
considered deleterious and likely disease-causative or not based on population 
data, segregation analysis, in silico analysis and in vitro functional analysis, and/
or recurrence in several individuals/families. We advise researchers and clinicians 
to submit unpublished mutations and variants to the database (contact person 
Carla Oliveira, carlaol@ipatimup.pt), together with the requested information 
on families/patients and mutations. The publication/submitter of every mutation 
will always be referred to in the database. 
Psychosocial effects of counselling
Even	 though	 it	 is	 well	 recognized	 that	 many	 individuals	 will	 benefit	 from	
genetic counselling and testing for hereditary cancer in general, there have 
also been reports that it may induce a number of psychosocial problems. In a 
review on individuals requesting genetic counselling and testing for hereditary 
cancer	 syndromes,	 six	dominant	problem	areas	were	 identified:	 (1)	 coping	with	
cancer risk; (2) practical problems (such as obtaining life insurance/loans and 
employment when found to be a mutation carrier); (3) family-related problems 
(e.g. communication problems with family members, feeling responsible for 
family members); (4) children-related problems (e.g. concerns for children having 
increased risk, fear of leaving young children); (5) living with cancer (e.g. fear of 
developing cancer, pain about the loss of family members); and (6) emotions (e.g. 
anxiety, anger, feelings of loss, but also relief and reassurance).51 These topics, 
when applicable, should be addressed during the counselling sessions. 
Pregnancy and assisted reproduction 
Although scientific data are lacking concerning timing of prophylactic 
gastrectomy and family planning, it is entirely possible for women to give birth 
to a healthy child after gastrectomy.52 Nutritional advice and follow-up with a 
dietician within this context is essential.
Individuals from hereditary cancer families are frequently concerned about the 
transmission of their predisposition of cancer to their children.53, 54 Health care 
professionals, including geneticists and psychosocial workers will be increasingly 
involved in discussions and decisional counselling regarding reproductive 
options in families with a known cancer predisposing mutation such as CDH1. 
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In the past decades, genetic testing for hereditary cancers before birth has 
become available through prenatal diagnosis (PND) and pre-implantation 
genetic diagnosis (PGD).55 We recommend that carriers of a CDH1 mutation with 
a desire to have children should be informed about all reproductive options, 
including PND and PGD.
Future research: other genes involved in HDGC predisposition 
Currently, three families that meet the new criteria have been described to carry 
germline CTNNA1 mutations.23, 24 Even though these families show a clinical 
picture similar to that of CDH1-mutation positive families,23 insufficient data 
is available to make a statement on disease penetrance. Given the functional 
connection between the two genes they may represent a genocopy. Mutation 
carriers could be given the option of prophylactic total gastrectomy (PTG) and 
other cancer prevention measures recommended for HDGC families, but with 
the precaution that such advice is being given based on very limited data. 
Other families have recently been described with BRCA2 and PALB2 mutations,24 
however we recommend that these families are managed no differently 
than other families with such mutations according to national guidelines. It 
is likely that other HDGC associated genes will be discovered through whole 
exome-, genome- or other unbiased next generation sequencing empowered 
methodologies. Indeed, using a combination of this approach and linkage 
analysis, mutations in MAP3K6 have recently been described.56 More needs to be 
understood about families with MAP3K6 mutations before they could be used to 
stratify risk in families. Until such data is available, a cautious approach in which 
all first-degree relatives of mutation carriers are followed is recommended. 
Without multiple mutation positive families for newly identified genes, it will be 
extremely difficult to ascribe pathogenicity to such mutations and to develop 
management guidelines.
SCREENING AND SURVEILLANCE
Gastric endoscopic screening and surveillance 
To clarify the terminology, we consider that individuals having endoscopy 
who do not know their mutation status or those who do not have a proven 
pathogenic CDH1 mutation undergo screening whereas mutation-positive 
individuals undergo surveillance. The consensus reached at the workshop 
was that individuals who tested positive for a pathogenic germline CDH1 
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mutation should be advised to consider prophylactic gastrectomy, regardless 
of endoscopic findings. However, the timing of surgery may vary according to 
the preferences and age, as well as the physical and psychological fitness of the 
individual. In patients proceeding for gastrectomy, a baseline endoscopy should 
be performed prior to surgery to look for macroscopic tumour as this may alter 
the treatment plan. This endoscopy is also performed to ensure that there is no 
other co-incidental pathology, such as Barrett’s oesophagus, which may alter 
the extent of the resection. When the stomach is macroscopically normal, the 
information on microscopic disease foci is useful to compare with findings in the 
surgical resection specimen and hence to increase knowledge on the likelihood 
of endoscopic detection of microscopic lesions. 
For individuals with a CDH1 mutation in whom gastrectomy is not currently being 
pursued (e.g. through patient choice or existence of physical or psychological 
comorbidity), regular endoscopy should be offered. In patients declining 
surgery, surveillance can have the advantage of helping individuals to come to 
a decision about the need for gastrectomy when microscopic foci of signet ring 
cells are detected. However, patients should be aware that delaying surgery can 
be a hazardous decision.57
The management of individuals with a CDH1 variant of uncertain significance 
and those in whom no mutation can be identified in the family is not 
straightforward. We would recommend that intensive endoscopic surveillance 
in an expert centre should be offered to these families who fulfil the HDGC 
criteria. Endoscopic screening has a valuable role in guiding clinical decision 
making and in one case series, lesions were detected in 2/7 CDH1-mutation 
negative individuals (1/5 families).57 Specifically, any malignant lesions detected 
endoscopically would prompt a referral for gastrectomy. However, all patients 
undergoing endoscopy for HDGC should be informed that, given the very focal 
and often endoscopically invisible nature of these lesions, it is quite possible 
that lesions will not be detected by random biopsies.
HDGC endoscopy protocol 
Endoscopy should be performed in centres with an experienced multidisciplinary 
team. However, it is appreciated that sometimes this is not practical for 
individuals who have to travel long distances. In this case, a local endoscopist 
in consultation with an expert centre on the endoscopy protocol and review of 
histology may be a helpful alternative.
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As noted above, the optimal frequency of endoscopy is not known. Based on 
current experience it is recommended that individuals should be offered annual 
endoscopy. The bleeding risk may be slightly higher than for other indications 
since more biopsies are taken. Therefore it is recommended that the local high-
risk endoscopy protocol is followed such that, if possible, anticoagulants (e.g. 
warfarin and clopidogrel) are stopped prior to the procedure. The endoscopy 
should be performed using a white light high definition endoscope in a 
dedicated session of at least 30 minutes to allow for careful inspection of the 
mucosa on repeated inflation and deflation and for collection of biopsies. The 
mucosa should be thoroughly washed before examination with a combination 
of mucolytics (N-acetylcysteine) and antifoaming agent (such as simethicone) 
mixed with sterile water. This washing is ideally done via a pump operated by a 
foot pedal. The macroscopic appearances of the gastric mucosa and any focal 
visible lesions should be recorded using still images or video for future reference 
and specifically sampled for histology prior to the collection of random biopsies.
Prior to examination for small foci, the stomach should be adequately inflated 
and deflated to check distensibility. Poor distensibility should raise alarm for a 
submucosal infiltrative process like linitis plastica. When this is the case, biopsies 
should be taken and further imaging such as a high resolution multi-detector CT 
scan combined with endoscopic ultrasonography (EUS) is suggested to visualize 
the gastric wall layers. No objective measures of distensibility are currently 
available and this is an area that may warrant future research.
Although an association between Helicobacter pylori infection and HDGC has 
not been proven, it is important to test for H. pylori to document the prevalence 
of infection. Since H. pylori is a WHO class 1 carcinogen, it is agreed that when 
individuals are infected it should be eradicated, especially in those opting for 
surveillance. A rapid urease test is the preferred test at baseline and additionally 
it is recommended to take random biopsies from the antrum and the corpus due 
to patchy colonization, especially in the presence of acid-suppression. 
Due to the tiny foci of signet ring cells, which can only be recognized by 
microscopy, multiple biopsies are required to maximize the likelihood of 
diagnosing them.39 The anatomical gastric localization in which foci are identified 
varies between studies; reasons for this remain to be clarified, but may include 
environmental factors or differences in the molecular pathogenesis.39, 57-65 
Therefore, it is recommended that any endoscopically visible lesions are 
biopsied including pale areas. Additionally, random sampling should be 
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performed comprising five biopsies taken from each of the following anatomical 
zones: pre-pyloric area, antrum, transitional zone, body, fundus and cardia. A 
minimum of 30 biopsies is recommended as described in the Cambridge protocol 
(Supplementary Protocol 1).22 Even though this will still lead to sampling bias 
due to the large gastric surface area, taking more biopsies is not feasible in 
practice.65 The biopsies may be taken using a standard forceps, ideally with a 
spike as this will seize the lamina propria in which signet ring cell foci are present. 
In the case of a well-defined visible lesion, an endoscopic mucosal resection can 
be helpful to achieve a more reliable histopathological specimen to document 
the degree of invasion. However, this should be done for diagnostic rather than 
therapeutic purposes in view of the multifocal nature of the lesions.
Figure 2. Pale areas in gastric mucosa of a patient with a germline CDH1 mutation harbouring 
signet ring cell focus during white light endoscopy (A) and narrow band imaging (B). H&E stain of 
biopsy specimen with signet ring cells (C). Scar area after biopsy during previous endoscopy (D). 
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Special mention should be given to pale areas, since these are more likely to 
harbour microscopic foci of abnormal cells, although they lack specificity 
leading to false positives (Figure 2).66 Recent data also suggests that these areas 
are visible on careful examination by white light, but Narrow Band Imaging may 
make them easier to visualize (A. Cats, personal communication 2014). As noted 
in the previous guidelines, chromoendoscopy with Congo-red and methylene 
blue is no longer recommended due to concerns over toxicity.66 Virtual 
chromoendoscopy using autofluorescence and trimodal imaging does not seem 
to confer much additional benefit over white light.57 In order to maximize the 
yield from endoscopy, specialist histopathology reporting is essential and the 
guidelines outlined in the pathology section below should be followed.
Endoscopic surveillance of colorectal cancer
Although there are case reports of colorectal and appendiceal signet ring cell 
carcinomas in CDH1 mutation carriers,26, 67-70 there is currently no evidence to 
suggest that the risk of colorectal cancer in CDH1 mutation carriers is significantly 
elevated and there is insufficient data to give recommendations on colorectal 
cancer screening. In CDH1 mutation families in which colon cancer is reported 
in mutation carriers, information should be collected concerning the age at 
diagnosis, whether the affected member(s) and first- or second-degree relatives 
are mutation carriers and whether the histopathology showed a mucinous 
component and/or signet ring cells. For such families, enhanced colonoscopy 
screening should be considered at age 40 or 10 years younger than the youngest 
diagnosis of colon cancer, whichever is younger, and repeated at intervals of 
3-5 years. In the absence of a family history, the national guidelines for colon 
cancer screening should be followed. It is imperative that data on colonoscopic 
screening in these individuals is collected so that these guidelines can be based 
more on evidence than on specialist opinion in the future.
Breast cancer surveillance
Knowledge about breast cancer risk in HDGC has slowly advanced since first 
reported in 2000,26 yet evidence is not sufficient such that recommendations 
can be made of comparable strength as in BRCA1/2. Genotype-phenotype 
correlations may eventually show some HDGC families do not have an increased 
LBC risk, but at present it should be assumed all women with a CDH1 mutation 
are at risk. When informing women with CDH1 mutation about the role of 
breast surveillance versus prophylactic mastectomy to manage their risk, the 
consultation covers similar territory as in BRCA1/2. There are however some 
important differences which must be carefully explained.
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Invasive LBC, the type which typically occurs in HDGC, makes up 5-15% of sporadic 
breast cancer. Invasive ductal cancer occurs in 85-95% of sporadic breast cancer 
and in BRCA1/2 cases.71 In contrast to ductal breast cancer, E-cadherin-deficient 
LBC invades in sheets or cords of cells, typically in single file, and does not 
form a well defined mass. Studies comparing different radiological modalities 
in sporadic LBC show sensitivity on mammography ranges from 34-92%.71 
Bilateral breast MRI needs to be part of the protocol in CDH1 mutation carriers. 
Given the fact that mammography has a low sensitivity for LBC, synchronous 
mammography at the time of MRI may add little. We therefore recommend 
annual breast MRI (which can be combined with mammography) starting at 
age 30 in women with a CDH1 mutation. An oncologist or breast surgeon should 
guide breast surveillance. Annual clinical breast examination and breast cancer 
awareness from the patient and her physicians are essential. 
Future research on gastric and breast surveillance
In light of emerging endoscopic technologies, such as Narrow Band Imaging, 
Blue Laser Imaging, I scan, autofluorescence imaging, IHb-enhancement and 
confocal endomicroscopy,72 research is required to further study the optimal 
methods for endoscopic monitoring of individuals at risk for DGC. Given the 
rarity of this condition, these need to be multicentre studies with strictly defined 
protocols. In addition, it is likely that the multiple biopsy protocol leads to 
scarring which can masquerade as pale areas (Figure 2D). It would therefore be 
very valuable to compare the yield of a targeted biopsy approach only with the 
current Cambridge protocol, which also includes multiple random biopsies. Such 
studies could also inform on the inter-observer variation in the identification 
of pale areas and help define features indicative of a signet ring cell focus. An 
endoscopic atlas created by endoscopists performing regular endoscopies on 
CDH1 mutation carriers would be very useful to help standardize protocols and 
improve lesion recognition.
There are no studies specifically addressing screening for LBC. Trials on breast 
screening in the general population and MRI screening in high risk groups or 
BRCA1/2 are informative, but do not directly extrapolate to the screening 
scenario in HDGC. The outcomes of the above stated recommendations of breast 
surveillance in HDGC women should be further prospectively investigated. 
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GASTRECTOMY AND MASTECTOMY
Prophylactic gastrectomy: Indications for and timing of surgery
Prophylactic gastrectomy should be strongly advised in carriers of a proven 
pathogenic germline CDH1 mutation. Some argue that the term “prophylactic 
gastrectomy” is inaccurate and favour the term “risk reduction gastrectomy”, 
because most mutation carriers already have microscopic signet ring cell 
carcinomas at the time of their surgery. Total gastrectomy for these patients, 
however, completely eliminates their risk of GC and is truly prophylactic in 
terms of preventing their death from invasive GC. 
The optimal timing of prophylactic gastrectomy is unknown and is usually highly 
individualized. Since this surgery has major impact on the quality of life, the 
decision to undergo prophylactic gastrectomy should be well informed, balanced, 
prepared and timed. Decisional counselling, outweighing the pros and the cons 
of the intervention is essential. The current consensus is that the procedure 
should be discussed and offered to pathogenic germline CDH1 mutation 
carriers in early adulthood, generally between age 20 and 30.58 Based upon the 
physical fitness of the mutation carrier and of surgery-related complications, 
prophylactic gastrectomy at an age above 75 should be carefully considered. 
Family phenotype, especially age of onset of clinical cancer in probands, should 
be taken into account. There is likely to be a dormant period in which the signet 
ring cell adenocarcinoma does not spread or progress since they have a low 
proliferative index and the age of prophylactic gastrectomy is generally lower 
than that of overt cancer.39 This may explain why so many individuals are found 
to have T-1 N-0 stage tumours after prophylactic gastrectomy.73 Patients who 
develop symptomatic, widely invasive DGC have a poor prognosis with as few 
as 10% having potentially curable disease.74 Even if potentially curable, five year 
survival rate still does not exceed 30%.75 As our understanding of the natural 
history of mucosal signet ring cell carcinoma improves, it may be possible to 
safely postpone prophylactic gastrectomy in some patients but until such time 
it is safer to recommend surgery early in adult life. This has implications for the 
long-term follow-up of prophylactic gastrectomy patients and re-enforces the 
need for multi-disciplinary teams to care for these patients for the rest of their 
lives, similar to patients who have undergone bariatric malabsorptive surgery 
for obesity.76
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Operation details
The requisite operation is a total gastrectomy with Roux-en-Y reconstruction, 
ensuring that the jejuno-jejunal anastomosis is at least 50 cm distal to the 
oesophago-gastric anastomosis, to reduce the risk of biliary reflux. The proximal 
resection line must be across the distal oesophagus containing squamous 
epithelium to ensure that no gastric cardiac mucosa is left behind. This can be 
confirmed by frozen section, or examination of the opened resection specimen 
in operating room, and can be guided by the use of on-table endoscopy to mark 
the squamo-columnar junction during the surgery.
The optimal extent of lymph node dissection (LND) in prophylactic gastrectomy 
is controversial.77 Lymph node metastases are not reported in asymptomatic 
CDH1 mutation carriers with negative preoperative surveillance biopsies or small 
foci of pT1a intramucosal carcinoma. Among patients with early stage intestinal 
adenocarcinoma of the stomach, the frequency of lymph node metastasis 
in patients with early intramucosal (pT1a) tumours is 2-5%,78-81 and up to 6% 
in the undifferentiated or diffuse types.78, 80 In pT1b tumours, with invasion of 
the submucosal layer, lymph node metastases are found in 17-28%, increasing 
with the depth of submucosal invasion.80, 81 The majority of patients undergoing 
prophylactic gastrectomy for HDGC will have at least T1a cancers. Because a 
preoperative gastroduodenosopy cannot exclude the presence of T1b lesions 
with their higher risk of metastases during the operation, a D1 LND (with the 
inclusion of lymph node stations 1-7) is reasonable. 
The	 formation	 of	 a	 jejunal	 pouch	 may	 improve	 eating	 for	 the	 first	 year	 after	
surgery but, as yet, prospective trials comparing pouch to straight Roux-en-Y 
reconstruction	have	not	convincingly	demonstrated	significant	long-term	benefits	
to justify the routine application of this more complex reconstructive procedure.82 
Surgeons should therefore use the reconstruction they are most familiar with. This 
also applies to whether the preferred surgical approach is open or laparoscopic.77, 
83 There are potential advantages of laparoscopic gastrectomy with reduced 
wound pain and faster overall return to full activities, but conclusive evidence 
for the superiority of this approach is still lacking. Any surgeon proposing to do a 
laparoscopic prophylactic total gastrectomy must be able to reassure the patient 
that this is without additional risk compared to open surgery.
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Prophylactic mastectomy
Prophylactic mastectomy is not routinely recommended but may be a reasonable 
option for some women. Literature about prophylactic mastectomy in HDGC is 
scarce, it is reasonable to consider prophylactic mastectomy on a case-by-case 
basis taking into account the family pedigree. National guidelines for high-risk 
women should be followed with respect to chemoprevention using selective 
oestrogen receptor modulators or aromatase inhibitors.
Figure 3. Mucosal signet ring cell carcinoma (pT1a) H&E (A), PAS-D (B), E-cadherin (C), and 
Cytokeratin staining (D) (original magnifications 200x).
HISTOPATHOLOGY
Histopathology of biopsies from individuals suspected for HDGC
Biopsies of individuals with a family history of DGC that are endoscopically 
screened by the Cambridge protocol should be examined thoroughly. The 
biopsies should be stained for Haematoxylin and eosin (H&E) at three levels 
and periodic acid-Schiff-diastase (PAS-D) as standard. All lesions should be 
recorded. Biopsies from potential carriers of a CDH1 mutation need careful 
evaluation by a pathologist with experience in the pathology of HDGC. In 
mutation carriers the detection of specific lesions may support a decision 
towards prophylactic gastrectomy. In individuals without known gene defects, 
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the detection of such lesions may be used as an additional argument that the 
patient is at high risk of developing cancer and that a prophylactic gastrectomy 
should be discussed. The specific lesions in HDGC are tiny foci of typical signet 
ring cells sometimes admixed with a low number of smaller atypical cells in the 
lamina propria without infiltration beneath the muscularis mucosa (see Figure 
3A-D). The two pre-invasive lesions of signet ring cell carcinoma are: (1) in situ 
signet ring cell carcinoma, corresponding to the presence of signet ring cells 
with hyperchromatic and depolarised nuclei within the basal membrane of a 
gland replacing the normal cells of the gland; (2) pagetoid spread of a row of 
signet ring cells below the preserved epithelium of glands and foveolae, and 
also within the basal membrane (see Figure 4A-B).84 
Criteria for the identification of signet ring cell lesions should be strictly 
followed in order to diminish the risk of overdiagnosing nonspecific changes 
and to distinguish them from lesions that mimic signet ring cell carcinoma 
(SRCC) or precursor lesions. In the gastrointestinal tract various benign “signet 
cell like changes” may mimic SRCC (Supplementary Figure 1).85-88 Therefore, 
confirmation of focal signet ring cell lesions in the stomach by a histopathologist 
with experience in this area is strongly recommended.
Figure 4. Precursor signet ring cell lesions: pagetoid spreading of signet ring cells (A) and in situ 
signet ring cell carcinoma (B) (H&E, original magnifications 400x). 
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Histopathology of prophylactic gastrectomy: classification of 
microscopic foci and determination of significance
Macroscopic examination and sampling of prophylactic gastrectomies should 
follow specific protocols that can be found in Supplementary Protocol 2. The 
histological examination should be made using a checklist, focusing on the 
items listed in Table 1. 
Table 1. Checklist for reporting of prophylactic gastrectomy specimens 
Features of ≥pT1b carcinoma(s) Growth pattern (diffuse infiltration versus localized tumour)
Anatomic location (cardia, fundus, body, transitional zone, antrum)
Measurements
Histological type according to WHO89 and Laurén’s90 classifications
Lymphatic, venous and neural invasion (present or absent)
TNM stage
Features of intramucosal precursor 
lesions and pT1a SRCC
Number of lesions 
Anatomic location (cardia, fundus, body, transitional zone, antrum)
Measurements
Aggressive features: pleomorphism, loss of mucin, spindle cells, small cells, mitoses
Stromal reaction related to lesions: desmoplasia; lymphocytic, eosinophilic or granulomatous 
inflammatory reaction
Surgical margin status (proximal oesophageal, distal duodenal mucosa, including donuts), to 
confirm there is no residual gastric mucosa and no tumour at margins. 
Lymph node status
Non-neoplastic mucosa: changes 
more commonly seen in this 
condition
Tufting/ hyperplastic mucosal changes
Surface epithelial vacuolisation
Globoid change
Other findings in surrounding 
mucosa
Inflammation (acute, chronic, erosion, ulceration)
Helicobacter pylori
Intraepithelial lymphocytes 
Lymphoid infiltrates
Glandular atrophy
Intestinal metaplasia 
Adenomatous dysplasia
Pathology data from over 100 total prophylactic gastrectomies in the setting of 
HDGC is published until now. Nearly all gastrectomies exhibit tiny mucosal foci of 
SRCC or in situ signet ring cells, although sometimes these were only discovered 
after	careful	review	by	a	pathologist	with	experience	 in	this	field.25, 36, 39, 59-64, 77, 91, 92 
There are numerous T1a carcinoma foci but only a low number of in situ carcinoma 
lesions, suggesting that invasion of the lamina propria by signet ring cells may occur 
without a morphologically detectable in situ carcinoma.63, 93 It is essential that the 
location	of	biopsies	within	gastrectomy	specimens	are	specifically	reported	to	learn	
more about the distribution of early HDGC in the stomach.
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Surgical margin status must confirm that there is no residual gastric mucosa and 
tumour at the margins. However, oesophageal cardiac-type glands (presumably 
normal constituents) are diffusely scattered in the lamina propria through all 
levels of the oesophagus. The risk to develop SRCC in these glands is unknown 
but has not been reported.94 Also, metaplastic and heterotopic gastric mucosa 
can be seen elsewhere in the gastrointestinal tract. In a prophylactic gastrectomy 
series of 19 patients, 3 cases (16%) showed heterotopic gastric mucosa in the 
duodenum, and mucosal SRCC was observed in one of them (RT van der Kaaij et 
al. 2014, unpublished data). 
Background changes in the gastric mucosa of prophylactic gastrectomy 
specimens encompass mild chronic gastritis, sometimes displaying the features 
of lymphocytic gastritis. Foveolar hyperplasia and tufting of surface epithelium, 
focally with globoid change, is also a frequent finding and, in some areas, 
vacuolization of surface epithelium is very striking, however this does not seem 
to be a specific finding.28, 36, 63, 93 Intestinal metaplasia and H. pylori infection are 
absent in most prophylactic gastrectomies described to date. 
Histopathology: advanced HDGC 
Like sporadic DGC, advanced HDGC predominantly presents as linitis plastica 
with diffuse infiltration of the gastric wall. Histology can show mainly or 
exclusively signet ring cells, however, more often these tumours are composed 
of a pleomorphic neoplastic infiltrate with a small subset of or without classic 
signet ring cells (poorly cohesive carcinoma). In a minority of cases, tumour 
cells are arranged in small aggregates, sometimes rosettes or glandular-
like structures. A component of extracellular mucin may also be present, in 
which the neoplastic cells float. Although there are no specific morphological 
characteristics indicating the hereditary nature of the tumour, in situ lesions 
and pagetoid spread of signet ring cells in the surrounding normal mucosa are 
important clues to the diagnosis.
Review of gastric specimens of 103 HDGC families without germline CDH1 
mutations showed a similar morphology compared to the advanced germline 
CDH1 mutation-related carcinomas (van der Post et al. 2014, unpublished data). 
Typical in situ lesions or pagetoid spread of signet ring cells however were not 
detected in these patients.
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Histopathology: lobular breast cancer
The association of LBC and germline CDH1 mutations was first reported by 
Keller et al.95 Large series of the histopathological findings in (prophylactic) 
mastectomies of CDH1 mutation carriers are not reported. Kluijt et al. described 
bilateral widespread foci of lobular carcinoma in situ (LCIS) in prophylactic 
mastectomies of two female patients with germline CDH1 mutations.36 There 
are no unique histopathological findings reported in (prophylactic) mastectomy 
specimens that can be used to distinguish these (pre-)malignancies from 
sporadic LBCs. However, only few patients opt for prophylactic mastectomy and 
these mastectomy specimens are generally not fully embedded and examined. 
Use of immunohistochemical stains
Widely invasive DGC may be easily detected on H&E sections. The use of 
histochemical stains for neutral mucins, such as PAS-D is useful for the detection 
or confirmation of tiny intramucosal carcinomas in which the neoplastic cells 
are dispersed among preserved foveolae and glands. This should be performed 
routinely in the examination of gastric biopsies taken during endoscopy and in 
gastrectomies from HDGC patients.96 A cytokeratin stain can help to confirm 
the epithelial nature of the signet ring cells, if there is any doubt. E-cadherin 
immunoexpression can be reduced or absent in early gastric carcinomas, 
contrasting with the normal membranous E-cadherin expression in adjacent 
non-neoplastic mucosa.39, 40, 97 In pagetoid spread and in situ carcinomas, 
E-cadherin immunoexpression can also be reduced or absent.63 However 
E-cadherin expression is not always reduced or absent, this depends on the 
mutation type and specific mechanisms of inactivation of the wild-type allele.40 
In DGC of patients without germline CDH1 mutations, the expression pattern 
of E-cadherin is also often reduced or absent. Therefore, E-cadherin staining 
should not be used as a pre-screening method to select patients eligible for 
germline CDH1 mutation analysis. 
In patients that present with both LBC and DGC, either synchronously or 
metachronously, a metastasis should be considered. Two primary tumours 
may be indicative for a hereditary background, but this is not always the 
underlying reason. Metastases from these tumours are often morphologically 
indistinguishable.98 Breast-associated immunomarkers are ER, BRST-2 and/or 
mammaglobin, while CK20 and HNF4A are suggestive for GC.99, 100 
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Centres of excellence for pathological diagnosis
The pathology of HDGC is unique but not easy to recognize. Experience in this 
pathology is needed to provide high quality diagnosis, both in biopsies and in 
resection specimens. In order to increase the experience of pathologists and 
the accuracy of the diagnosis, especially of precursor lesions of HDGC, it would 
be useful to build a virtual bank of the different types of lesions observed in 
the setting of HDGC. Furthermore, the working group agreed that the use of 
(scanned) slides to be submitted for evaluation by experienced pathologists in 
the field should be seriously considered. 
It is pivotal to examine the full gastrectomy and full mastectomy specimens 
of CDH1 mutation carriers to determine the stage of cancer and additionally 
to better understand the phenotype and biology of this disease. Experience 
in the examination of prophylactic gastrectomies for HDGC is quite limited 
in most pathology departments due to the rarity of these surgical specimens. 
Additionally, the routine workload of most centres is incompatible with 
performing the detailed examination of hundreds of sections typically obtained 
after totally embedding these stomachs. In the event of a lack of pathologist 
experience in dealing with these cases, or restricted time available due to the 
pathologist’s workload and laboratory resources, the entire formalin-fixed 
gastrectomy or mastectomy specimen can be send to an experienced pathology 
laboratory. An alternative option is to totally embed the stomach or breast, 
perform H&E and PAS-D stain on all blocks and send the slides and blocks to 
an experienced centre for specialist pathology reporting. If these alternative 
strategies are not feasible, and it is not possible to totally embed the gastric 
or breast specimen, this should be communicated to clinicians and the patient. 
Furthermore, in the event of not finding foci of SRCC, the gastrectomy should 
not be reported as negative for carcinoma, but as ‘no carcinoma found in xx% of 
mucosa examined’.
Future research on molecular pathogenesis
A critical question that remains unanswered is how long early lesions of HDGC 
can remain indolent until there is emergence of clinical disease that may be 
rapidly progressive and lethal. Continuing collection of data from patients 
who opt for endoscopic surveillance is essential to help answer this question. 
Also, a thorough analysis of the mechanisms responsible for the second hit 
inactivation of CDH1 in the very early lesions of HDGC is necessary to define 
strategies for chemoprevention. 
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The molecular background of HDGC patients without CDH1 mutations remains 
to be clarified, including any specific morphological features of GC in the setting 
of other hereditary cancer syndromes. Majewski et al. reported a family with a 
germline CTNNA1 mutation presenting with multiple DGC cases and intramucosal 
signet	ring	cells.	Immunohistochemistry	of	α-E-catenin	showed	absent	staining	
in the signet ring cells, while tumours from 10 other HDGC pedigrees without 
CDH1 and CTNNA1 mutation stained positively.23 Two additional families 
have recently been described, one of which shared an immunohistochemical 
phenotype	with	 loss	 of	 α-catenin	 and	 cytoplasmic	 rather	 than	membraneous	
E-cadherin.24 This finding suggests either that the pathogenicity of CTNNA1 
mutations may be mediated through loss of E-cadherin function or that the 
cancer initiating potential of CDH1	 mutations	 is	 imparted	 through	 α-catenin	
associated pathways. More research is needed to understand the role and 
mutation detection rate of CTNNA1 mutations.
POSTSURGICAL CARE AND NUTRITION
Post-operative care
The psychological, physiological and metabolic impact of a total gastrectomy 
should not be underestimated. The physical impact of a gastrectomy is difficult 
to predict for any individual, but there is an expectation that most patients will 
return to a full and active life after their operation. Reassuringly, global quality-
of-life scores recover to pre-surgery levels at around 12 months post-operatively, 
however problems with eating, abdominal pain and reduced body image persist 
beyond this time.101 
Enhanced post-gastrectomy recovery programs are now well established. These 
programs may include pre-operative carbohydrate loading, preferably the 
avoidance of a naso-gastric tube or abdominal drain, early mobilization with 
good analgesia (epidural or local anaesthetic wound catheters), resume oral 
intake within 3-5 days, and discharge from hospital within 7-10 days. In addition, 
patients often require considerable support during the first 12 months after 
surgery. Implementation of this support will depend upon the local health care 
services and the distances required for patients to attend the centre. Specialist 
nurses and dieticians should maintain regular contact by telephone and the use 
of modern video-conferencing should be encouraged. Collection of clinical data 
in a national registry allows patients, if they choose, to contribute to HDGC 
syndrome research. 
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There are different issues related to mastectomy (prophylactic or otherwise), 
a second major surgery with a significant recovery period. Mastectomy has a 
different impact concerning self-image, self-esteem, physical appearance and 
loss of feminine identity. Therefore a team of dieticians, physiotherapist and 
psychologist should be available for optimal physical and socio-emotional 
recovery during post-operative care of both gastrectomy and mastectomy.
Nutrition
The main adjustments with regards to diet and nutrition post-gastrectomy have 
to do with: (1) maintaining weight; (2) ensuring adequate fluid, nutritional and 
caloric intake, and (3) behavioural modifications surrounding eating. Experienced 
dieticians focus on nutritional problems and strategies for maintaining weight 
after surgery, while patients focus on lifestyle changes. Patients are often 
discouraged by weight loss. The median weight loss one year post-surgery is 
10 kg.101 This means that patients who are underweight pre-operatively or who 
have a history of eating disorders need very careful counselling and support. 
Anatomical changes can make the act of eating difficult, and patients may 
become disappointed by these hurdles. This can further complicate weight 
management with the psychological burden of eating. In the early stages of 
recovery, intentional eating, drinking, management of symptoms and resting 
can quickly become draining. It is important for patients to have realistic 
expectations for their progress and improvement over time. Common post-
surgical symptoms, risks and treatment options are listed in Table 2.
Following a prophylactic gastrectomy, patients initially have to eat frequent 
small meals. Eating too much and/or too quickly will cause abdominal pain. 
Dumping syndrome is a group of symptoms commonly experienced as a result 
of altered gut anatomy following gastrectomy, caused by rapid entry of food 
into the small intestine at an earlier stage of digestion. This leads to a shift of 
fluid from the bloodstream to the small intestine to aid in digestion, and may 
lead to cardiovascular and abdominal symptoms. Late dumping is caused by 
a rapid rise and subsequent decrease in blood sugar levels by delayed insulin 
secretion. After gastrectomy, food moves rapidly and directly into the small 
intestine, where it digests faster. Also, the pancreas produces more insulin in 
a short time. This excessive insulin production allows for a rapid decrease in 
the blood sugar.107 These symptoms may be more common in the immediate 
post-operative period and often subside over time. Dumping syndrome can be 
minimized or eliminated through dietary choices and modified eating habits, 
adequate adjustments are unique from patient to patient. With time, however, 
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these symptoms tend to improve.101 Other problems may include lactose 
intolerance, steatorrhoea, small bowel bacterial overgrowth, anastomotic 
strictures and postprandial fullness.108, 109 Patients should be warned that their 
tolerance to alcohol will reduce after gastrectomy and that absorption of some 
medications can be affected. 
Table 2. Post-gastrectomy symptoms and treatment options
Symptoms Treatment
Early dumping (15-30 min after eating) Modification of diet and eating habits 
Late dumping (1.5-3 hrs after eating) Modification of diet and eating habits 
Lactose intolerance Diet modifications, supplementation with lactase enzymes
Fat malabsorption Pancreatic enzyme replacement may be necessary, especially fats and fat-soluble 
vitamins such as vitamin D 102
Small bowel bacterial overgrowth/ Blind 
loop syndrome
Antibiotics, sometimes surgery
Dysphagia and anastomotic strictures Modification of eating habits (more deliberate mastication and smaller bites)
Upper endoscopy with balloon dilatation to widen the stricture
Sometimes post-surgical intervention
Changing response to usage of alcohol Alertness physician and patient
Absorption of medication can be affected Alertness physician and patient
Monitoring deficiencies of iron, vitamin 
B12, folate, and trace elements
Supplementing of vitamin B12 and/or folate.103-105 Intravenous iron infusions may 
become necessary if individuals are unable to tolerate iron orally, unable to absorb 
sufficient iron through the gut, or require rapid increase in iron levels to avoid other 
health complications or a blood transfusion.
Hypocalcaemia, osteoporosis, osteopenia 
and osteomalacia
Calcium and Vitamin D are required to reduce risk of bone disease. When levels cannot 
be maintained through consumption of calcium-rich foods, supplements such as 
vitamin D, calcium carbonate, calcium phosphate and calcium citrate can be used. 
Calcium citrate does not require acid for absorption, making it a strong choice of 
supplement.106
Bile reflux (due to the absence of the 
gastroesophageal valve)
Type of surgical procedure (appropriate length of the Roux limb) reduces the 
occurrence of bile reflux. 
Use of wedge pillow for sleeping
Limiting oral intake to 2-3 hours before going to bed.
As a result of malabsorption, post-gastrectomy patients are at risk for nutritional 
deficiencies.	Monitoring	of	nutritional	levels	in	post-surgical	follow-up	is	essential,	
as	deficiencies	increase	risk	for	other	symptoms	and	health	concerns.	All	patients	
require lifelong vitamin B12 supplementation (either oral, subcutaneous or 
intramuscularly)	 to	 correct	 identified	 deficiencies,	 and	 close	 monitoring	 for	
conditions	 such	 as	 iron	 deficiency,	 anaemia,	 hypocalcaemia,	 osteoporosis	 and	
trace	element	deficiencies.	Many	dieticians	recommend	patients	to	take	a	daily	
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multi-vitamin preparation with iron, however it remains important to monitor 
iron levels since absorption will change after gastrectomy. While these are the 
most	commonly	reported	symptoms,	attention	should	be	paid	to	any	significant	
and prolonged changes, such as hair loss or extreme fatigue. These symptoms 
and changes away from the patient’s baseline may be indicative of nutritional 
deficiencies,	which	may	need	to	be	identified	and	treated.
Patients should consult a dietician prior to surgery, as an awareness of baseline 
nutritional status and dietary habits will benefit the patient in post-surgical 
nutrition, diet, and weight management. While there are some basic dietary 
principles that apply to most gastrectomy patients, there are no absolute 
rules. Each patient’s recovery is unique, from food and quantity tolerances, to 
comfortable eating habits. Variability is observed between patients, but also for 
individual patients during the course of their recovery. The most notable changes 
occur within the first year, however deficiencies should be carefully followed 
since they can also develop over years. Patients are encouraged to continue to 
experiment and discover what is best suited to their needs and tolerances. 
Further studies are needed to elucidate the relationship in post-gastrectomy 
patients between diet, nutrition, drug absorption, changes in body composition 
and the direct impact on quality of life, both in the short and long term. 
PATIENT ADVOCACY AND THE NEXT STEPS IN 
PATIENT CARE AND HDGC RESEARCH
In patients’ experience, the process that HDGC families go through to find local 
medical care providers with experience with HDGC is frustrating. Faced with the 
lack of universal expertise, patients and advocacy groups have started working 
together to locate local care providers with expertise, or facilitate connecting 
local care providers with experts at globally-recognized multidisciplinary 
centres of excellence. Medical expertise in HDGC has to continue to grow and 
this expertise has to be communicated within the medical community, such that 
support structures for HDGC patients will become more easily accessible and 
established within existing medical systems.
Given the rare nature of HDGC, there is currently no singular global expertise 
portal for genetic counselling, psychosocial support, gastroenterology, surgery, 
pathology and post-surgery follow-up for HDGC families. The geography of 
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existing expertise centres does not nearly cover broadly enough the areas where 
these resources are needed. With the emerging trend towards telemedicine, and 
the development of various patient advocacy groups, notably, “No Stomach For 
Cancer”110, “DeGregorio Family Foundation for Stomach and Esophageal Cancer 
Research”111 in the United States, and “Stichting CDH1”112 in the Netherlands, we 
see the potential for collaboration between patients, medical professionals and 
patient advocacy groups to the end of empowering patients by directing and 
connecting them with the appropriate resources and expert opinions. 
Author footnote
These guidelines are the result of consensus statements agreed during the eighth 
workshop of the International Gastric Cancer Linkage Consortium (IGCLC) held 
on 19-21 March 2014 at the Radboud university medical center in Nijmegen, the 
Netherlands.
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SUPPLEMENTARY FILES
Supplementary Figure 1. Mimickers of signet ring cells
(A) Vacuolization of superficial epithelium; (B) Globoid cells in hyperplastic epithelium; (C) “Signet 
cell change”: in ischemic columnar mucosa, cells can lose their cohesion, displace into the lumen of 
glands and resemble signet ring cells; (D) Clear/ glassy cell changes: the cytoplasm displays a glassy 
vacuole that is PAS negative; (E) Cells with clear changes, probably regenerative changes; (F) Clear 
mucous neck cells in the neck region; (G) Detached cells that resemble signet ring cells, probably due 
to fixation effect; (H) Capillaries; (I) Xanthoma. 
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Supplementary protocol 1. Endoscopy protocol for HDGC
1. Annual endoscopy is recommended ideally in a centre with an interest and 
experience in HDGC.
2. Endoscopy to be performed using high definition zoom gastroscope and 
use of mucolytics such as N-acetylcysteine is encouraged to obtain good 
visualization.
3. Inspect and photograph the entire gastric mucosa paying particular 
attention to any focal lesions. 
4. Clinical biopsies:
- Take antral biopsy for rapid urease breath test (CLO-test) or for 
(immuno-)histochemical analysis at first surveillance endoscopy 
for H. pylori status.
- Biopsy focal lesions for clinical histopathology and record the 
anatomical position of any lesion (see below). 
- Regardless of targeted biopsies taken now proceed to biopsy each 
gastric anatomical area in turn, taking five samples from each area: 
a. Prepyloric area
b. Antrum
c. Transitional zone
d. Body
e. Fundus
f. Cardia
Total: approximately 30 biopsies
5.  Research biopsies: provided that the patient has given informed consent an 
additional biopsy should be taken from focal lesions and each anatomical area.
Endoscopic evaluation of new modalities such as trimodal imaging or confocal 
microendoscopy should be done in the context of a research protocol.
Routine Clinical Biopsy processing:
1. Record position of biopsy by anatomical area and cross sectional circumference 
(by dividing circumference into four equal parts: lesser curve, greater curve, 
anterior wall, posterior wall) and give distance in cm from the teeth e.g. 
gastric body, greater curve at 50 cm.
2. All clinical specimens from each anatomical area should be separately labelled 
and sent to the histopathology laboratory with clinical information stating 
that this is a screening procedure to look for microscopic foci of signet ring 
cells	in	a	patient	that	fulfils	the	IGCLC	criteria	for	HDGC.
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Supplementary protocol 2. Protocol and reporting of CDH1 
mutation-related gastrectomy specimens
Macroscopic examination and sampling of prophylactic gastrectomies should 
follow	 specific	 protocols.	 After	 painting	 the	 margins	 or	 removing	 the	 margins	
before	fixation,	dissection	of	 the	omentum	and	 retrieval	of	 lymph	nodes,	 fresh	
gastrectomy specimens should be opened along the greater curve and pinned onto 
a cork board. A life size specimen photo should be used as a template to identify 
the exact location of the tissue blocks. The collection of fresh tissue samples 
from any macroscopic lesion and normal looking mucosa should be considered 
for	 research	purposes.	Overnight	fixation	 in	buffered	 formalin	 is	 recommended	
before sampling for routine histopathology, including any macroscopically 
abnormal areas such as pale lesions. Sections of the margins should be taken 
(and labelled) and the remainder of the stomach should be sectioned completely 
(each	 section	 2	 cm	 x	 0.3	 cm,	 full	 thickness)	 and	 blocked	 (paraffin	 embedded).	
The location of each section should be marked on the map of the stomach. Any 
macroscopic	lesions	identified	should	be	precisely	localized	within	the	map.	This	
method usually results in 200-300 tissue blocks per stomach. An alternative is to 
use an adaptive version of the Swiss roll technique.1 However, in case a carcinoma 
of	>T1a	is	discovered	unexpectedly,	this	option	is	suboptimal	as	it	may	be	difficult	
to localize the remainder of the tumour or it may be lost in the processing. Another 
technique is to use giant histological sections with the whole-mount technique, 
also called large-format histology. This method will save time and blocks, as each 
stomach is represented in approximately 25 blocks. The histological examination 
should be made using a checklist focusing on the items listed in Table 2.
REFERENCE
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ABSTRACT 
The aim of this study was to determine the yield of endoscopic screening in 
first-degree relatives (FDR) of CDH1-negative hereditary diffuse gastric cancer 
(HDGC) patients. 
Retrospective observational cohort study. In two expert centers in the 
Netherlands data were collected on FDR from families fulfilling the international 
HDGC criteria that underwent endoscopic screening. Extensive inspection of 
the stomach was performed by gastroscopy, taking random and/or targeted 
stomach biopsies to identify diffuse-type gastric cancer. 
Between 2004 and 2016, 90 persons (40% men, mean age 48 years) from 40 
families were offered endoscopic screening. The mean number of endoscopies 
per person was three. The mean follow-up time was 46 months and mean 
endoscopic interval was 20 months. Signet ring cell carcinoma foci restricted 
to the mucosa (pT1a) were identified in four persons (4%) from one family, 
which afterwards was diagnosed with a germline CTNNA1 mutation. Advanced 
poorly cohesive gastric carcinoma was diagnosed in one person of another 
family. Intestinal metaplasia was diagnosed in 38 persons (42%) and low-grade 
dysplasia in four persons (4%). Additionally, in 40 persons (44%) scar tissue was 
observed in the gastric mucosa, which can hinder the endoscopic detection of 
small white lesions typical for HDGC.
Endoscopic screening in HDGC families without a pathogenic CDH1 mutation may 
be reasonable, as we detected signet ring cell carcinomas in 6% of persons screened. 
However, the criteria and frequency of screening may have to be reconsidered.
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INTRODUCTION
Comparable to other Western countries, the incidence of non-cardia gastric 
cancer has markedly declined in the Netherlands during the last decades.1, 2 In 
particular, the incidence of intestinal-type gastric cancer (IGC) has decreased, 
but	the	incidence	of	diffuse-type	gastric	cancer	(DGC)	seems	to	be	increasing.3-6 
Especially younger gastric cancer patients are more often diagnosed with DGC.7-9
IGC can largely be attributed to Helicobacter pylori infections in a genetically 
susceptible host according to the Correa sequence,10 but the pathogenesis of 
DGC is less well understood. It has been suggested that H. pylori plays a role 
in the development of DGC as well.11, 12 In DGC genetic variations may play an 
important role. However, recent exome sequencing studies in families that fulfill 
criteria of hereditary diffuse gastric cancer (HDGC) failed to identify monogenic 
causes in most of the families (I.P. Vogelaar et al, 2016 submitted).13 Mainly 
pathogenic CDH1 mutations, causing a dysfunction in the adhesion molecule 
E-cadherin, are found in a select group of HDGC families.13, 14
Individuals with heterozygous CDH1 mutations have a high cumulative risk of up 
to 70% to develop DGC.13 As DGC develops from small mucosal foci of signet ring 
cells with a diffuse scattered growth pattern, it can be difficult to detect DGC 
by endoscopy, even in advanced stage. Therefore prophylactic gastrectomy is 
offered to individuals with confirmed pathogenic CDH1 mutations. Depending 
on personal circumstances and preferences, some patients opt for annual 
endoscopic surveillance according to the Cambridge protocol.15 Surveillance 
studies have shown that small, pale, non-elevated lesions can represent early-
stage DGC, histologically showing signet ring cells within the lamina propria.15, 
16 However, these lesions can be difficult to detect as becomes apparent from 
the observation that even in experienced hands, endoscopy often reveals no 
abnormalities or only a few pale lesions, while resection specimens show tens to 
hundreds of small signet ring cell carcinomas (SRCCs).17-20 
More than 70% of HDGC probably cannot be attributed to a germline CDH1 
mutation.13, 21, 22 The risk to develop DGC for these families is unknown, but is 
presumably lower than reported in CDH1 families. Little is known about the 
outcomes of screening in first-degree relatives (FDR) of patients who fulfill 
HDGC criteria but tested negative for pathogenic CDH1 gene mutations. 
Although evidence is lacking, the HDGC consensus guideline suggests annual 
endoscopic screening for first degree relatives of patients fulfilling HDGC criteria 
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but without a detectable genetic defect.15 In the current study, we describe the 
outcomes of endoscopies in FDR from HDGC families without a pathogenic 
germline CDH1 mutation. The primary endpoint was the endoscopic yield of 
microscopic early-stage DGC.
METHODS
Study population
This study, conducted by the Netherlands Cancer Institute/ Antoni van 
Leeuwenhoek (NKI/AVL) and Radboud university medical center, is a 
retrospective observational cohort study. All clinicopathological data were 
collected from medical records and anonymously stored in a combined 
database, from persons who underwent endoscopic gastric screening between 
March 2004 and September 2016. Persons above age 18 who were FDR of an 
affected person in a family fulfilling the updated HDGC criteria of 2015 were 
included (Table 1).15 
Families were only included if genetic counseling had been performed. Family 
pedigrees of at least three generations were analyzed for the number of affected 
family members with gastric cancer and other malignancies. Germline CDH1 
mutation analysis was performed in the affected patient with gastric cancer 
(index patient). When DNA of an affected patient was not available, one or more 
relatives were tested to exclude a pathogenic germline CDH1 mutation. Testing 
for other gene mutations, including TP53, MMR genes, PTEN, BRCA1/2, STK11, 
SMAD4 and BMPR1a was performed when the family met the criteria for testing 
of that specific cancer syndrome according to the national and international 
guidelines.15, 23, 24 The original histopathological reports from patients with 
gastric cancer were reviewed to confirm the diagnosis of DGC.
Information of persons was collected on age at endoscopy, number of 
endoscopies, prior malignancies, prior infection with Helicobacter pylori, 
endoscopic abnormalities, endoscopic signs of scar formation, histopathological 
findings of gastritis, H. pylori infection, atrophy, intestinal metaplasia, dysplasia 
and carcinoma. All persons in both centers were informed about the current 
screening guideline, the lack of evidence for endoscopic screening and its 
procedural related risk. All persons gave their informed consent.
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Table 1. Baseline characteristics of 90 persons who underwent gastroduodenoscopy
Persons (families) 90 (40)
Men (%) 36 (40)
Women (%) 54 (60)
Total number of endoscopies 285
Mean interval between endoscopies in months (SD; range)* 20 (17; 7-129)
Mean follow-up time in months (SD; range)* 46 (40; 9-146)
Mean number of endoscopies per person (SD; range) 3 (3; 1-12)
Mean number of biopsies (range)** 27 (0-52)
Mean number of random biopies (range)*** 25 (3-46)
Mean number of targeted biopsies (range)**** 5 (1-24)
Number of endoscopies with at least 25 biopsies of 5 anatomic areas 157 (55%)
Mean age during the first endoscopy in years (SD; range) 48 (13; 22-72)
HDGC criteria 201025: number of persons (families) 59 (30)
Three or more first- or second-degree family members with a diagnosis of DGC independent of age 7 (4)
Two or more cases of gastric cancer in first- or second-degree relatives, one confirmed DGC before 
the age of 50 years
26 (13)
Individual with DGC diagnosed before the age of 40 years 25 (12)
Combination of DGC and LBC in first- or second-degree relatives, one diagnosed before the age of 
50 years
1 (1)
Not fulfilling HDGC criteria 2010 31 (10)
HDGC criteria 201515: number of persons (families) 90 (40)
Two or more cases of gastric cancer in first- or second-degree relatives, one confirmed DGC 
independent of age
64 (27)
Individual with DGC diagnosed before the age of 40 years 25 (12)
Combination of DGC and LBC in first- or second-degree relatives, one diagnosed before the age of 
50 years
1 (1)
Abbreviations: SD = standard deviation; HDGC = hereditary diffuse gastric cancer; DGC = diffuse 
gastric cancer; LBC = lobular breast cancer
*Included are 69 persons (21 persons had only 1 endoscopy and no follow-up), **Included are 
all endoscopies (in 2 no biopsies were taken), ***Included are 270 endoscopies (in 15 no random 
biopsies were taken), ****Included are 188 endoscopies (in 97 no targeted biopsies were taken)
Endoscopic screening protocol 
In NKI/AVL an endoscopic screening program for persons at risk for the 
development of DGC started in 2004. In the Radboud university medical center 
the endoscopic screening protocol started from 2010 onwards. Endoscopy 
was performed under conscious sedation with midazolam or propofol. From 
November 2008 onwards, following the first International Gastric Cancer 
Linkage Consortium (IGCLC) consensus meeting, gastroscopies were performed 
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in line with to the consensus protocol.25 During at least 30 minutes, the gastric 
mucosa was thoroughly inspected, searching for lesions which might be typical 
for early diffuse gastric cancer. A biopsy was taken from each aberrant mucosal 
lesion. Additionally, multiple random biopsies were taken from each of the 
following anatomical regions of the stomach: antrum, transitional zone, body, 
fundus and cardia. Although there was no strict screening protocol before 2008, 
all gastroscopies were performed with thorough inspection, often with both 
targeted as well as random biopsies from the gastric mucosa. 
The endoscopic screening in NKI/AVL and in the Radboud university medical 
center was performed or supervised by one of three gastroenterologists (AC, 
JvD, TB) with experience in HDGC. In NKI/AVL a white light high definition 
endoscope with narrow band imaging (Olympus GIF-H180/GIF-H190) was used 
from 2008. In the Radboud university medical center Pentax 3.2 EG29-i10 with 
iscan modality was used from 2014. Before that period Olympus 160-series 
endoscopes were used in both centers. Although the protocol does not describe 
screening with narrow band imaging, it was used extensively in our centers as it 
facilitates visualization of the gastric pit structure and the typical white lesions 
that during the course of the study were to represent signet ring cell foci. 
Persons were included if they underwent at least one screening gastroscopy 
with more than ten random biopsies from at least four anatomical regions. 
Endoscopies were included if the goal of the gastroscopy was screening. 
Endoscopies for evaluation of complaints or interval endoscopies for follow-up 
of dysplasia or cancer were noted but excluded from the analysis.
Histological sampling and examination of biopsies of gastric 
mucosa
The primary outcome measure was the endoscopic yield of microscopic early-
stage DGC (including mucosal signet ring cell foci). Other lesions that are 
associated with (especially intestinal-type) gastric cancer such as atrophic 
gastritis, intestinal metaplasia and dysplasia, are considered secondary findings, 
since the relationship of these lesions and DGC is not clear. Experienced 
pathologists analyzed all gastric biopsies. Biopsies were examined using 
standard stains: Haematoxylin and Eosin (H&E) and PAS-diastase (mucin-stain). 
Additional (immuno-)histochemical stains were used in case of gastritis for the 
detection of H. pylori or to detect or confirm another specific diagnosis. 
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RESULTS
Baseline characteristics
Between March 2004 and September 2016, 90 persons from 40 families fulfilling 
the 2015 HDGC criteria underwent endoscopic screening of the stomach. 
The baseline characteristics, including number of persons and family per 
HDGC criterion, are shown in table 1 and supplementary table 1. In total, 285 
endoscopies were performed during the 12,5 years of the study of which 52 
before November 2008. Forty percent of the persons were men. The mean age 
(during the first endoscopy of each person) was 48 years (SD 12.9, range 22-
72 years). One to 18 family members were screened per family. In 75 persons 
(83%) at least 25 random biopsies of 5 gastric regions were taken during at least 
one endoscopy, in the other 15 persons more than 10 random biopsies were 
taken of at least 4 anatomic regions. Twenty-one persons underwent only one 
endoscopy, 30 underwent two endoscopies and 39 persons had three or more 
endoscopies. The mean endoscopic interval for persons receiving more than 
one endoscopy was 20 months and mean follow-up time was 46 months. None 
of the persons had a known medical history of gastric dysplasia or malignancy. 
Germline pathogenic CDH1 mutation was excluded in all families, in 32 families 
by testing the diffuse gastric cancer (index) patient, and in eight families by 
testing one or more family members of the index patient because no genetic 
material was available of the index patient. 
Yield of the screening program (Table 2, 3; Figure 1)
DGC	was	detected	in	five	persons,	all	cases	were	stage	I.	 In	one	person	a	highly	
suspicious tumor in the gastric body was detected during endoscopy, in the other 
persons	the	finding	of	DGC	was	found	in	random	biopsies.	Well-defined	small	pale	
lesions that can represent small SRC foci, as described in CDH1 mutation carriers, 
were not found. The most advanced tumor was detected in a woman of 51 years 
(H190	endoscope).	She	was	first	screened	at	age	44	and	Barrett’s	mucosa	with	high-
grade dysplasia was detected in the distal esophagus. After ablative treatment of 
the Barrett’s esophagus, followed by seven years without endoscopic screening, a 
non-symptomatic tumor of 2 cm was found in the greater curvature of the body of 
the	stomach	which	was	confirmed	DGC	histologically.	After	treatment	with	neo-
adjuvant	chemotherapy,	 the	 resection	specimen	showed	a	diffuse	carcinoma	 in	
the body of the stomach of 7 cm, growing into the peritoneal surface with omental 
metastases (ypT4aN0M1 DGC). Four siblings were previously diagnosed with 
advanced	 DGC	 (diffuse-type	 histology	 was	 reviewed	 and	 confirmed).	Germline	
CTNNA1 mutation was excluded in two siblings with DGC using Sanger sequencing.
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Table 2. Biopsies with diffuse gastric cancer, dysplasia and intestinal metaplasia
  Families (%) Persons (%) Endoscopies (%) Biopsies (%) Random biopsies (%) Targeted biopsies (%)
Total 40 (100) 90 (100) 285 (100) 7751 (100) 6825 (100) 926 (100)
Diffuse gastric cancer 2 (5) 5 (6) 7 (2) 27 (0.3) 7 (0.1) 20 (2)
Dysplasia 3 (8) 4 (4) 4 (1) 5 (0.06) 2 (0.03) 3 (0.3)
Intestinal metaplasia 21 (53) 38 (42) 84 (29) 302 (4) 212 (3) 90 (10)
Table 3. Outcomes of endoscopies per anatomic location
  Diagnose Pylorus Antrum Transitional zone Body Fundus Cardia Total#
Random Diffuse gastric cancer 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 4 (2) 7 (4)
  Dysplasia 0 (0) 2 (2) *** 0 (0) 0 (0) 0 (0) 0 (0) 2 (2)
  Intestinal metaplasia 4 (4) 65 (26) 23 (10) 19 (6) 3 (3) 14 (9) 70 (29)
  Total 2 (2) 265 (90) 263 (90) 267 (90) 206 (87) 256 (88) 270 (90)
                 
Targeted Diffuse gastric cancer 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 1 (1)
  Dysplasia 0 (0) 0 (0) 2 (1) 0 (0) 1 (1) 0 (0) 2 (2)
  Intestinal metaplasia 10 (9) 27 (17) 14 (8) 13 (7) 3 (3) 7 (4) 38 (25)
  Total 26 (19) 79 (47) 75 (48) 93 (49) 40 (29) 25 (18) 188 (82)
n (N) = endoscopies (in N persons)
In four other persons, mucosal foci (pT1a) of signet ring cell carcinoma (SRCC) 
were diagnosed. The first case was a 75 year old man. SRCC was found in the 
fundus with random biopsies without visible lesions (H180 endoscope) in 
2010. Three earlier (2004-2008) and five later (2011-2015) gastroscopies with 
H180 and H190 endoscopes with biopsies did not reveal abnormalities in this 
patient. In the second case, a 42 year old male, random biopsies from the 
cardia showed SRCC foci in 2005 and 2006 (a second and third screening). 
No visible lesions were seen (GIF Q160 scope). No endoscopic or histologic 
abnormalities were found in two following gastroscopies. In 2010 again SRCC 
was found in the cardia without endoscopic visible lesions (H180 endoscope). 
Gastrectomy was performed afterwards. Multiple T1a SRCC foci were found in 
the resection specimen. Two other men of 40 and 41 years old underwent their 
first gastroscopy in 2010 (H180 endoscope). No endoscopic lesions were found, 
but random biopsies revealed SRCC foci, in the fundus in one and in fundus and 
cardia in the second. In both men gastrectomy was performed and multiple T1a 
SRCC foci were found in both gastrectomy specimens. 
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These four persons with SRCC foci belonged to one family (in which a total of 18 
members were screened). The persons in this family were included because of 
the first HDGC criterion (families with two or more patients with gastric cancer 
at any age, one confirmed DGC). In an additional family member of this specific 
family there was, next to intestinal metaplasia, a single atypical gland suspicious 
for in-situ signet ring cell carcinoma. However, more extensive abnormalities 
could not be confirmed in six follow-up endoscopies during the next five years. 
The findings in this family led to exome sequencing which revealed a mutation 
in the CTNNA1 gene, encoding the alpha-E-catenin molecule.26 In none of the 
other 38 families gastric malignancies were detected. 
Low-grade dysplasia was diagnosed in four persons (4%) of whom two belonged 
to the same family in which a pathogenic CTNNA1 mutation was detected. In the 
first person (man, 63 years) low-grade dysplasia was found in a random biopsy 
in the antrum (2005, GIF Q160 scope). In the second person (woman, 64 years) 
there was a small elevation in the fundus, which was diagnosed histologically 
as a tubulovillous adenoma with low-grade dysplasia (2014, H180 endoscope). 
Later analysis showed the man was carrier of the CTNNA1 mutation, whereas the 
woman was not. In a third person (man, 47 years) the transitional zone showed 
a patchy aspect endoscopically which histologically was diagnosed as extensive 
intestinal metaplasia and low-grade dysplasia within a background of chronic 
inflammation (2014, EG29-i10 endoscope). In the fourth person (man, 62 years) 
erosive lesions were found in the antrum, which was microscopically diagnosed 
as extensive intestinal metaplasia with low grade dysplasia (2013, EG29-i10 
endoscope). In the last person low-grade dysplasia was diagnosed again in 
biopsies in a second endoscopy after three months. Follow-up endoscopies in 
the following three years did not show dysplasia. In the other three persons, 
low-grade dysplasia was detected only once and was not diagnosed during 
follow-up endoscopies and biopsies (follow-up 1.5, 3 and 10 years). 
Intestinal metaplasia was diagnosed in 84 of the 285 endoscopies performed 
(29%). The biopsies with intestinal metaplasia belonged to 38 persons (42%) 
with a mean age at diagnosis of 52 (SD 12.5, range 30-76 years). Intestinal 
metaplasia was isolated to the distal region (antrum/ pylorus/ transitional zone) 
of the stomach in 63%. Intestinal metaplasia was found in 29% multifocal, in 
3% proximal (cardia) and in 5% in the gastric fundus and/or body. Non-specific 
chronic inflammation was the most common abnormality of the gastric mucosa 
in all persons (60 persons, 67%). Twenty-two persons had signs of active gastritis 
(24%) with histologically H. pylori inflammation in seven cases. An additional 10 
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persons had had H. pylori inflammation before screening started, nine of these 
patients also developed intestinal metaplasia. Furthermore, subtle endoscopic 
scar formation of the gastric mucosa, identified during follow-up after the first 
endoscopy was observed in 39 persons (43%) and in one person during the first 
endoscopy. Biopsies of 82 endoscopies (29%) did not show any abnormality (no 
inflammation, atrophy, intestinal metaplasia, scar formation, polyps, dysplasia 
or carcinoma). 
No serious adverse events were reported in medical charts after endoscopy.
DISCUSSION
During a period of 12,5 years, 90 persons from 40 HDGC families without germline 
CDH1 mutations were endoscopically screened. In this endoscopic screening 
program attention is paid to early-stage diffuse gastric cancer, namely mucosal 
SRCC in biopsies, which may be seen as small pale lesions during endoscopy as 
was learned from screening in CDH1 mutation carriers. SRCC foci (pT1a) were 
found in random biopsies of four persons from one family in which additional 
genetic analysis revealed a germline CTNNA1 mutation in all four.26 In a patient 
from another family advanced DGC was found during the screening program. In 
none of the other 38 families gastric cancer was detected. 
Due to the very focal nature of small mucosal signet ring cell carcinomas, the 
endoscopic detection is extremely difficult, as was demonstrated before even in 
patients with a very high chance of having SRCC foci.27, 28 Therefore endoscopic 
surveillance is not accepted as a safe alternative for prophylactic gastrectomy in 
individuals with a proven pathogenic CDH1 mutation. Our study highlights the 
diagnostic difficulties in individuals without a known germline mutation, and 
therefore unknown risk, when an advise on prophylactic gastrectomy cannot 
be given. In some patients in this study after the first positive random biopsy, 
follow-up biopsies were negative, to become positive again in subsequent 
endoscopies. No mucosal abnormalities were visualized in these patients during 
endoscopy. Possibly, the evolutions of the quality of endoscopes, the increasing 
resolution and the availability of NBI increases the visualisation of subtle lesions 
as the authors of this paper experience in the surveillance of individuals with a 
germline CDH1 mutation (unpublished data). However, in the current study we 
could not confirm this. One could argue that a limitation of this study is that, 
due to the long timeframe with long follow-up, different quality of endoscopes 
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have been used. However, subtle lesions could not be visualised in screening 
with both older and newer generation endoscopes, even in the knowledge of 
biopsy proven SRCC. This finding suggests that currently endoscopy alone 
without random biopsies is not sensitive enough as a screening modality in our 
study population. 
The HDGC criteria were principally set up to select families for genetic CDH1 
testing and were recently broadened to test more families for this devastating 
syndrome.15 It is not clear whether these CDH1 testing criteria make sense as 
endoscopic screening criteria as well, when families are proven CDH1 negative. 
In only 0.3% of the 7732 biopsies in this study invasive carcinoma was found. 
However, when we take into account the number of persons and number of 
families enrolled, the yield of cancer is considerable, i.e. 6% and 5% respectively. 
Especially when we bear in mind that in this heterogeneous HDGC study group 
far less than 50% of persons screened are at increased gastric cancer risk. 
Kim et al. developed an algorithm for gastroscopic screening in the United States 
in which they propose screening of all individuals with a FDR with a diagnosis of 
gastric cancer. They recommend to start screening 10 years before the age at 
diagnosis in the FDR or at age 50 (whatever comes first).29 It is a very topical 
matter of debate when a screening program is considered useful. Recently, 
Harris et al. suggested the “balance-approach” to evaluate the usefulness of 
screening.30 Screening should only be considered if there is evidence that the 
magnitude of health benefit outweighs the magnitude of harm and this net 
benefit justifies the required use of resources. For well-established screening 
programs such as colorectal cancer screening, all these criteria are met. For 
HDGC screening, this balance is questionable. 
The current study is the largest cohort study on individuals at risk for DGC 
described thus far. However, the numbers presented are still too small and 
follow-up is too short to calculate an accurate life time risk for FDR of CDH1-
negative DGC patients fulfilling HDGC criteria. Lim et al. described screening 
in seven persons fulfilling HDGC criteria without CDH1 mutations and found 
SRCC foci in two of seven persons (28%).17 For a more accurate risk calculation 
for the development of DGC in non-CDH1 HDGC families, larger studies with 
long follow-up are needed. Besides large cohort follow-up, our suggestion for 
future research would be to also use existing large genealogy databases. Several 
Scandinavian countries, Australia31 and the state of Utah in the US32 have 
genealogy databases that include large numbers of people. These databases 
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could be linked to cancer registries and hospital data to identify families with 
HDGC and determine risk in family members. 
Interestingly, biopsies in this cohort revealed a much higher incidence of 
dysplasia (4%) and intestinal metaplasia (42%) than generally reported in 
the Netherlands. Both are associated with H. pylori infection and thought to 
be a risk factor in the development of gastric cancer, especially IGC.33-36 Den 
Hoed et al. investigated the prevalence of premalignant gastric lesions in 383 
asymptomatic patients (without a family history of gastric cancer) by taking two 
biopsies from the antrum and two from the body.37 Dysplasia was found in 1.4% 
of subjects. They found intestinal metaplasia in 7% of subjects, increasing to 
13% in the age group 60-70 years.37 H. pylori infection was demonstrated in 22% 
of persons in their study and is in line with our results (19%). Our high frequency 
of dysplasia and intestinal metaplasia may be influenced by a more extensive 
inspection and biopsy protocol; a 30-biopsy protocol has, to our knowledge, 
not been described in a healthy control group of persons without a family 
history of gastric cancer. Another possibility is that gastric cancer in families 
without a confirmed monogenic cause is pathophysiologically different, more 
heterogenic, kind of cancer.
In the 285 endoscopies performed in this study no serious adverse events 
happened and although gastroscopy is not without complications risks, it is 
a relatively safe procedure. We report scar formation of gastric mucosa in 40 
participants (44%), appearing endoscopically as small pale lesions. As first 
described by Shaw et al. in 2005, foci of SRCC can also appear as small pale 
lesions.16 This may mimic scars endoscopically, however microscopically this does 
not pose a diagnostic dilemma. In our analysis some participants underwent up 
to 12 endoscopies with on average 25 random plus additional targeted biopsies 
per endoscopy. Except for one, no scars were found at baseline endoscopies, 
suggesting that scars were mostly induced by prior gastric biopsies. Although 
the shape of the lesion often suggests that it is a scar rather than a SRCC focus, 
these scars may hinder endoscopic screening. Also, it is unknown if taking 
biopsies from the gastric mucosa and thereby inducing inflammatory responses 
with release of cytokines, influences carcinogenic pathways in this population. 
On the other hand, four SRCCs in this study were found because of random 
biopsies and not because of visible lesions, indicating that random biopsies 
cannot be omitted in screening. Two of the four individuals with SRCC foci were 
diagnosed at the first screening endoscopy.
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In summary, this study presents the largest cohort of gastroscopy screening 
of a well-defined group at risk of HDGC. In these first-degree relatives from 
HDGC patients without a germline mutation in CDH1, endoscopic screening 
with extensive biopsy collection resulted in the identification of DGC in 6% of 
asymptomatic persons. Screening may therefore be justified in this population, 
although adjustments in the endoscopic interval and stricter inclusion criteria 
for the screening program could be considered. 
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Histopathological characteristics of hereditary gastric 
adenocarcinoma 
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ABSTRACT
We investigated histopathological characteristics of gastric cancer in patients 
with a hereditary cancer syndrome and the role of immunohistochemistry to 
define these cases. 
Morphological characteristics were assessed in patients with gastric carcinoma 
and a germline CDH1 mutation (n= 27), Lynch syndrome (n= 29) or with early-
onset or positive family history without a known germline mutation (n= 122). In 
a subset, sequential immunohistochemistry (seqIHC) was performed by using 
four different E-cadherin antibody clones. In Lynch syndrome gastric cancer 
cases microsatellite instability and/or expression of mismatch repair proteins 
were examined. 
Exclusively in CDH1 germline mutation-related gastric cancer cases, precursor 
lesions in surrounding normal tissue can be detected. Although >95% of CDH1-
associated tumors had presented with focal signet ring cell morphology, only 
22% were predominantly of the signet-ring cell type. In fact these tumors 
were quite heterogeneous with respect to morphology including glandular and 
mucinous components. Compared to CDH1-related gastric cancers, diffuse-
type gastric carcinoma in patients without a known germline mutation seem 
to be more heterogeneous with more often microglandular and extracellular 
mucinous differentiation. Irrespective of the presence of a germline CDH1 
mutation, E-cadherin staining was abnormal. In Lynch syndrome most cases 
showed mismatch repair deficiency, 14% of cases did not show microsatellite 
instability without MSI. 
We conclude that in young and familial gastric cancer patients, precursor lesions 
are pathognomonic for a germline CDH1 mutation. No other histological criteria 
are	 specific	 and	 only	 the	 minority	 is	 of	 the	 signet-ring	 cell	 type.	 E-cadherin	
immunohistochemistry	 does	 not	 aid	 in	 the	 differentiation	 of	 cases	 with	 and	
without a germline CDH1 mutation. Gastric cancer observed in patients with 
Lynch syndrome may also develop independent of the Lynch syndrome genotype.
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INTRODUCTION
Only 6–7% of gastric cancer patients present before the age of 50, and less than 
2% before the age 40.1 Familial aggregation of gastric cancer is seen in up to 
10% of all cases. Familial gastric cancer can be classified as hereditary diffuse 
gastric cancer (HDGC), familial intestinal gastric cancer (FIGC) and, when the 
histopathology of tumors is unknown, as familial gastric cancer FGC).2 Among 
these groups, only 1-3% is related to known specific genetic causes with the 
most important gastric cancer susceptibility genes for HDGC being CDH1 and 
CTNNA1. Gastric cancer risk is elevated in several other hereditary syndromes, 
including GAPPS (Gastric Adenocarcinoma and Proximal Polyposis of the 
Stomach), Li-Fraumeni, Peutz-Jeghers and juvenile polyposis. The gastric cancer 
risk in Lynch syndrome and hereditary breast and ovarian cancer syndromes is 
not clear. There have been multiple reports published about the early stages of 
DGC in CDH1 mutation carriers but few histological details of the presentation 
of advanced stages of familial gastric cancer are available.
We have investigated whether histopathology can help in the recognition of 
hereditary gastric cancer. We have examined the histopathologic characteristics 
and immunohistochemical profile of gastric adenocarcinoma in patients with a 
germline mutation in CDH1, the mismatch repair genes and with early-onset or 
familial gastric cancer without a known mutation.
METHODS
Gastric biopsies and gastrectomies were collected from families that were 
tested for a germline CDH1 mutation between January 1999 and January 2014 
in the Genome Diagnostic Laboratory of the Department of Human Genetics at 
the Radboud university medical center (Nijmegen, The Netherlands). Patients 
with advanced gastric cancer (>pT1a) fulfilled one of the following criteria:
- Confirmed pathogenic CDH1 germline mutation (n=27);
-  HDGC patients that fulfilled updated CDH1 testing criteria3, but without 
a mutation in CDH1 or CTNNA1 and without a family history that fits with 
another cancer syndrome (n=100);
- FIGC patients that fulfilled criteria set by Caldas et al2 (n=22).
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All patients were from families that received genetic counseling at one of the 
following national centers: The Netherlands Cancer Institute (Amsterdam), 
VU University Medical Center (Amsterdam), Academic Medical Center 
(Amsterdam), University Medical Center Groningen (Groningen), University 
Medical Center Utrecht (Utrecht), Maastricht University Medical Center 
(Maastricht), Leiden University Medical Center (Leiden), Erasmus University 
Medical Center (Rotterdam), or Radboud university medical center (Nijmegen). 
Details about CDH1 mutation analysis can be found in a previous study.3 Next to 
the groups described above, gastric cancer specimens were also collected from 
Lynch patients with gastric cancer (n=29) that were counseled in the Radboud 
university medical center (n= 16) or registered at the Dutch Hereditary Cancer 
registry (n= 13) (described before by Capelle et al).4
Histology reports, slides and tumor blocks were collected from patients with 
gastric cancer who gave written informed consent. These were retrospectively 
retrieved from the pathology department archives of hospitals throughout 
the Netherlands. Clinicopathological information was gathered for each 
case by reviewing patient clinical history and molecular testing, pathology 
reports, gross photographs and slides. All cases were reviewed and histological 
parameters were scored (see table 1). Immunohistochemistry for e-cadherin, 
using a sequential immunohistochemistry (SeqIHC) protocol was performed 
on a selection of HDGC cases, details can be found in Supplementary file 1. 
Microsatellite instability (MSI) analysis and immunohistochemistry for mismatch 
repair genes were performed on gastric cancer specimens from Lynch syndrome 
patients. MSI analysis and immunohistochemistry were performed essentially 
as described previously.5 
RESULTS
Histology of gastric carcinomas (>pT1a) of patients with a 
pathogenic germline CDH1-mutation (Figure 1A-F)
Gastric biopsies and/or gastrectomy specimens were collected of 27 patients 
with gastric cancer and a confirmed pathogenic germline CDH1 mutation. 
Four of these patients were diagnosed with gastric cancer diagnosed during 
presymptomatic surveillance of the stomach. Clinicopathological characteristics 
can be found in table 1. Clinical characteristics and germline mutations of these 
families were reported before3, in the current study details on histology of these 
patients are reported. 
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Table 1. Clinicopathologic characteristics of advanced gastric cancer
Variable HDGC in patients 
with a germline 
CDH1 mutation
Gastric cancer 
in patients with 
Lynch syndrome
HDGC without a 
detected germline 
mutation
Early-onset IGC 
or FIGC without a 
detected germline 
mutation
Number of cases (%) 27 (100) 29 (100) 100 (100) 22 (100)
Number of families 18 27 81 15
Biopsy (%) 26 (96) 14 (48) 72 (72) 6 (27)
Resection specimen (%) 14 (52) 19 (66) 48 (48) 18 (82)
Anatomic location stomach (bulk of the tumor)
Proximal: cardia 3 (11) 4 (14) 11 (11) 3 (14)
Body: fundus/corpus (%) 8 (30) 13 (45) 31 (31) 9 (41)
Distal: antrum/pre-pylorus (%) 6 (22) 9 (31) 30 (30) 7 (32)
Whole stomach/ linitis plastica (%) 10 (37) 0 0 0
Stomach NNO (%) 0 3 (10) 28 (28) 3 (14)
patients with multiple tumors >pT1a (%) 2 (9) 0 3 0
Patients with pT1a foci (%) 4 (15) 0 0 0
Laurén classification
Intestinal (%) 0 17 (59) 0 20 (91)
Diffuse (%) 27 (100) 12 (41) 100 (100) 0
Other/ indeterminate (%) 0 0 0 2 (9)
WHO classification
Tubular (%) 0 17 (59) 0 19 (86)
Papillary (%) 0 0 0 0
Mucinous (%) 0 0 7 (7) 2 (9)
Poorly cohesive (incl. SRCC) 27 (100) 12 (41) 93 (93) 0
Mixed (%) 0 0 0 1 (5)
Other (%) 0 0 0 0
Histopathological features
(Micro-)glandular component (%) 7 (26) 16 (55) 41 (41) 22 (100)
Mucinous lakes (%) 2 (9) 6 (21) 18 (18) 2 (9)
Poorly cohesive cells (%) 27 (100) 18 (62) 100 (100) 4 (18)
Signet ring cells (%) 26 (96) 12 (41) 96 (96) 2 (9)
>50% signet ring cells (%) 5 (19) 5 (17) 46 (46) 0
Cord forming pattern (%) 10 (37) 1 (3) 29 (29) 0
In-situ lesions 6 (22) 0 0 0
Pagetoid lesions 3 (11) 0 0 0
Intraepithelial signet ring cells in the 
tumor area 2 (7) 1 (3) 12  
Haemorrhage (%) 5 (19) 0 1 (1) 0
Globoid (%) 8 (30) 1 (3) 16 (16) 4 (18)
Vacuolization (%) 10 (37) 1 (3) 9 (9) 1 (5)
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All patients presented with diffuse gastric cancer. Almost all patients (26/27) had 
at least a small component of typical signet ring cells, however only five patients 
presented with a signet ring cell carcinoma defined as a tumor with more than 
50% signet ring cells (only one with >90% signet ring cells). Most tumors had 
a heterogeneous morphology showing a mixture of atypical cells including 
signet ring cells and poorly cohesive polymorphic cells with different growth 
patterns as cords of atypical cells (37%), (micro-)glandular components (26%) 
and mucinous lakes (9%). Most patients (70%) presented at advanced stage (III 
or IV), therefore 13 patients did not have surgery and gastrectomy specimens 
were not available of these patients. In some patients multiple precursor lesions 
were found in normal tissue at distance of the tumor bulk. In-situ signet ring 
cells were found in six patients (43% of gastrectomy cases), of which three 
patients also had pagetoid spread of signet ring cells. These lesions were not 
History of Helicobacter pylori 
gastritis (%) 6 (22) 3 (10) 13 (13) 1 (5)
Intestinal metaplasia (%) 3 (11) 2 (7) 34 (34) 13 (59)
Atrophic gastritis (%) 3 (11) 2 (7) 5 (5) 4 (18)
Neoadjuvant chemotherapy (%) 3 (11) 1 (3) 12 (12) 1 (5)
Mean age at presentation
42 (SD 12; Range 
23-75)
56 (SD 14; Range 
23-75)
47 (SD 16; Range 
17-85)
52 (SD 18; Range 
25-83)
Gender M/F 17F, 10M 8F, 21M 63F, 37M 8F, 14M
Stage at diagnosis
I (%) 3 (11) 7 (24) 10 (10) 4 (18)
II (%) 5 (19) 7 (24) 12 (12) 1 (5)
III (%) 3 (11) 4 (14) 18 (18) 9 (41)
IV (%) 16 (59) 8 (28) 56 (56) 8 (36)
NA (%) 0 3 (10) 4 (4) 0
Number of patients with other 
malignancies (excl skin carcinoma, %) 2 (7) 16 (55) 5 (5) 0
Other malignancies
Lobular breast 
cancer
Colorectal cancer; 
endometrial cancer; 
urothelial tract 
cancer; prostate 
cancer; esophageal 
cancer; chronic 
lymphoid leukemia
Thyroid cancer; 
squamous cell 
cancer tongue; 
ductal breast cancer; 
melanoma 0
Abbreviations: HDGC= hereditary diffuse gastric cancer; FIGC= familial intestinal gastric cancer; 
IGC= intestinal-type gastric cancer; M= male; F= female; NA= not available 
Table 1. Continued
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reported in initial pathology reports. Intraepithelial signet ring cells nearby the 
tumor were found in two patients. It is unclear if these intraepithelial signet ring 
cells really reflect a precursor lesion (in-situ signet ring cell carcinoma) or that it 
is overgrowth of signet ring cells of normal glands in the tumor area. Therefore 
these lesions were not considered as confirmed in-situ lesions. Six patients 
presented with more than one tumor, of which two patients with two advanced 
tumors, one patient with three tumors and three patients with multiple pT1a 
tumors at distance from the main tumor bulk. Presence or history of Helicobacter 
pylori gastritis was observed in six patients and atrophic gastritis with intestinal 
metaplasia in three patients. 
E-cadherin protein expression in diffuse gastric cancer (Table 2)
SeqIHC	 E-cadherin	 analysis	 was	 performed	 on	 33	 formalin-fixed	 paraffin-
embedded gastric carcinomas of 13 patients (13 lesions) without and 9 patients 
(20 lesions) with a germline CDH1 mutation. E-cadherin protein expression was 
assessed	 using	 four	 different	 E-cadherin	 antibody	 clones.	Details	 of	 results	 are	
depicted	 in	 supplementary	files	3	and	4	and	summarized	 in	 table	1.	Most	cases	
showed	 similar	 or	 slight	 differences	 in	 E-cadherin	 expression	 patterns	 of	 all	
four	 different	 anti-E-cadherin	 clones	 (supplement	 2).	 Total	 loss	 of	 E-cadherin	
expression was observed in 2 of 13 (15%) CDH1 mutation-negative and in only 1 of 
20 (5%) CDH1 mutation cases. This indicates that total loss of e-cadherin staining 
in	diffuse	gastric	cancer	is	not	seen	frequently,	and	is	not	an	indication	for	a	CDH1 
mutation. Variable expression with absence versus presence of staining was seen 
in	four	cases:	case	1,	22,	27	and	30	(see	table	supplementary	file	3).	Since	in	cases	
1,22 and 30, the other antibodies also showed a low percentage and intensity of 
staining, this was interpreted as variable staining. However, case 27 did show total 
loss of e-cadherin antibody HECD-1 while the other antibodies showed moderate 
expression	 in	 most	 cells.	 Unfortunately	 insufficient	 material	 was	 available	 to	
investigate DNA for second hit mechanisms. 
Table 2. Sequential immunohistochemistry results e-cadherin staining using four different 
antibodies
Pattern of staining CDH1 mutation (n=20) Without CDH1 mutation (n=13)
Absent (0% expression) 1 (5%) 2 (15%)
Slight (<10% expression) 5 (25%) 1 (8%)
Aberrant (10-75% expression or >75% 
irregular/ cytoplasmic staining)
14 (70%) 10 (77%)
Crisp membranous (>75% staining) 0 0
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Gastric cancer in patients with Lynch syndrome (Table 1 and 3, 
Figure 1G-J)
We have examined gastric cancer samples of 29 patients (27 families) that 
were diagnosed with gastric cancer and Lynch syndrome. Twenty gastric 
cancer samples showed MSI and/or immunohistochemical loss of mismatch 
repair proteins in line with the germline mutation of the patient. In five cases 
MSI or immunohistochemistry results were inconclusive (n=1) or material was 
unavailable for analysis (n=4). 
Four cases (14%) showed microsatellite stability (MSS) and/or preservation of 
immunohistochemical staining of the mismatch repair (MMR) proteins, therefore 
these tumors were not likely related to Lynch syndrome (Table 3). These MSS GC 
cases belonged to patients with Lynch syndrome; two of four patients had other 
neoplasms belonging to the Lynch syndrome spectrum, including colorectal 
adenomas and carcinomas, urothelial tract cancer and sebaceous adenomas. 
The ages varied from 39 to 77, two were diffuse- and two were intestinal-type 
GC. Two GC specimens showed a background of atrophic gastritis with intestinal 
metaplasia.
The 25 patients with gastric cancer proven or likely belonging to the Lynch 
syndrome spectrum had a pathogenic germline mutation in MLH1 (n=10), MSH2 
(n=13) or MSH6 (n=2). Fourteen patients (56%) presented with gastric cancer 
as their first Lynch syndrome associated invasive malignancy. The other 11 
patients initially presented with colorectal (n=7), endometrial (n=2) or urothelial 
tract cancer (n=2). Fifteen patients had intestinal and ten diffuse histology of 
the gastric cancer. Of the intestinal cases, three cases showed histology that fits 
with the diagnosis medullary carcinoma. 
Clustering of gastric cancer was observed in one family (three cases), in only 
one case the gastric cancer seems likely to be developed in the setting of Lynch 
(immunohistochemical loss of MSH6). The other two cases showed MSS and 
retained immunohistochemical expression of the mismatch repair proteins. 
Other clinicopathologic characteristics can be found in table 1 and 3. 
Histology of HDGC in patients without a germline mutation in 
CDH1 or CTNNA1 and without a family history that fits with 
another syndrome (Figure K-L)
Gastric cancer specimens and/or biopsies were collected from 100 patients that 
presented with gastric cancer and fulfilled 2015 CDH1 testing criteria.6 Forty-
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Figure 1. Histopathology of familial and early-onset gastric cancer (H&E slides). A-F are 
gastrectomy images from patients with a pathogenic germline CDH1 mutation. A: pagetoid spread 
of signet ring cells in surrounding normal tissue (original magnification 400x); B: in situ signet ring 
cells and formation of mucosal signet ring cell carcinoma (original magnification 400x); C: poorly-
differentiated gastric cancer (original magnification 200x); D: mucinous differentiation (original 
magnification 25x); E and F: microglandular formation (original magnifications 50x and 400x). 
G-J are gastrectomy images from patients with Lynch syndrome. G: intestinal-type gastric cancer 
(original magnification 100x); H: medullary-type gastric cancer (original magnification 250x); I: 
poorly-differentiated gastric cancer (original magnification 250x); J: signet ring cell carcinoma with 
signet ring cells into pre-existent glands (original magnification 400x). K and L are from HDGC 
patients without a known germline mutation. Both show signet ring cells in glands, probably 
reflecting overgrowth of normal glands, giving the impression of in situ-like lesions (original 
magnifications 250x).
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nine patients fulfilled a diagnosis of HDGC according to the original criteria set 
up by Caldas et al.: two patients with gastric cancer of which one below the age 
of 50 or three confirmed diffuse gastric cancer. 2 28 patients presented with 
diffuse gastric cancer before the age of 40 years without a family history of 
gastric cancer. See details on characteristics in table 2. 
Compared to CDH1-related gastric cancers, these gastric cancers seem to 
be more heterogeneous with more often microglandular and extracellular 
mucinous differentiation. Intestinal metaplasia was found in 34% compared 
to 9% in CDH1-related gastric cancer. In 12 cases there were signet ring cells 
inside and along normal glands in the tumor area. This may reflect tumor 
growth into normal glands and may mimic precursor lesions seen in the context 
of CDH1-related gastric cancer (Figure 1K-L). No convincing typical in situ or 
pagetoid precursor lesions at distance of the tumor bulk were observed in these 
gastrectomy specimens. 
Histology of gastric adenocarcinoma in patients with FIGC
Gastric cancer specimens and/or biopsies were evaluated from 22 patients (15 
families) that presented with intestinal-type gastric cancer before the age of 
40 (n=5) or fulfilled the following criteria2: (1) at least two first/second degree 
relatives affected by intestinal gastric cancer, one diagnosed before the age of 
50 (n=5); or (2) three or more relatives with intestinal gastric cancer at any age 
(n=12). In ten specimens MSI was examined and MSI due to hypermethylation of 
the MLH1 promoter was detected in two patients. A history of H. pylori gastritis 
in this category was not increased compared to the other patients with a familial 
history (only one patient was diagnosed with H. pylori). 
DISCUSSION
In the current study we present for the first time a comparison of the histological 
characteristics of patients with gastric cancer and a germline mutation in CDH1, 
Lynch syndrome or early-onset or familial intestinal or diffuse-type gastric 
cancer without a known germline mutation. Noteworthy, the majority of CDH1 
mutation related gastric cancer cases did not present with predominant signet-
ring cell cancer. Precursor lesions in the surrounding ‘normal’ gastric tissue, 
which were not reported in original pathology reports, could have led to the 
suspicion or diagnosis of a germline CDH1 mutation in most gastrectomies. 
Therefore in daily practice expertise is needed and attention should be paid to 
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precursor lesions in the evaluation of all diffuse type gastrectomy specimens. 
Importantly, most CDH1-related gastric cancer cases show retained but aberrant 
immunohistochemical expression of E-cadherin protein. The majority of gastric 
cancer cases in Lynch syndrome can be defined by MMR-deficiency. Besides 
the presence of precursor lesions, there were no histological features of gastric 
cancer, that could distinguish between CDH1, Lynch syndrome or early-onset or 
familial gastric cancer without a known mutation. 
Caldas et al. described 13 germline CDH1 mutation-related gastric cancer cases, 
11 were of the diffuse-type and two were of the mixed-type (with both diffuse 
and intestinal/glandular components).2 In the present study we also describe 
(micro-)glandular components in five patients (22%) with a germline CDH1 
mutation. It is important that (micro-)glandular growth does not exclude a 
diagnosis of CDH1-related gastric cancer. 
We	 examined	 the	 ability	 of	 four	 different	 E-cadherin	 antibodies	 (recognizing	
different	 epitopes)	 to	 predict	 that	 gastric	 cancer	 arises	 in	 the	 context	 of	 a	
germline CDH1 mutation. Biallelic CDH1 gene inactivation does not invariably 
lead to complete loss of immunohistochemical E-cadherin protein expression 
which	 confirms	 previous	 reports.7-11 Although the international HDGC guideline 
does not recommend E-cadherin immunohistochemistry as a prescreening 
method to select patients for CDH1 mutation analysis,6 in daily practice there are 
laboratories that erroneously use E-cadherin immunohistochemistry on gastric 
cancer samples to predict and prescreen tissue for clinical genetic CDH1 testing. 
In literature various scoring criteria for the assessment of E-cadherin expression 
in DGC are used and often membranous expression was not assessed on 
irregularity. Distinguishing between normal and abnormal expression is very 
difficult, since even in normal gastric glands E-cadherin often is only expressed 
at the basolateral membrane and reduced or absent at the luminal membrane. 
The question remains how normal E-cadherin expression is defined in gastric 
cancer, since even though E-cadherin is expressed it might be a mutant protein. 
This stresses the difficulty of scoring E-cadherin expression in diffuse-type 
gastric cancer. In the current study, E-cadherin staining was defined as absent 
(0% expression), as aberrant (any degree of abnormal cytoplasmic, irregular 
or diminished membranous expression) or ‘normal’ (>75% crisp membranous 
expression with the same intensity as surrounding normal glands). Using this 
scoring system, we did not encounter ‘normal’ expression, however, we found 
>75% irregular membranous expression in seven cases (three without and four 
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with a germline CDH1 mutation). In daily practice, it is likely that this would 
be interpreted as ‘positive/ retained/ normal’ E-cadherin staining (see also 
supplementary files 3 and 4). There was little variability between the different 
E-cadherin antibodies. Total absence or focal (<10%) staining of E-cadherin was 
seen in only six of 20 cases (30%) with a CDH1 mutation and in 3/13 cases without 
a CDH1 mutation (23%). Overall, the E-cadherin antibody clone that was used did 
not influence staining results, although clone N-20 showed a lot of background 
staining and was difficult to interpret. E-cadherin staining was highly variable 
between individuals with the same CDH1 germline mutation and in the same 
individual between different gastric cancer lesions suggesting that the second 
inactivating hit of the wild-type allele is decisive for E-cadherin expression.
Oliveira et al. found in 80% of HDGC families somatic CDH1 epigenetic and 
genetic alterations. Next to a somatic mutation, the second hit in HDGC 
lesions can also be promoter hypermethylation of CpG islands (50%), loss 
of heterozygosity (LOH) (12.5%) or a combination of both (18.8%).10 Somatic 
mutations affecting exon 8 and 9 are considered to be a hotspot in CDH1.12-14 So 
depending on the E-cadherin antibody clone used, truncated protein might be 
missed by immunohistochemistry since its epitope may have been altered. In 
2002, Becker et al.34 showed a DGC case with a somatic mutation resulting in an 
in-frame exon 8 deletion, which similar to our results in one case did not show 
any immunoreactivity by using anti-E-cadherin clone HECD-1 while other anti-E-
cadherin clones did show retained immunoreactivity. In our case somatic mutation 
analysis	was	not	possible	due	to	insufficient	amount	of	DNA	of	the	tumor.	
We have also examined the characteristics of gastric cancer in Lynch syndrome. 
The frequency of gastric cancer in patients with Lynch syndrome differs among 
populations, gender and the gene that is mutated, varying from 0.2-30%.15, 
16 Most reports in Western countries show a cumulative GC risk by age 70 in 
the range of 2-6%.4, 17-22 There seems to be no clustering of gastric cancer in 
the majority of families with Lynch syndrome. Three studies showed that the 
majority (around 75%) of GC associated with Lynch syndrome is of the intestinal-
type and are characterized by microsatellite instability,4, 23, 24 however in our 
study a significant proportion (40%) had diffuse type histology. Four cases did 
not show MSI or loss of immunohistochemical expression of mismatch repair 
proteins. Therefore it is very well possible that the origin of GC is not related to 
MMR deficiency. For family risk and counseling it is important to confirm that 
Lynch syndrome patients with GC have MMR deficiency in their tumor. 
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Germline mutations in CDH1 were initially reported in 30-50% of HDGC families, 
however recent publications of larger cohorts found germline CDH1 mutations in 
a minority of cases (<25%).3, 25, 26 The molecular basis for familial aggregation or 
early-onset of gastric cancer remains largely unknown. In patients without a CDH1 
germline mutation, we did not find specific histopathological characteristics in 
GCs of 100 diffuse-type and 22 intestinal-type cases. In conclusion, important 
indications for gastric cancer related to a germline CDH1 mutation are the 
presence of precursor lesions. Only the minority is predominantly of the signet-
ring cell type. Importantly, E-cadherin staining does not exclude the presence of 
a germline mutation in the CDH1 gene. 
Box 1. Clinicopathologic characteristics of hereditary gastric cancer
CDH1 mutation -Multiple mucosal SRC carcinomas (pT1a);
-Foci of in-situ or pagetoid spreading of SRCs;
-Poorly cohesive carcinoma with (a small subset of typical) SRCs;
-May contain areas of (micro-)glandular growth, mucinous lakes and cords of tumor cells;
-E-cadherin expression or absence does not discriminate between hereditary and sporadic diffuse type GC
Lynch syndrome -Intestinal or diffuse histology
-History of a Lynch syndrome associated malignancy
-Mismatch repair deficiency
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Supplementary file 1. Sequential immunohistochemistry (seqIHC) 
four antibody clones of E-cadherin
For seqIHC, in addition to formalin-fixed paraffin-embedded (FFPE) material 
(n=13) of 13 patients without a germline CDH1 mutation, FFPE material from 
20 carcinomas of 13 patients (5 families) with a pathogenic germline CDH1 
mutation was selected. From patients without a germline CDH1 mutation one 
slide per patient was assessed, whereas from patients with a germline CDH1 
mutation one to multiple slides of different tumors were analyzed (since these 
patients often have multiple intramucosal gastric carcinomas). For each section 
the normal nondisrupted glands within the foveolar zone adjacent to the 
tumor lesion were used as a positive internal control for E-cadherin expression. 
Additionally, on each slide non-malignant tissue containing pancreas, appendix 
and liver as a positive control was present for E-cadherin expression. 
To test the specificity and reliability of different antibodies against E-cadherin 
on FFPE gastric tumor material, IHC was performed using four different anti-
E-cadherin primary antibodies (Supplementary file 2). For IHC, 4 µm FFPE 
slides were mounted on SuperFrost Plus slides using Milli-Q and a heat plate at 
42°C. Slides were dried for 45 minutes in a stove at 56°C. Tissue sections were 
deparaffinized in xylene and rehydrated with ethanol. Heat-induced antigen 
retrieval (HIER) was performed by boiling in EDTA for 10 minutes at 100°C 
using the pre-treatment (PT) Module™ (Thermo Fisher Scientific, Landsmeer, 
The Netherlands). Endogenous peroxidase activitity was blocked by 10 minutes 
incubation in 3% H2O2 in methanol. E-cadherin antibodies (clones HECD-1, 
SPM471 and 4A2C7) were diluted in Normal antibody Diluent (ImmunoLogic, 
Duiven, The Netherlands). Slides were labeled with primary anti-E-cadherin 
antibody by 1 hour incubation at room temperature. Next, sections were 
incubated in Power Vision 1:2 plus Poly-horseradisch peroxidase (HRP)-anti-
mouse/rabbit/rat solution (ImmunoLogic, Duiven, The Netherlands) for 30 
minutes. E-cadherin antibody clone N20: Prior to incubation with this primary 
antibody, slides were blocked with 20% normal horse serum in 1% BSA-PBS to 
prevent background staining. Primary antibody incubation was followed by 5 
minutes rinse in PBS and 30 minutes incubation with biotinylated anti-goat IgG 
(S21) 1:200 diluted in 1% BSA-PBS, and 5 minutes rinse in PBS. Next, slides were 
incubated for 45 minutes with avidin–biotin-complex (ABC), VECTASTAIN® Elite 
ABC Kit (Standard) (Brunschwig Chemie, Amsterdam, The Netherlands), which 
was diluted 1:100 in 1% BSA-PBS. After labeling with secondary antibody, slides 
were washed with PBS for 5 minutes.
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Visualization was done with NovaRed (Vector Laboratories, Burlingame, USA) or 
Bajoran Purple (Biocare Medical, Concord, USA) for 10 min. These chromogens 
were used since they can be destained, this in contrast to 3,3’-diaminobenzidine 
(DAB) which is a commonly used chromogen.1 Cells were counterstained with 
hematoxylin. 
The same slide was stained with four different antibodies against E-cadherin, 
using a sequential IHC (seqIHC) procedure, described before by Van den Brand 
et al.2 Slide scanning was performed by using the Pannoramic 250 Flash II 
system (3D Histech, Budapest, Hungary). After scanning, the cover slips were 
removed from the slides by O/N incubation in xylene. The next day, slides were 
hydrated in xylene and ethanol, and rinsed in tap water and PBS. Antibodies 
on slides were stripped by 1 hour incubation in stripping buffer containing 2% 
Sodium Dodecyl Sulfate (SDS), 62.5 mM tris-hydrogen chloride (Tris-HCl) pH 7.5 
and	0.8%	β-mercaptoethanol.	Next,	slides	were	washed	15	minutes	in	tap	water,	
dehydrated for 1 minute in 99.5% ethanol and briefly washed in demineralized 
water and PBS, respectively. Destained slides were all checked on complete loss 
of antibodies by light microscopy. After stripping, slides were labeled with the 
subsequent anti-E-cadherin antibodies, according to previously described IHC 
procedure. E-cadherin staining in diffuse-type gastric cancer was considered 
to be normal when >75% epithelial cells had crispy membranous expression 
without increased cytoplasmic expression, absent (0) when all cells within the 
lesion lost E-cadherin expression, and abnormal (aberrant) when there was 
reduced (<75%), membranous irregular/dotted and/or cytoplasmic expression. 
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Supplementary file 2. Schematic image of the CDH1 gene with 
CDH1 germline mutations and E-cadherin antibodies used for 
seqIHC 
The germline mutations in hereditary diffuse gastric cancer samples are shown 
above and the E-cadherin antibody clones below the gene. Precursor: protein 
precursor domain; Sig: signal peptide; TM: transmembrane domain.
Supplementary file 3. Table with scoring results E-cadherin 
antibodies (seqIHC) 
Case Patient CDH1 germline mutation N20 HECD-1 SPM471 4A2C7 S
E I % E I % E I % E I %
1 1 No 0 0 0 0 0 0 0 0 0 1 1 1 1
2 2 No 1 1 2 1 1 2 1 2 3 1 2 3 2
3 3 No 1 2 3 1 2 3 1 2 3 1 2 3 3
4 4 No 1 1 2 1 1 2 1 2 2 1 1 2 2
5 5 No 1 2 3 1 2 3 1 2 3 1 2 3 3
6 6 No 0 0 0 0 0 0 0 0 0 0 0 0 0
7 7 No 1 1 1 1 1 1 1 1 1 1 2 2 2
8 8 No 1 1 2 1 1 2 1 2 2 1 2 3 2
9 9 No 1 2 3 1 2 3 1 2 3 1 2 3 3
10 10 No 1 1 2 1 1 2 1 2 2 1 1 2 2
11 11 No 1 1 2 1 1 2 1 2 2 1 1 3 2
12 12 No 1 1 1 2 1 1 2 2 1 1 1 2 2
13 13 No 0 0 0 0 0 0 0 0 0 0 0 0 0
14 14 c.1135_1137+5delinsTTAGA 0 0 0 0 0 0 1 2 1 1 2 1 1
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15 15 c.1135_1137+5delinsTTAGA 1 2 1 1 1 1 1 1 1 1 1 1 1
16 15 c.1135_1137+5delinsTTAGA 1 1 3 1 1 2 1 2 3 1 2 3 2
17 16 c.1135_1137+5delinsTTAGA 1 2 2 1 1 2 1 2 2 1 2 3 2
18 17 c.187C>T; p.(Arg63*) 1 1 3 1 1 3 1 1 3 1 2 3 3
19 17 c.187C>T; p.(Arg63*) 0 0 0 0 0 0 0 0 0 0 0 0 0
20 17 c.187C>T; p.(Arg63*) 1 1 1 1 1 1 1 1 1 1 1 1 1
21 17 c.187C>T; p.(Arg63*) 1 1 2 1 1 2 1 2 3 1 2 3 2
22 18 c.187C>T; p.(Arg63*) 1 1 1 0 0 0 1 1 1 1 1 1 1
23 18 c.187C>T; p.(Arg63*) 1 2 3 1 2 3 1 2 3 1 2 3 3
24 19 c.2195G>A; p.(Arg732Gln) 1 1 2 1 1 1 1 1 2 1 1 2 2
25 20 c.2195G>A; p.(Arg732Gln) 1 1 2 1 2 2 1 2 2 1 2 2 2
26 20 c.2195G>A; p.(Arg732Gln) 1 1 3 1 1 3 1 1 3 1 2 3 3
27 21 c.2195G>A; p.(Arg732Gln) 1 1 2 0 0 0 1 1 3 1 1 3 2
28 21 c.2195G>A; p.(Arg732Gln) 1 1 1 1 2 2 1 1 1 1 2 2 2
29 21 c.2195G>A; p.(Arg732Gln) 1 1 1 1 1 2 1 1 1 1 1 2 2
30 21 c.2195G>A; p.(Arg732Gln) 1 1 1 1 1 1 0 0 0 1 1 1 1
31 21 c.2195G>A; p.(Arg732Gln) 1 1 2 1 1 2 1 1 2 1 1 2 2
32 21 c.2195G>A; p.(Arg732Gln) 1 1 3 1 1 3 1 1 3 1 1 3 3
33 22 c.1476_1477del; p.(Arg492fs) 1 1 2 1 2 2 1 2 2 1 2 3 2
E= expression: 0= no expression; 1= irregular and/or cytoplasmic expression; 2= normal crisp 
membranous expression. I= intensity: 0= no expression; 1= weak to moderate expression; 2= strong 
expression comparable to normal surrounding glands. %= percentage: 0= no expression; 1= less 
than 10%; 2= 10-75%; 3= more than 75%.  S= summary/ interpretation overall: 0= no expression; 
1= focal <10% expression; 2= 10-75% expression; 3= >75% irregular expression; 4= >75% crisp 
membranous expression
Supplementary file 3. Continued
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Supplementary file 4. Examples of seqIHC E-cadherin staining
Case 19: total loss of E-cadherin expression in signet ring cells with some 
background staining of E-cadherin antibody N20 (original magnification 250x). 
Case 5: strong membranous irregular E-cadherin expression >75% of poorly 
cohesive tumor cells (original magnification 250x).
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Case 27: variability in staining with complete absence of staining with HECD-
1 and moderate to strong expression with the other E-cadherin antibodies 
(original magnification 250x).
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Chapter 6
HNF4A immunohistochemistry facilitates distinction 
between primary and metastatic breast and gastric 
carcinoma 
Rachel S van der Post, Peter Bult, Ingrid P Vogelaar, Marjolijn J L Ligtenberg, 
Nicoline Hoogerbrugge, J Han van Krieken
Virchows Archiv 2014; 464(6):673-9
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ABSTRACT
The distinction between primary gastric adenocarcinoma and gastric metastatic 
breast carcinoma can be difficult. Expression of hepatocyte nuclear factor 4A 
(HNF4A) has been described as being specific to distinguish between neoplastic 
gastric and breast epithelial cells. The aim of this study was to validate the use 
of HNF4A with immunohistochemistry in discriminating gastric from breast 
carcinomas. 
Immunohistochemical expression of HNF4A, estrogen receptor (ER), 
progesterone receptor (PR) and BRST-2 were determined in primary sporadic 
gastric adenocarcinomas (n= 107) and breast carcinomas (n=105). The same 
markers and clinicopathological features were studied in one patient with 
breast metastasis of gastric cancer, six patients with gastric metastases of 
breast cancer and 13 patients with both primary gastric and breast carcinomas. 
HNF4A expression was seen in 106 of 107 primary gastric adenocarcinomas and 
was absent in all 105 primary breast carcinomas (sensitivity 99%, specificity 
100%). ER, PR, and BRST-2 were 100% specific for breast carcinomas with 
sensitivities of 77, 58 and 38%, respectively. The metastasis of gastric carcinoma 
to the breast showed strong expression of HNF4A. None of the metastases of 
breast carcinomas to the stomach showed expression of HNF4A. Tissues of 
patients with two primary carcinomas showed strong expression of HNF4A in all 
gastric carcinomas and no expression in breast carcinomas. 
Our results indicate that HNF4A is a very good marker to discriminate between 
primary and metastatic gastric and breast carcinomas.
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INTRODUCTION
The distinction between patients with metastatic carcinomas and patients with 
two primary tumors of gastric and breast origin is important, both for prognosis 
and treatment strategy, especially with the improved treatment strategies 
resulting in longer survival of patients with metastatic breast carcinoma. 
Furthermore, two primary tumors may be indicative for a hereditary background, 
particularly in young patients. Approximately 3% of gastric cancer cases arise in 
the setting of hereditary diffuse gastric cancer (HDGC).1 A significant portion of 
these families has germline mutations in the CDH1 gene, encoding e-cadherin, of 
which carriers have a risk of developing diffuse gastric cancer of approximately 
80%.1 In addition, women with a CDH1 mutation have an about 60% risk of 
developing lobular breast carcinoma.1-3 Also carriers of a germline mutation in 
BRCA2 have increased risks of both breast and gastric cancer.4-6 
Metastases from breast cancer to the stomach are relatively rare, with incidences 
varying from 0.1-0.3% in retrospective series and up to 10% in autopsy series.7-12 
Vice versa, gastric adenocarcinoma metastatic to the breast occurs even less 
frequently with fewer than 30 case reports in the English literature so far.13-15
The distinction between metastatic breast and primary diffuse gastric carcinomas 
in the stomach can be difficult due to nonspecific findings using radiological, 
endoscopical, and histological methods. The presentation of metastatic breast 
carcinoma in the stomach is often a ‘linitis plastica’ appearance as a result of 
diffuse intramural infiltration by tumor.10, 12 This is characterized by narrowing of 
the stomach lumen, rigidity, and diminished peristalsis on endoscopy, mimicking 
primary diffuse cancer.10, 12 The morphology of especially invasive lobular breast 
cancer, but also poorly differentiated invasive ductal carcinoma, can resemble 
diffuse (signet ring cell) and undifferentiated gastric cancer with infiltration of 
tumor cells in the mucosa. Antibodies currently used for immunohistochemistry 
are helpful but have variable sensitivities and specificities. Recently, Koyama 
et al., described a study in which they performed immunohistochemistry in 
21 patients with gastric involvement of metastatic breast carcinomas.16 The 
marker hepatocyte nuclear factor 4A (HNF4A) was identified as especially 
specific in discriminating a breast cancer metastasis from a primary gastric 
adenocarcinoma.16
HNF4A is an orphan member of the nuclear receptor superfamily and is involved 
in the development of the visceral endoderm and in the metabolism of fatty 
156
HNF4A staining in gastric and breast carcinoma
acids, lipoproteins, glucose, amino acids, and blood coagulation factors.16-19 
Immunohistochemical analysis showed expression of HNF4A in epithelial cells 
of endodermal tissues, including the stomach, gut, liver, and pancreas but not 
in most other organs including mammary glands and ovaries.18 Previous studies 
report that carcinomas originating from epithelial cells of HNF4A-postive 
organs maintain HNF4A expression.16-18, 20 This suggests that HNF4A might be 
useful for determining the primary sites of metastatic tumors. However, staining 
interpretation is complex since it was also shown that tumors from HNF4A-
negative organs could acquire positive staining of HNF4A, which is the case in 
ovarian mucinous adenomas and carcinomas.21
The aim of this study was to validate the sensitivity and specificity of HNF4A in 
primary breast and gastric carcinomas and to assess its value in the differentiation 
between primary and metastatic tumor in a case series of tissue samples from 
patients with carcinomas in both the stomach and breast. 
METHODS
Tissue samples of gastric adenocarcinomas (n=107), breast carcinomas (n=105), 
normal gastric mucosa (n=25), and normal mammary glandular tissue (n=10), 
all from individual patients, were collected for validation. Cases were retrieved 
randomly from the surgical pathology files of the Radboud university medical 
center, the Netherlands between 1998 and 2011. Tissue microarrays (TMAs) 
were constructed from formalin-fixed paraffin-embedded (FFPE) archival 
specimens. One core biopsy (3 mm in diameter) was taken from histological 
representative regions and arranged in a new recipient paraffin block (tissue 
array block). Control samples included tissue from normal liver. 
Tissue samples of cases diagnosed with metastatic breast cancer to the 
stomach (n=6) or gastric carcinoma to the breast (n=1) or both primary gastric 
and primary breast tumors (n=13) were collected of patients known at the 
Department of Human Genetics of the Radboud university medical center 
and from the pathology files of ten pathology laboratories throughout the 
Netherlands (Radboud university medical center, Sint Franciscus gasthuis 
Rotterdam, Hospital Bethesda Hoogeveen, Erasmus Medical Center Rotterdam, 
University Medical Center Utrecht, Canisius Wilhelmina Hospital Nijmegen, 
Hospital Zorgsaam Terneuzen, BovenIJ Hospital, VU University Medical Center 
Amsterdam, Rijnstate Hospital Arnhem). The primary origin of the tumor 
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was based on the original histological results. For these cases, whole section 
analyses instead of TMA’s were performed. Cases were treated according to the 
FEDERA (Dutch Federation of Biomedical Societies) code, with anonymous use 
of redundant tissue for research purposes. 
Immunohistochemistry
HNF4A has nine isoforms that are generated by alternative P1 and P2 promoter 
usage and splicing.18 In the stomach, the expression pattern of P1 and P2-
HNF4A is different.18 In the present study we have used the HNF4A antibody 
clone H1415, that recognizes both P1-driven and P2-driven HNF4A and that 
was described as the most reliable marker for staining in various histological 
subtypes of gastric carcinoma.16, 18, 20
Immunohistochemical staining was performed on 4-µm-thick, FFPE tissue 
sections	 that	 were	 prepared	 on	 coated	 slides	 and	 dried	 for	 30	 min	 at	 55˚C.	
Tissue sections were deparaffinized in xylene and rehydrated with alcohol. 
Antigen	 retrieval	was	done	by	boiling	 in	 citrate	buffer	 (pH	6.7)	 at	 96˚C	 for	 30	
minutes. Endogenous peroxidase activity was blocked by exposing the slides 
to 3% peroxidase for 10 min. Sections were incubated with HNF4A antibody 
(clone H1415, Perseus Proteomics) at 1:200. This dilution was determined 
after examining several retrieval schemes and dilution series, to obtain the 
best results. Next, sections were incubated with Poly-HRP-GAM/R/R IgG for 
30 min. Visualizing was done with DAB for 5 min. Nuclei were counterstained 
with hematoxylin. Slides were dehydrated, cleared in xylene and mounted 
with micromount. Antibodies for breast tissue included estrogen receptor 
(ER) 1:80 clone SP1 from Thermo Scientific; progesterone receptor (PR) 1:250 
clone PgR636 from DAKO; and BRST-2 or gross cystic disease fluid protein-15 
(GCDFP-15) 1:40 clone D6 from Signet laboratories/ Sanbio. The above described 
protocol for immunohistochemistry was used except that antigen retrieval was 
done using EDTA, citrate (pH 6.0), and pronase, respectively. 
Assessment of staining
Staining interpretation was done by the investigator (RSvdP) and two expert 
pathologists (PB and JHvK). Staining was assessed as follows: no staining at 
all in tumor cells was regarded as a negative result; staining in less than 10% 
of tumor cells was considered as focal positivity and staining of 10% to 50% 
of tumor cells was considered as limited expression. Finally diffuse staining 
was regarded as >50% positive cells. Normal immuno-reactivity of HNF4A, 
ER and PR was defined as the presence of nuclear staining and for BRST-2 
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as cytoplasmic staining. To determine sensitivity and specificity, cases with 
completely negative staining were regarded as negative, and cases with any 
staining were considered positive. 
Statistical analysis
The Fisher exact test was used to analyze each 2-by-2 table of discrete data; 
p<0.05 was considered statistically significant. 
RESULTS
Validation of HNF4A staining
Normal gastric tissue of all 25 cases (24 biopsies and 1 gastrectomy) showed 
strong nuclear expression of HNF4A in foveolar cells with weak or no expression 
in chief cells and parietal cells, in concordance with results of Tanaka et al.18 
Ninety-four percent (101/107) of primary gastric adenocarcinomas showed 
limited to diffuse staining for HNF4A on TMAs (Table 1). In case the staining 
was scored as less than 10 percent (5 cases) or completely negative (1 case), 
whole slides of gastric adenocarcinoma tissue were stained. In 5 cases only 
part of the tumor stained weakly while most of the tumor stained diffusely on 
whole tissue slides. One case remained completely negative, also when using 
more concentrated dilutions of antibody and staining different slides of various 
tumor blocks. Surrounding normal gastric mucosa of this case showed staining 
of HNF4A, indicating that quality and fixation of the specimen was adequate. 
Histological evaluation revealed an intestinal type carcinoma in the gastric 
stump. Its location in the gastric stump does not seem to explain the aberrant 
staining, as 7 other gastric stump carcinomas, available on the TMA, showed 
limited to diffuse staining. 
The ten samples of normal breast tissue did not show any staining for HNF4A. HNF4A 
staining was also negative in all 105 breast carcinomas (37 invasive lobular breast 
carcinomas, 66 ductal breast carcinomas, and 2 mucinous breast carcinomas).
Validation of ER, PR and BRST-2 staining
ER was positive in 77% breast carcinomas (35/37 lobular,44/66 ductal, and 
2/2 mucinous carcinomas showed expression). Fifty-seven percent of breast 
carcinomas were PR positive (25/37 lobular, 34/66 ductal, and 1/ 2 mucinous 
carcinomas) and 38% of breast carcinomas were BRST-2 positive (22/37 lobular, 
18/66 ductal, and 0/2 mucinous carcinomas). ER, PR, and BRST-2 lacked 
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expression in gastric cancer cases and therefore were 100% specific for breast 
cancer.
Patients with both breast and gastric cancer
Six patients presented with invasive lobular carcinoma and metastasis to the 
stomach, based on the original histological reports, immunohistochemical stains 
and clinical course. The median age at diagnosis of the primary breast cancer 
was 50 years (range 42 to 64) and of the gastric metastasis 56 years (range 47 
to 71); all metastatic breast cancers lacked staining of HNF4A (Figure 1A-D and 
Table 2). In all patients, ER and BRST-2 expression was high in primary breast 
cancer and metastases (Table 2). In one of these six patients (patient 5) the 
pathology report of the gastric biopsy mentioned both metastases of the breast 
cancer and a signet ring cell carcinoma of the stomach. This was not supported 
by immunohistochemistry. HNF4A was completely negative and there was high 
expression of ER, PR and BRST-2 in various tumor samples available of stomach, 
breast and ovaries (gastric biopsy and autopsy material). 
One patient was diagnosed with metastasis of diffuse gastric cancer to the 
breast, synchronously with the diagnosis of the gastric cancer (50 years of age, 
2 months between both diagnoses). Both the primary tumor and the metastasis 
were HNF4A positive, while ER, PR, and BRST-2 did not show expression (Figure 
1E-H and Table 2).
Thirteen patients presented with two primary carcinomas, one of the breast and 
the other of the stomach. According to initial pathology reports and review of 
cases, nine out of 13 patients had invasive ductal breast cancer, while the other 
Table 1. HNF4A expression in gastric carcinomas (TMA validation set)
Histological type of gastric 
carcinoma
Negative HNF4a 
staining
Focal HNF4a 
staining
Limited HNF4a 
staining
Diffuse HNF4a 
staining
Number of cases
Intestinal (tubular or papillary 
carcinoma)
1 4 14 43 62
Diffuse (poorly cohesive carcinoma, 
incl. signet ring cell morphology)
0 0 3 18 21
Undifferentiated carcinoma 0 1 3 10 14
Mucinous carcinoma 0 0 1 7 8
Mixed carcinoma 0 0 0 2 2
Total gastric samples 1 5 21 80 107
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Figure 1) A-I. H&E and HNF4A expression of breast and gastric carcinomas. A-D: patient (no 4) with 
primary lobular breast carcinoma (A,B) with metastases to the stomach (C,D) without expression 
of HNF4A (B,D). Note nuclear expression of HNF4A in normal gastric glands (D). E-H: patient 
(no 7) with primary diffuse gastric carcinoma (E,F) with metastases to the breast (G,H). Both in the 
stomach (F) and in the breast (H) diffuse staining of HNF4A. I-L: patient (no 11) with both primary 
carcinomas of the breast (I,J) and stomach (K,L). There is no expression of HNF4A in the breast (J) but 
diffuse expression in signet ring cells of the stomach (L). Original magnification of all images 200x.
G
I
H
J
LK
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four had invasive lobular breast cancer. The histology of gastric cancer showed 10 
diffuse	and	three	intestinal	carcinomas.	The	median	age	at	diagnosis	was	49	years	
(range	33-79)	 for	 the	first	and	58	years	 (range	40-85)	 for	 the	second	tumor.	The	
disease-free interval between diagnoses in patients with two primary carcinomas 
was approximately 4 years longer than in patients with metastatic disease. Four 
patients presented with gastric and 8 patients presented with breast cancer as the 
first	primary	tumor.	One	patient	had	a	synchronous	diagnosis	of	both	gastric	and	
breast cancer. In all patients, the primary tumors of the stomach stained positive 
for HNF4A, whereas the primary tumors of the breast were negative for HNF4A. 
In the primary gastric carcinomas there was no expression of ER, PR, and BRST-2. 
In the primary breast carcinomas there was expression of ER in 9/13, PR in 6/13 and 
BRST-2 in 11/13 cases (Figure 1I-L and Table 2). 
Table 2. Results of immunohistochemical expression in patients with a metastatic breast carcinoma 
(case 1-6), metastastatic gastric carcinoma (case 7), and 2 primary carcinomas of the breast and 
stomach (case 8-18)
Index No Gender Breast - histology HNF4A ER PR BRST-2 Stomach HNF4A ER PR BRST-2
1 F LBC 0 3 3 3 Metastasis LBC 0 3 1 2
2 F LBC 0 3 2 3 Metastasis LBC 0 3 1 2
3 F LBC NA NA NA NA Metastasis LBC 0 3 2 3
4 F LBC 0 3 3 3 Metastasis LBC 0 3 2 3
5 F LBC 0 3 2 3 Metastasis LBC 0 3 0 3
6 F LBC 0 3 0 3 Metastasis LBC 0 3 0 3
7 F Metastasis DGC 3 0 0 0 DGC 3 0 0 0
8 F LBC 0 3 0 3 DGC 3 0 0 0
9 F LBC 0 3 0 2 DGC 3 0 0 0
10 F LBC 0 3 2 2 DGC 3 0 0 0
11 F DBC 0 3 3 2 DGC 3 0 0 0
12 M DBC 0 3 3 1 DGC 3 0 0 0
13 F DBC 0 3 3 1 DGC 3 0 0 0
14 F DBC 0 0 0 3 DGC 3 0 0 0
15 F DBC 0 2 0 3 DGC 3 0 0 0
16 F DBC 0 0 0 0 IGC 3 0 0 0
17 F DBC 0 3 3 2 IGC 3 0 0 0
18 F DBC 0 0 0 0 DGC 3 0 0 0
19 F DBC 0 0 0 2 IGC 3 0 0 0
20 F LBC 0 3 2 2 DGC 3 0 0 0
LBC= invasive lobular breast carcinoma; DBC= invasive ductal breast carcinoma; IGC= intestinal-
type gastric carcinoma; DGC= diffuse gastric carcinoma
staining pattern: 0=no staining; 1= focal <10%; 2= limited 10-50%; 3= diffuse >50% expression.
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DISCUSSION
The present study shows that HNF4A is a highly useful marker in discriminating 
primary and metastatic breast from gastric carcinomas with a sensitivity of 99% 
and specificity of 100%, supporting the data of Koyama et al.16 We also confirmed 
that ER, PR, and BRST-2 staining could be helpful, since none of the primary 
gastric cancers did show expression of these markers. However, since a portion 
of primary breast carcinomas are negative for ER, PR, and BRST-2, absence of 
staining for these antibodies does not exclude breast cancer. Furthermore, in 
general a positive marker is more reliable than a negative one, because technical 
failure can never be excluded in case of absent staining without a positive 
internal control. 
To the best of our knowledge this study describes the largest validation series of 
HNF4A staining to discriminate primary breast and primary stomach cancers thus 
far presenting data of 107 gastric and 105 breast cancer samples. Our data are 
supported by the study of Tanaka et al., in which HNF4A immunohistochemistry 
in	 the	 stomach	 was	 performed	 with	 a	 sensitivity	 and	 specificity	 of	 100%	 in	 14	
gastric cancer cases.18 In another study of Takano et al., expression was shown in all 
differentiated-type	early	gastric	carcinoma	samples	of	39	patients.20 In our series, 
one out of 107 gastric carcinomas tested negative, which could not be explained by 
technical failure as the surrounding normal gastric mucosa was positive.
Histological	 differentiation	 between	 primary	 or	 metastatic	 breast	 and	 gastric	
carcinoma	can	be	difficult.	It	has	been	suggested	that	univacuolated	signet	ring	cells	
are a feature of metastastic lobular breast carcinomas, rather than primary gastric 
carcinoma.22	 However,	 metastatic	 breast	 and	 primary	 diffuse	 gastric	 carcinoma	
often contain both uni- and multivacuolated signet ring cells.16, 22 All metastatic 
breast carcinomas in our series were lobular breast carcinomas, while most patients 
with two primary carcinomas had an invasive ductal breast carcinoma. 
Currently, for the differential diagnosis between gastric and breast carcinomas 
a panel that includes breast-associated immunomarkers ER, PR, BRST-2, and/or 
mammaglobin and the stomach-associated immunomarkers CDX2 and CK20 are 
often used. Breast carcinomas never show expression of CDX2 and almost never 
CK20 (approximately 1%).16,18,22-28 The disadvantage of these markers is that they 
are positive in only about 50% of gastric carcinomas (Table 3). With expression in 
99% of gastric cancers and 0% of breast cancers HNF4A outperforms both CDX2 
and CK20 as a positive predictor for gastric cancer. 
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Table 3. Literature of immunohistochemical expression in breast and gastric carcinoma
Antibody* Primary GC** Primary BC** Metastatic BC in GI-tract** p-value†
ER 16,22-25,27 0 81 (75-89) 74 (72-76) <,001
PR 16,23 0 71 (69-75) 33 (33) <,001
BRST-2 16,23,27 0 56 (33-75) 69 (62-78) <,001
CK7 22-25,27 59 (35-92) 92 (81-100) 90 (90) <,001
CK20 16,22-25,27,28 52 (18-100) 1 (0-5) 0 <,001
CDX2 16,22,23,25-27 57 (18-100) 0 0 <,001
HNF4A 16,18 100 0 0 <,001
MUC1 22,25,29,30 32 (17-67) 100 NA‡ <,001
MUC2 22,23,25,29,30 54 (42-92) 27 (3-100) 24 (24) <,001
MUC5AC 16,22,23,29,30 63 (38-85) 5 (0-17) 5 (5-6) <,001
MUC6 16,23,25,29 35 (27-58) 27 (8-50) 0 0,36
*Studies are included when immunohistochemistry was performed in both primary GC and BC
**data are given as percentage (range) of expression in cases
‡NA= not available
† Primary gastric adenocarcinoma versus primary breast carcinoma
In conclusion, our data validate HNF4A as a good marker and can be added to 
an immunohistochemical panel to differentiate between primary gastric cancer 
and breast cancer derived metastasis in the stomach. 
Acknowledgements: The authors would like to thank Monique Link (technical 
assistance).
165
6
REFERENCES
1.	 Fitzgerald	RC,	et	al.	Hereditary	diffuse	gastric	cancer:	updated	consensus	guidelines	for	clinical	
management and directions for future research. J Med Genet 2010; 47:436-44.
2. Pharoah PD, et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation 
carriers	from	hereditary	diffuse	gastric	cancer	families.	Gastroenterology 2001; 121:1348-53. 
3.	 Benusiglio	PR,	 et	 al.	CDH1	germline	mutations	 and	 the	 hereditary	 diffuse	gastric	 and	 lobular	
breast cancer syndrome: a multicentre study. J Med Genet 2013; 50:486-9.
4. Jakubowska A, et al. A high frequency of BRCA2 gene mutations in Polish families with ovarian 
and stomach cancer. Eur J Hum Genet 2003; 11:955-8. 
5. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. 
MedGenMed 2005; 7:60.
6. Moran A, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 
mutations. Fam Cancer 2012; 11:235-42. 
7. Graham WP, GASTRO-INTESTINAL METASTASES FROM CARCINOMA OF THE BREAST. Ann 
Surg 1964; 159:477-80. 
8. Choi SH, Sheehan FR, Pickren JW. METASTATIC INVOLVEMENT OF THE STOMACH BY BREAST 
CANCER. Cancer 1964; 17:791-7. 
9. Cifuentes N, Pickren JW. Metastases from carcinoma of mammary gland: an autopsy study. J 
Surg Oncol 1979; 11:193-205.
10. Reiman T, Butts CA. Upper gastrointestinal bleeding as a metastatic manifestation of breast 
cancer: a case report and review of the literature. Can J Gastroenterol 2001; 15:67-71. 
11. Almubarak MM, et al. Gastric metastasis of breast cancer: a single centre retrospective study. Dig 
Liver Dis 2011; 43:823-7. 
12. Taal BG, et al. The spectrum of gastrointestinal metastases of breast carcinoma: I. Stomach. 
Gastrointest Endosc 1992; 38:130-5.
13.	 Sato	T,	et	al.	Metastatic	breast	cancer	from	gastric	and	ovarian	cancer,	mimicking	inflammatory	
breast cancer: report of two cases. Breast Cancer 2008; 15:315-20. 
14. Hamby LS, et al. Gastric carcinoma metastatic to the breast. J Surg Oncol 1991; 48:117-21. 
15. Boutis AL, et al. Gastric signet-ring adenocarcinoma presenting with breast metastasis. World J 
Gastroenterol 2006; 12:2958-61. 
16. Koyama T, et al. Hepatocyte nuclear factor 4A expression discriminates gastric involvement by 
metastatic breast carcinomas from primary gastric adenocarcinomas. Hum Pathol 2011; 42:1777-84. 
17. Kojima K, et al. The expression of hepatocyte nuclear factor-4alpha, a developmental regulator 
of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas. 
Pathology 2006; 38:548-54. 
18. Tanaka T, et al. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear 
factor-4alpha in the pathogenesis of human cancer. J Pathol 2006; 208:662-72. 
19. Sladek FM, et al. Liver-enriched transcription factor HNF-4 is a novel member of the steroid 
hormone receptor superfamily. Genes Dev 1990; 4:2353-65. 
20. Takano K, et al. Immunohistochemical staining for P1 and P2 promoter-driven hepatocyte 
nuclear	 factor-4alpha	may	 complement	mucin	 phenotype	 of	 differentiated-type	 early	 gastric	
carcinoma. Pathol Int 2009; 59:462-70.
21. Sugai M, et al. Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous 
tumors. Pathol Int 2008; 58:681-6.
22. Chu PG and Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of 
the stomach, breast, and colon. Am J Clin Pathol 2004; 121:884-92.
166
HNF4A staining in gastric and breast carcinoma
23. O’Connell FP, Wang HH, Odze RD. Utility of immunohistochemistry in distinguishing primary 
adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol 
Lab Med 2005; 129:338-47. 
24 Tot T. The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic 
lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal 
tract. APMIS 2000; 108:467-72. 
25 Chu PG et al. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical 
study of 175 cases. Am J Surg Pathol 2011; 35:1830-6.
26.	 Werling	RW	et	al.	CDX2,	a	highly	sensitive	and	specific	marker	of	adenocarcinomas	of	intestinal	
origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg 
Pathol 2003; 27:303-10. 
27. Dennis JL et al. Markers of adenocarcinoma characteristic of the site of origin: development of a 
diagnostic algorithm. Clin Cancer Res 2005; 11:3766-72. 
28. Moll R et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by 
monoclonal antibodies. Am J Pathol 1992; 140:427-47. 
29.	 Nguyen	 MD,	 et	 al.	 Mucin	 profiles	 in	 signet-ring	 cell	 carcinoma.	 Arch Pathol Lab Med 2006; 
130:799-804.
30.	 Lau	SK,	Weiss	LM,	Chu	PG.	Differential	expression	of	MUC1,	MUC2,	and	MUC5AC	in	carcinomas	
of various sites: an immunohistochemical study. Am J Clin Pathol 2004; 122:61-9. 
167
6
168
169
7
Chapter 7
Unraveling genetic predisposition to familial or early 
onset gastric cancer using germline whole exome 
sequencing
Ingrid P Vogelaar, Rachel S van der Post, J Han J M van Krieken, Liesbeth Spruijt, Wendy A 
G van Zelst-Stams, C Marleen Kets, Jan Lubinski, Anna Jakubowska, Urszula Teodorczyk, 
Cora M Aalfs, Liselotte P van Hest, Hugo Pinheiro, Carla Oliveira, Shalini N Jhangiani, 
Donna M Muzny, Richard A Gibbs, James R Lupski, Joep de Ligt, Lisenka E L M Vissers, 
Alexander Hoischen, Christian Gilissen, Maartje van de Vorst, Jelle J Goeman, Hans K 
Schackert, Guglielmina N Ranzani, Valeria Molinaro, Encarna B Gómez García, Frederik 
J Hes, Elke Holinski-Feder, Maurizio Genuardi, Margreet G E M Ausems, Rolf H Sijmons, 
Anja Wagner, Lizet E van der Kolk, Inga Bjørnevoll, Hildegunn Høberg-Vetti, Ad Geurts 
van Kessel, Roland P Kuiper, Marjolijn J L Ligtenberg* and Nicoline Hoogerbrugge*
*Shared last authors
European Journal of Human Genetics 2017; 25(11):1246-1252. 
170
Germline exome sequencing in gastric cancer patients
ABSTRACT
Recognition of individuals with a genetic predisposition to gastric cancer 
(GC) enables preventive measures. However, the underlying cause of genetic 
susceptibility to gastric cancer remains largely unexplained. We performed 
germline whole exome sequencing on leukocyte DNA of 54 patients from 53 
families with genetically unexplained diffuse-type and intestinal-type GC to 
identify novel GC predisposing candidate genes. As young age at diagnosis and 
familial clustering are hallmarks of genetic tumor susceptibility, we selected 
patients that were diagnosed below the age of 35, patients from families with 
two cases of GC at or below age 60 and patients from families with three GC 
cases at or below age 70. All included individuals were tested negative for 
germline CDH1 mutations prior to or during the study. Variants that were 
possibly deleterious according to in silico predictions were filtered using several 
independent approaches that were based on gene function and gene mutation 
burden in controls and GC tumors. Despite a rigorous search, no obvious 
candidate GC predisposition genes were identified. This negative result stresses 
the importance of future research studies in large, homogeneous cohorts.
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INTRODUCTION
Annually, almost one million people develop gastric cancer (GC) and 
approximately 723,000 people die of this disease worldwide.1 This makes GC the 
fifth most common malignancy and the third leading cause of cancer-related 
mortality worldwide.1 In Western Europe, the incidence of gastric cancer (GC) 
is 8.8 per 100,000 persons for men and 4.3 per 100,000 persons for women.1 GC 
is a multifactorial disease in which both genetic and environmental factors are 
involved. The main environmental factor is infection with Helicobacter pylori, 
which increases the risk of developing GC about six-fold.2 The World Health 
Organization (WHO) classified H. pylori as a class I carcinogen in 1994.3,4 
GC is a heterogeneous disease and can be roughly divided into three main types; 
diffuse-type GC, intestinal-type GC and a remaining group composed of mixed 
and indeterminate GC types.5 Diffuse-type GC (DGC) consists of poorly cohesive 
single cells without gland formation. Due to the frequent presence of signet ring 
cells, this type of GC is often referred to as signet ring cell carcinoma. Intestinal-
type GC (IGC) is composed of glandular or tubular components with various 
degrees of differentiation.6 In both low- and high GC incidence countries, 
around 8-30% of patients with GC have a familial history of GC.7-11 Germline 
CDH1 pathogenic mutations, predisposing to hereditary diffuse gastric cancer 
(HDGC), have been encountered in a subset of GC families.12-19 The International 
Gastric Cancer Linkage Consortium has recently broadened the CDH1 testing 
criteria with the aim to identify as many CDH1 mutation carriers as possible.20
Families in whom no germline CDH1 mutation can be identified remain genetically 
unexplained and may carry pathogenic mutations in other, yet unknown, GC 
susceptibility genes. Recently, DGC families with mutations in CTNNA116,21 and 
MAP3K622 have been described, but the exact contribution of these genes to 
GC predisposition remains unclear until more families with mutations in these 
genes are reported. In families with IGC exhibiting an autosomal dominant 
inheritance pattern, genetic susceptibility genes may also play a role, but no 
genes have yet been associated with this type of GC.
The aim of the current study was to identify novel candidate GC susceptibility 
genes using whole exome sequencing of germline DNA isolated from the blood of 
patients suspected of genetic predisposition for GC, but without CDH1 mutations.
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MATERIALS & METHODS
Patient selection for exome sequencing
In our exome sequencing cohort, 54 patients from 53 families meeting one of 
the following criteria were included: one gastric cancer diagnosed below the 
age of 35 years, two GC cases diagnosed in first- or second-degree relatives at 
or below the age of 60 years (index diagnosed at or below the age of 50 years) 
or three cases of GC in first- or second-degree relatives diagnosed at or below 
70 years of age. The majority of the patients (n=33) had previously been proven 
negative for CDH1 mutations. For each family a single patient was included, 
with the exception of one family for which two patients were tested. Patient 
characteristics are shown in Table 1. This study was approved by the medical 
ethics committee of the Radboud university medical center, reference number 
2013/201 and the Institutional Review Board of the Baylor College of Medicine.
Exome sequencing, variant annotation and exclusion of normal 
variation
Detailed information on the sequencing statistics of individual samples can be 
found in Supplementary Table 1. Whole exome sequencing of genomic DNA 
extracted from peripheral blood cells of the patient was performed using the 
5500XL SOLiD platform (Life Technologies, Bleiswijk, the Netherlands) for 26 
samples and on the Illumina HiSeq (2x100bp paired end; Illumina) for 13 samples 
(BGI, Copenhagen, Denmark).
Exome enrichment was performed using either the human SureSelect All Exon 
50Mb kit (n=11) or the human SureSelect All Exon V4 kit (n=28), targeting the 
coding regions of approximately 21,000 human genes (Agilent Technologies, 
Santa Clara, CA, United States). Reads were mapped to the Human Genome 
Reference Assembly GRCh37/hg19 using LifeScope software (Life Technologies) 
for samples sequenced on the SOLiD instrument and variants were called with 
the DiBayes algorithm. Exomes that were sequenced on the Illumina instrument 
were mapped using BWA and variants were called with GATK. All variants were 
annotated using an in-house annotation pipeline, as described previously.23,24
For 15 patients, exome sequencing was performed through the Human Genome 
Sequencing Center at Baylor College of Medicine, according to previously 
described methods.25,26 Sequencing was performed on the Illumina HiSeq 
2000 platform (Illumina). Subsequently, reads were mapped and aligned 
to the Human Genome Reference Assembly GRCh37/hg19 using the BCM-
173
7
HGSC Mercury pipeline.27 Variant calling was performed with the Atlas228 
and SAMtools29 algorithms; variant annotation was performed with an in-
house developed annotation pipeline30 based on ANNOVAR.31 Custom scripts 
were used incorporating multiple databases to retrieve more information on 
identified variants.
From	our	total	set	of	variants	we	selected	high-confidence	(≥5	variant	reads	or	
≥20%	variant	 reads)	non-synonymous	variants	 that	were	absent	 from	dbSNP	
or had a dbSNP (v132) frequency <1% and which occurred at most once in 
our in-house variant database (2,096 exomes, the majority of which are from 
European ancestry).23
Enrichment of truncating variants compared to controls
The number of different truncating variants (nonsense variants, indels leading 
to a frameshift and variants in canonical splice sites) per gene was established 
for our dataset and an independent in-house database containing 2,329 exomes. 
Also, the number of genes with a given number of variants was determined for 
the combined datasets. The Fisher’s exact test (incorporated in the IBM SPSS 
Statistics Software package version 20, IBM Corporation, USA) was used to 
determine whether the number of variants for a certain gene in our set was 
enriched compared to the control dataset. To correct for multiple testing we 
used the modified Bonferroni procedure for discrete data32 based on the number 
of genes with the same number of truncating mutations observed in the gene 
of interest. All genes with a p-value <0.05 after multiple testing correction were 
included for further analysis.
Variant prioritization based on gene function
Missense	 variants	 with	 a	 PhyloP	 ≥3	 in	 selected	 pathways	 (see	 below)	 were	
analyzed using the Alamut 2.0 software package (Interactive Biosoftware, 
Rouen, France), which incorporates SIFT,33 Align GVGD35 and dbSNP (build 135). 
Missense variants that were predicted deleterious/damaging by at least two of 
these programs were considered possibly deleterious. Data was analyzed using 
Alamut software between September 2013 and December 2014. 
These possibly deleterious missense variants and the truncating variants were 
prioritized based on gene function using the following criteria. The first criterion 
used included variants in known hereditary (gastric) cancer predisposing 
genes. For this analysis we used an in-house generated list of 113 genes (see 
Supplementary Table 2). In addition, we assessed the recently described GC 
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predisposing genes CTNNA116,21 and MAP3K622 for variants. Second, we selected 
genes putatively involved in GC development. A gene list (see Supplementary 
Table 2) for this category was composed by combining a list of known tumor-
suppressor genes36 with genes from the following KEGG pathways37: regulation 
of actin cytoskeleton (entry 04810), adherens junction (entry 04520), focal 
adhesion (entry 04510), epithelial cell signaling in Helicobacter pylori 
infection (entry 05120) and pathways in cancer (entry 05200). Third, based 
on the detection of a homozygous putatively deleterious variant in MYD88 
in one of the patients of this cohort,38 we used the Resource of Asian Primary 
ImmunoDeficiencies (RAPID) gene list,39 an in-house generated candidate gene 
list	and	three	KEGG	pathways	(JAK-STAT	pathway	(entry	04630),	NFκB	pathway	
(entry 04064) and TLR pathway (entry 04620)37 to select variants known to 
predispose to immunodeficiencies. As a fourth criterion, we selected genes with 
a high expression in the stomach (based on data from the Tissue-specific Gene 
Expression and Regulation (TiGER) database40). The combined gene list for the 
categories mentioned above can be found in Supplementary Table 2. 
The National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing 
Project (ESP; 6,503 exomes) database (hereafter referred to as EVS41), which 
contains sequencing data of approximately 6,500 individuals of European and 
African descent was used to assess whether selected variants were present 
in individuals selected for other diseases than cancer. Furthermore, we used 
a second in-house database containing 2,329 exomes with high coverage to 
exclude common variants. Finally, the database from the Exome Aggregation 
Consorium (ExAc42) was used to obtain the frequency of specific variants in a 
larger control population. 
For all truncating variants affecting genes not represented in the selected 
pathways presented above, the possible relation of the affected gene with GC 
tumorigenesis was evaluated based on the known function of the gene. Variants 
described in this manuscript and Supplementary Tables are submitted to the 
Leiden Open Variant Database (LOVD, ID numbers 103989 – 104041).
Validation of variants and CDH1 exon 1 germline mutation analysis 
by Sanger sequencing
The DNA sequence surrounding the variant was amplified using polymerase 
chain reaction (PCR, primer sequences and PCR conditions are available on 
request) and screened for mutations using Big-Dye terminator sequencing 
(BigDye Terminators (v 1.1) Applied Biosystems, USA). Analysis was performed 
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on an ABI 3730 DNA Analyzer (Applied Biosystems). Subsequently, the data 
were analyzed using Vector NTI advance v11.0 (Invitrogen Corporations, USA) 
or Chromas Lite (Technelysium, Australia). For mutation analysis of CDH1 exon 
1 in a subset of the patients, primers surrounding the intron-exon boundaries 
of this exon were used. PCR and sequencing was performed as described for 
variant validation.
RESULTS
Patient cohort and characteristics
Whole-exome sequencing was performed on germline DNA from 54 patients 
of 53 families. In this cohort 23 patients below the age of 35 were included (two 
without a family history of GC), 16 patients had two cases of GC in the family at 
or below the age of 60 and 15 patients were from families with three or more 
GC cases at or below 70 years of age; in this group two patients from one family 
were included. The mean age at diagnosis of all patients included was 37.9 years 
(SD 11.9, range 22-70). According to the original pathology reports, 27 patients 
had DGC, 8 patients had IGC, one GC was mixed-type and 18 tumors were 
‘adenocarcinoma not otherwise specified’. For 17 cases, we were able to review 
and confirm the histology of the GC (12 patients with DGC and five with IGC). 
For the remaining cases no revision could be performed.
Exome sequencing statistics
Three different enrichment kits and two different sequencing platforms were 
used for exome sequencing. On average, 5.2 Gb of data aligned to targets was 
generated per sample (range: 2-10.2 Gb), hitting 98.9% of the targets (96-
99.98%) with an average coverage of 81.7x (36.8-132x). A coverage of at least 10-
fold was reached for 93.3% of the targets (81.1-99.31%) and 87.7% was covered 
at least 20-fold (68.9-98.19%). The statistics for individual exome sequencing 
data can be found in Supplementary Table 1. Approximately 9,200 variants from 
54 cases remained (average 170, range 87-379). To test our quality settings, we 
performed Sanger sequencing on a subset of these variants and found that we 
were able to confirm 93% of the variants.
Variants in previously described gastric cancer predisposition genes
None of the cases carried pathogenic mutations in CDH1. Also, no variants 
were found in CTNNA1, which has recently been described as GC-predisposing 
gene.16,21 Three variants were identified in MAP3K6; two missense variants 
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(p.Y591C and p.L541P) and one amino acid deletion (p.K1125del). MAP3K6 has 
been associated with familial GC.22 However, based on the high number of MAP3K6 
variants found in non cancerous controls, we did not follow up on these variants.
Enrichment of truncating variants compared to controls
As the deleterious effect of truncating variants (nonsense variants, indels 
leading to a frameshift and variants in canonical splice sites) is most prominent, 
we tested whether the recurrence of truncating mutations in a given gene was 
different from that in a control exome sequence dataset of 2,329 individuals. 
In our dataset, in 12 genes two different truncating variants occurred 
(Supplementary Table 3). After correction for multiple testing, no enrichment 
of truncating variants was found in these genes compared to the control cohort.
Occurrence of homozygous or compound heterozygous variants
To explore the occurrence of pathogenic changes in GC predisposition genes 
that follow a recessive inheritance pattern, we explored whether missense and/
or truncating variants occurred in a homozygous or compound heterozygous 
form in our set of patients with an age at diagnosis below 35. Apart from a 
germline homozygous missense variant in MYD88 in a patient with GC at age 23 
and recurrent candidiasis, which we previously published,38 no other candidate 
genes were found.
Variant prioritization based on gene function
Because of the large amount of missense and truncating variants, prioritization 
was performed based on the function and recurrence of the affected genes. 
To select variants that may be involved in GC predisposition, we created a 
gene list composed of 1,899 genes (for details see Materials and Methods 
and Supplementary Table 2). Our exome data were then filtered for variants 
in these genes. After in silico prediction, 252 possibly deleterious variants 
were identified using this approach (on average 5 per patient, range 1-11). The 
number of variants in the individual pathways and databases can be found in 
Table 2, variant details are shown in Supplementary Table 4 (excluding variants 
that were not confirmed after validation using Sanger sequencing). Twenty-
one variants were identified in known cancer predisposing genes (Table 2 and 
Supplementary Table 4), including four different heterozygous variants (two 
truncating and two missense) in the ATM gene, previously associated with a 
small increased GC risk (RR = 3.39, 95% CI = 0.86 to 13.4).43 No obvious candidate 
GC predisposition genes were identified from either the hereditary cancer list, or 
the other pathways we selected. In addition, for all truncating variants affecting 
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genes not represented in the selected pathways, the putative relation with GC 
tumorigenesis of the affected gene was evaluated based on the known function 
of the gene. This did not result in a convincing candidate gene.
DISCUSSION
In the current study, whole-exome sequencing was performed on germline 
DNA from 54 GC patients from 53 families with the aim to identify novel GC 
susceptibility genes. In order to increase the likelihood of finding a putative 
causative mutation underlying GC, these patients were selected from families 
at high risk of a genetic predisposition, who met strict inclusion criteria. No 
clear novel GC predisposition gene was identified. Mutations in CDH1 were 
not detected in the 21 cases for which no CDH1 mutation analysis had been 
performed prior to our study. 
In two recent studies, germline mutations in CTNNA1 were identified in families 
with GC.16,21 This gene is in the same pathway as E-cadherin, making it a plausible 
GC predisposition gene. In our dataset of 54 patients no mutations in CTNNA1 
were found, which indicates that mutations in this gene probably do not explain 
a large proportion of the early onset gastric or familial cancer in patients that 
tested negative for germline CDH1 mutations. Gaston et al. reported on variants 
in the MAP3K6 gene in familial GC.22 We have also observed variants in this gene, 
but we do not consider this gene a strong GC candidate gene for two reasons. 
Firstly, in the study by Gaston et al. the gene variant p.P946L was identified in a 
large family, but the variant does not completely segregate with the disease.22 
Secondly, this variant occurs quite frequently in the ExAc database (n=640 / 
0.5% allele frequency). This argues against its pathogenicity, simply because it 
is not expected that a variant that occurs so frequently in a database containing 
exomes of people without suspicion of hereditary cancer would cause GC, a 
relatively rare form of hereditary cancer.
The observation that frequently occurring variants are reported as candidate 
genes for GC development stresses the importance to determine the frequency 
of variants in candidate genes in local and public control datasets in addition to 
assessment of functional relevance. In the current study, we have used three 
datasets to compare our exome data with. The first one is an independent 
in-house database containing 2,329 exomes sequenced with high coverage. 
The second one is the EVS database,41 which contains sequencing data of 
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approximately 6,500 individuals of 263 European and African descent. The third 
is the ExAc database,42 containing exome data of 60,706 unrelated individuals. 
These datasets allowed for more stringent filtering of the data. 
Even	though	we	identified	over	9,200	rare	variants	in	these	54	patients,	we	were	
unable to unequivocally show that among these are the disease-causing variants 
and, therefore, GC predisposing genes. There may be several reasons for the fact 
that	we	did	not	find	clear	candidate	genes	in	the	current	study.	For	example,	the	
large	amount	of	variants	in	our	dataset	may	have	influenced	our	ability	to	recognize	
candidate genes as such. Additionally, a gene similar to the previously described 
CTNNA1 mutations (which account for only a small portion of GC families) may 
well have remained undetected in our dataset. Furthermore, our strictly selected 
patient cohort might be too small to identify candidate genes, especially to 
determine enrichment of genes or pathways compared to controls. Another 
reason is that, even though we used strict criteria for the selection of families, 
the patient group that we included in this study is still quite heterogeneous. We 
included patients with both DGC and IGC, who were either diagnosed at young 
age or had a family history of GC. For a number of cases the histological subtype 
was unknown, underscoring the importance of extensive pathological review and 
reporting of GC according to current guidelines.20 It may be very well possible that 
performing whole-exome sequencing in a more homogeneous patient cohort 
may allow for improved detection of candidate genes, although other studies also 
did not identify promising new GC predisposition genes.16,44,45 Also, we performed 
exome sequencing, whereas predisposing variants may also be in nonprotein 
coding parts of the genome, currently not analyzed. Since we collected only one 
family	member	for	each	family	and	affected	family	members	are	often	deceased	
due to the cancer, we were not able to follow-up on potential candidate genes. 
Finally, it could be possible that some of the patients we included developed 
cancer because of chance and occasional familial clustering or complex inheritance 
involving multiple genomic alterations.
Future perspectives
Taken together, we performed exome sequencing in 54 CDH1 mutation-
negative patients from 53 families. In this study we did not identify obvious 
candidate genes for GC predisposition. Future studies should be performed 
in larger, homogeneous patient groups and we would suggest that data from 
different research groups should be combined to identify candidate genes in 
these families. If candidate genes are identified this way, it will enable better 
preventive care in carriers of these mutations.
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Table 2. Number of potential deleterious variant calls in different pathways.
Pathway / gene list (number of genes in pathway) Total number of variants 
KEGG Actin cytoskeleton (151)1 17
KEGG Adherens junction (73)1 20
KEGG Focal adhesion (205)1 43
KEGG Helicobacter pylori (68)1 4
KEGG JakSTAT pathway (158)1 3
KEGG NFkB signaling (92)1 12
KEGG TLR pathway (106)1 7
KEGG Pathways in cancer (327)1 48
TiGER database (207)2 16
Asian Primary ImmunoDeficiencies (247)3 38
In-house generated gene list of genes predisposing to immunodeficiencies (271) 37
In-house generated gene list of genes predisposing to hereditary cancer (113) 21
Human TSGene (716)4 107
1See reference 37; 2See reference 40; 3See reference 39; 4See reference 36. 
Supplementary material (available upon request)
Supplementary table 1: Whole-exome sequencing statistics for individual 
exomes.
Supplementary table 2: Gene list generated by combining several databases.
Supplementary table 3: Variant list for genes with multiple truncating mutations 
in multiple families.
Supplementary table 4: Variant list.
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ABSTRACT
In approximately 10% of all gastric cancer (GC) cases, a heritable cause is 
suspected, but in the majority of these cases, a causative germline defect 
remains unknown. Possibly, a subset of these GCs is explained by germline 
mutations in the novel candidate GC predisposing genes CTNNA1, MAP3K6 or 
MYD88. However, the GC predisposing effect of germline mutations in these 
genes and the frequency of such aberrations in GC patients have not been fully 
established yet. 
We sequenced a large cohort of unexplained young and/or familial GC patients 
(n=286) without a CDH1 germline mutation for germline variants affecting 
CTNNA1, MAP3K6 and MYD88 using a targeted next generation sequencing 
approach based on single-molecule molecular inversion probes (smMIPs).
Predicted deleterious germline variants were not encountered in MYD88, but 
recurrently observed in CTNNA1 (n=2) and MAP3K6 (n=3) in our cohort of GC 
patients. In contrast to deleterious variants in CTNNA1, deleterious variants in 
MAP3K6 also occur frequently in the general population. 
Based on our results MAP3K6 should no longer be considered a GC predisposition 
gene, whereas deleterious CTNNA1 variants are confirmed as an infrequent 
cause of GC susceptibility. The relevance of biallelic MYD88 germline mutations 
remains to be established.
191
8
INTRODUCTION 
In familial or early-onset gastric cancer (GC) cases, a heritable germline 
aberration may underlie the development of GC. Elucidation of these germline 
defects is crucial to improve the clinical management of these patients and their 
relatives at risk. Pathogenic germline mutations in the CDH1 gene predispose 
to the development of hereditary diffuse gastric cancer (HDGC) with high GC 
risk of up to 70%.1, 2 In more than 75% of the families that fulfil the CDH1 testing 
criteria3 a causative germline mutation in CDH1 cannot be identified.2, 4, 5 In 
addition to these unexplained HDGC families, no heritable germline defects 
predisposing to the development of familial mixed- and intestinal-type GC have 
been identified yet. Consequently, the putative causative germline aberration 
remains unknown for the majority of GC patients.
The introduction of next generation sequencing has revolutionized the 
identification of novel germline defects predisposing to (Mendelian) diseases, 
including heritable cancer syndromes.6-8 CTNNA1, MAP3K6 and MYD88 are 
considered novel candidate GC predisposing genes.9-11. Thus far, only the 
recurrence of CTNNA1 mutations was confirmed in an independent study.2 
Here, we describe the sequencing of germline DNA of a large cohort of CDH1 
mutation-negative GC patients (n=286) for variants affecting CTNNA1, MAP3K6 
and MYD88 to further determine their potential role as GC predisposing genes.
MATERIALS AND METHODS
Patient selection
Our selected cohort was counselled in 16 different centres throughout Europe 
and contained 299 GC patients from 297 families (Netherlands (n=193), Poland 
(n=76), Germany (n= 12), Italy (n=12), Portugal (n=5), Norway (n=1)). All patients 
had early-onset GC (before the age of 50) and/ or a family history of GC with 
first- and/or second-degree relatives with GC (for details see supplementary 
file 1). Since germline variants in MAP3K6 have also been identified in patients 
with intestinal-type GC and the predisposing phenotypes of CTNNA1 and MYD88 
germline mutations are uncertain, patients with all histologic adenocarcinoma 
subtypes of GC (i.e. intestinal-, diffuse- and mixed-type) were included. The 
absence of CDH1 germline mutations was confirmed in all patients previously 
tested outside the Radboud university medical center using smMIP-based 
targeted sequencing of CDH1 on germline DNA. For 13 patients samples were 
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excluded,	as	the	coverage	did	not	fulfill	our	pre-determined	quality	criteria	(≥95%	
of the open reading frame covered with at least 15 unique reads). Therefore, 
our cohort contained 286 GC patients without a causative pathogenic germline 
aberration affecting CDH1. Prior to this study whole-exome and targeted 
MYD88 sequencing was performed for 38 and 62 patients, respectively.11, 12 This 
study was approved by the medical ethics committee of the Radboud university 
medical center, reference number 2013/201.
Targeted sequencing and data analysis
To determine the germline status of CTNNA1, MAP3K6 and MYD88 in GC 
patients, we applied targeted sequencing using single-molecule molecular 
inversion probes (smMIPs) on blood-derived DNA of these patients according 
to previously published methods13-16. Data was analyzed using the SeqNext 
software package version 4.3.0 (JSI medical systems GmbH). The ExAC database, 
containing whole-exome sequencing data derived from 60,706 individuals, was 
used as a control dataset to establish the variant allele frequency of variant calls 
in the general population (Exome Aggregation Consortium (ExAC), Cambridge, 
MA (http://exac.broadinstitute.org) [01/04/2017 accessed]).17 For details, see 
Supplementary file 2.
RESULTS
Targeted smMIP-based sequencing of CTNNA1, MAP3K6 and MYD88 was 
performed on germline DNA samples derived from 286 GC patients from 284 
families without a causative germline mutation affecting CDH1. Variant calling 
could not be performed for three of these samples due to a low amount of total 
aligned unique reads obtained for these samples (153, 190 and 3.695 unique 
reads, respectively), see Figure 1A. For the remaining 283 samples, representing 
147 patients fulfilling HDGC criteria, 26 patients fulfilling FIGC criteria, 76 
patients with familial GC and 34 patients diagnosed with GC between the age of 
40 and 50, the total number of aligned unique reads (median number of aligned 
unique reads: 26.012 [range 6.373-145.043]), as well as the average coverage of 
the protein coding regions (including canonical splice sites) of CTNNA1, MAP3K6 
and MYD88 was high (Supplementary file 3). In total 331 non-synonymous 
variants were called. After exclusion of common SNPs (MAF>0.01; n=303), 28 
variants remained for subsequent interpretation (Figure 1A and Table 1).
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Figure 1. panel figure
A) Flowchart representing patient inclusion and subsequent germline analysis for CTNNA1, 
MAP3K6 and MYD88. aone truncating germline variant in CTNNA1 was identified in a relative 
of an known CTNNA1 family 9. bone missense variant was identified in a homozygous state and 
previously reported 11. B) Pedigree of the Polish HDGC patient (746A) who carried a p.Asn443fs 
variant in CTNNA1. C) Pedigree of the Dutch HDGC patient (432A) who carried a p.Arg330fs variant 
in CTNNA1. D) Microscopic image of DGC of patient 432A. Poorly cohesive polymorphic cells 
proliferate individually underneath normal gastric glands with foamy cytoplasm and sometimes 
signet ring cell morphology (H&E, 250x).  Abbreviations: Leu= leukemia, GC= gastric cancer, DGC= 
diffuse-type gastric cancer
A)
B)
D)
C)
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In CTNNA1 a heterozygous germline variant was observed in seven patients 
(Table 1). An individual with the frameshift mutation p.Arg27fs turned out to be a 
family	member	of	the	first	reported	CTNNA1 family 9 and this case was discarded 
from further analyses. Two frameshift variants, p.Asn443fs and p.Arg330fs, were 
not observed in the control dataset and were concidered deleterious. The variant 
p.Asn443fs	 was	 identified	 in	 a	 Polish	 HDGC	 patient	 diagnosed	 with	 a	 poorly	
differentiated	(not	otherwise	classified)	gastric	adenocarcinoma	at	age	30	(family	
pedigree provided in Figure 1B). The variant p.Arg330fs was encountered in a Dutch 
HDGC	patient	diagnosed	with	a	diffuse-type	GC	(poorly	cohesive	adenocarcinoma,	
with	signet-ring	cell	differentiation,	according	to	the	WHO	classification)	at	age	
40 (family pedigree provided in Figure 1C). Subtotal gastrectomy revealed a 
tumor extending into the subserosal fat tissue with three lymph node metastases 
(classified	as	a	stage	 IIIA,	TNM	7th edition 18, see microscopic image Figure 1D). 
There	was	a	background	of	chronic	inflammation	with	intestinal	metaplasia.	Four	
missense variants were recurrently encountered in the general population and are 
likely benign SNVs based on in-silico predictions (Table 1).
In MAP3K6 a total of 18 heterozygous variants (12 unique variants) were 
observed in 16 patients (Table 1). A nonsense variant (p.Gln1188*) and canonical 
splice site variant (c.1256-2A>G; identified in two unrelated patients), were 
recurrently encountered in the control dataset at low frequency. Two missense 
variants, p.Asp200Tyr and p.Pro946Leu, which have previously been associated 
with familial GC, occur two and three times in our cohort, respectively.10 
However, both variants are also frequently observed in the control dataset. The 
variant frequencies in our GC cohort and the control dataset are not significantly 
different (P=0.8 and P=1.0, respectively). Similarly, one highly conserved and 
predicted deleterious missense variant, p.Pro985Leu, was observed in two GC 
patients, but was observed at similar frequencies in the control dataset (P=0.2). 
Five other missense variants, representing four different SNVs, were weakly 
conserved (PhyloP <2) and/or predicted to be benign using in silico predictions 
(Table 1). The three remaining missense variants, p.Ala334Val, p.Leu541Pro and 
p.Tyr591Cys, which were called in the germline of three different GC patients, 
are moderately/highly conserved, predicted (possibly) pathogenic and (nearly) 
absent in the control dataset (Table 1).
In MYD88 the homozygous p.Arg238Cys variant was detected in the patient 
already reported by us 11. Two unrelated GC patients had a heterozygous missense 
variant,	p.Thr84Ile	and	p.Arg173His.	These	variants	affect	poorly	conserved	amino	
acids and are likely benign based on in-silico predictions (Table 1). 
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To determine a potential enrichment of strong loss-of-function germline variants 
(i.e.	nonsense	variants,	frameshift	variants	and	variants	affecting	a	canonical	splice	
site) in CTNNA1, MAP3K6 and MYD88 in our GC cohort compared to the general 
population, the frequency of such variants was established in 60,706 individuals 
with exome data in the public domain. The cumulative variant allele frequency 
(cVAF) of strong loss of function germline variants in CTNNA1 and MYD88 is low 
in the general population (cVAF: 0.000057879 and 0.000074822, respectively). In 
contrast, such variants in MAP3K6 are relatively common (cVAF: 0.004688221). 
Based on these numbers, the number of germline truncating alleles in CTNNA1 was 
highly	significantly	enriched	in	GC	patients	compared	to	the	general	population	
(2/564 vs. 7/121,412, P< 0.0001), whereas this was not the case for strong loss-
of-function	 alleles	 affecting	MAP3K6 (3/566 vs. 509/121,412, P=0.94) or MYD88 
(0/566 vs. 9/121,412, P=0.84). (for details see Supplementary file 2).
DISCUSSION
To further establish the GC predisposing effect and prevalence of germline 
aberrations affecting CTNNA1, MAP3K6 and MYD88, we sequenced a large 
cohort of unexplained, CDH1-negative, familial and/or young GC patients (n=283) 
using a targeted next generation sequencing approach. These 283 patients had 
early-onset GC (before the age of 50) and/or a family history of GC; 148 patients 
fulfilled HDGC/CDH1 testing criteria.19 This cohort was significantly enriched 
for truncating germline variants in CTNNA1, confirming that loss-of-function 
mutations in CTNNA1 predispose to the development of (familial) HDGC.
The putative GC predisposing role of CTNNA1, encoding the protein αE-catenin, 
was first established in a large Dutch HDGC family with multiple affected family 
members.9	αE-catenin	functions	in	the	same	junctional	complex	as	E-cadherin,	
encoded by the main HDGC predisposing gene CDH1. Subsequent screening by 
Majewski et al. of 25 other HDGC pedigrees did not reveal any additional loss-
of-function germline variants affecting this gene.9 Hansford et al. revealed two 
additional families with a germline mutation affecting CTNNA1 in 144 HDGC/
FGC.2 In the current study, we detected two germline truncating mutations in 
CTNNA1 in two unrelated GC cases. Therefore, a total of five CTNNA1 mutation-
positive GC families have now been identified (see supplementary file 4). The 
clinical picture of these CTNNA1 families is similar to that of CDH1 mutation-
positive families, except that no lobular breast cancer was reported thus far. The 
diffuse morphology could not be established for all affected relatives because 
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not all original pathology reports or specimens were available. The age of onset 
of cancer in confirmed CTNNA1-mutation carriers with GC varies between 22 to 
72 years.2 The incidence of heterozygous germline mutations in CTNNA1 is low in 
unexplained GC families (~1-2%). Due to the limited number of CTNNA1 families 
identified, proper estimation of disease penetrance and evidence-based advice 
on preventive measurements is not yet possible. 
Heterozygous germline aberrations affecting MAP3K6 were reported in multiple 
unrelated individuals with familial GC.10 Initially, a heterozygous missense 
mutation (p.Pro946Leu) was identified, that partly co-segregated with the 
development of GC in a large family. Remarkably, a 80 years old homozygous 
family member was never diagnosed with cancer. Subsequent targeted screening 
on germline DNA derived from 115 unrelated unexplained GC cases with intestinal 
and/or diffuse-type GC revealed five additional heterozygous germline variants 
affecting MAP3K6 (i.e., one frameshift- and four missense variants).10 However, 
most of these variants are recurrently encountered in control cohorts as well, 
and in silico predictions to determine their pathogenicity, reveal inconsistent 
results. In our study, we also found multiple variants in MAP3K6, however, these 
also occur frequently in the general population. In fact, strong loss-of-function 
germline variants affecting MAP3K6 are encountered in approximately 0.5% of 
the general population, clearly conflicting with a highly-penetrant predisposing 
effect of a, in Western populations, rare phenotype like GC. Therefore, germline 
aberrations affecting MAP3K6 are unlikely to be involved in high-penetrant GC 
predisposition. 
In contrast to the proposed dominant inheritance patterns of GC predisposition 
due to CTNNA1 and MAP3K6 mutations, we previously reported that germline 
mutations	 affecting	 MYD88 may predispose to the development of GC in a 
recessive manner.11 A homozygous missense variant (p.Arg238Cys) in MYD88 was 
identified	in	an	individual	suffering	from	recurrent	candidiasis	and	diffuse-type	GC	
at young age (23y). This mutation results in an impaired immune response and, 
possibly, an increased GC risk.11	Identification	of	additional	GC	patients	with	biallelic	
deleterious MYD88 variants would have further supported the role of MYD88 in GC 
predisposition, however such variants were not detected in our cohort. 
To evaluate the role of proposed cancer predisposing genes, it is crucial to 
test large cohorts in independent studies, as incorrect associations between 
germline aberrations and an increased lifetime risk to develop cancer will result 
in unnecessary screenings and inappropriate clinical management of carriers of 
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such aberrations. In the current study, we confirm that inactivating mutations 
in CTNNA1 are an infrequent cause of DGC predisposition. However, based on 
our data MAP3K6 should no longer be considered a GC predisposition gene. 
Biallelic MYD88 mutations as a cause of GC susceptibility are at most rare and a 
definitive association remains to be confirmed in other patients.
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Supplementary 1. Clinical criteria of included gastric cancer 
patients (n=299)
Category Criteria* Number
HDGC HDGC Criteria 2015:
One DGC <40 years (n=51)
Two or more GC, one DGC<50 (n=55)
Three or more DGC at any age (n=9)
1 DGC & 1 LBC, 1<50 (n=2)
New criterion HDGC guidelines 2015, 2 GC at least 1 DGC, not fulfilling one of the criteria 
above (n=33)
150
FIGC Criteria:
One IGC <40 years (n=11)
Two or more GC, one IGC<50 (n=14)
Three or more IGC at any age (n=3)
28
FGC/EOGC Familial GC or early-onset GC <40 years with mixed histology or (partly) 
unknown (not from all relatives were histology reports available):
Index with DGC (n=5)
Index with MGC (n=8)
Index with IGC (n=30)
Histology unknown (n=43)
86
Other One GC between age 40 – 50: 
Index with DGC (n=23)
Index with MGC (N=2)
 Index with IGC (n=4)
Index with GC, histology unknown (n=6)
35
*Included are first/second degree relatives affected by gastric cancer 
Supplementary 2. Materials and Methods
smMIP-based targeted sequencing
To determine the germline status of CDH1, CTNNA1, MAP3K6 and MYD88 in 
GC patients, we applied smMIP-based targeted sequencing on blood derived 
DNA of these patients (according to previously published methods13-16). Briefly, 
81 smMIPs were designed to target both DNA strands of the protein encoding 
genomic regions of CDH1 independently (i.e., double tiling). These smMIPs 
contained a stretch of eight random nucleotides to enable molecular tagging 
(smMIP sequences are available upon request). To sequence the open reading 
frame of CTNNA1, MAP3K6 and MYD88, a total of 63, 78 and 16 smMIPs were 
designed, respectively (smMIP sequences are available upon request). In 
contrast to the CDH1 smMIPs, these smMIPs contained a stretch of five random 
nucleotides for molecular barcoding and most genomic regions were only 
targeted by one smMIP. Following smMIP capture and endonuclease treatment 
(final volume 27µl), 20µl of the mixture was distributed equally across four PCR 
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reactions. A unique barcoded reverse primer was used per sample to enable 
subsequent equimolar pooling of multiple libraries. Sequencing of these pooled 
libraries was performed using the Illumina NextSeq 500 system. 
Data analysis
Prior	to	data	analysis,	fastq	files	were	separated	using	the	sample	specific	barcodes.	
Next,	these	fastq	files	were	analyzed	using	the	SeqNext	software	package	version	
4.3.0; JSI medical systems GmbH). Consensus reads were generated using the eight 
(CDH1)	 or	 five	 (CTNNA1, MAP3K6, MYD88) basepair molecular tags and variants 
were	called	if	the	corresponding	variant	was	observed	in	≥3	unique	reads,	≥5%	of	
all	unique	reads	and	≥10	unique	reads	were	observed	at	the	corresponding	genomic	
position.	After	manual	exclusion	of	mapping	artefacts	and	low	confident	variant	calls	
(percentage	variant	reads	≤10),	all	non-synonymous	variants	in	the	protein	coding	
regions	and	variants	affecting	 the	canonical	 splice	 sites	were	 selected.	The	ExAC	
database, containing whole-exome sequencing data derived from 60,706 individuals, 
was used as a control dataset to establish the variant allele frequency of germline 
variants in CDH1, CTNNA1, MAP3K6 and MYD88 in the general population (Exome 
Aggregation Consortium (ExAC), Cambridge, MA (http://exac.broadinstitute.org) 
[01/04/2017 accessed].17 To predict the pathogenicity of encountered germline 
variants, in silico analyses were performed using the Alamut software package 
(Alamut Visual version 2.9 (Interactive Biosoftware, Rouen, France)). 
Statistics
A two-tailed Chi-square test with Yates’ correction was performed to determine the 
potential	enrichment	of	germline	variants	affecting	CTNNA1, MAP3K6 and MYD88 
in GC patients compared to the general population (i.e., ExAC database). Patient 
270A, who is a family member of a previously published CTNNA1 family9, was 
excluded from the statistical analysis which was applied to determine if strong loss-
of-function germline variants in CTNNA1 were enriched in our GC cohort compared 
to the general population (reducing the number of CTNNA1 alleles in our cohort 
from 566 to 564).
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Supplementary 3. Average coverage of the open reading frame of 
CDH1, CTNNA1, MAP3K6 and MYD88 using smMIP-based targeted 
sequencing
Black and white boxes represent alternating exons, including the canonical 
splice sites of the respective genes. Coverage of the open reading frame was 
determined based on the average number of reads obtained per smMIP in 
107 (CDH1) and 283 (CTNNA1, MAP3K6 and MYD88) germline DNA samples of 
gastric cancer patients, respectively. X-axis: alternating exons. Y-axis: average 
number of unique reads mapping to the corresponding region.
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Chapter 9
Summarizing discussion and future perspectives 
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Summarizing and discussion
The aim of this thesis was to gain more knowledge on clinicopathological 
and molecular characteristics of familial and early-onset gastric cancer. 
The hereditary gastric cancer guidelines were evaluated, histopathologic 
characteristics were explored and genetic causes of familial and early-onset 
gastric cancer were investigated. In this chapter a summary with discussion 
points of the previous chapters is presented as well as future perspectives. 
EVALUATION OF HEREDITARY DIFFUSE GASTRIC 
CANCER GUIDELINES 
Guilford et al. detected germline variants in the CDH1 gene, encoding E-cadherin, 
as the cause of hereditary diffuse gastric cancer (HDGC) in three families of 
Maori descent.1 In 1999, the International Gastric Cancer Linkage Consortium 
(IGCLC) defined families with the HDGC syndrome (OMIM #137215)) as those 
fulfilling one of the two following criteria:2
• Two or more documented cases of diffuse gastric cancer (DGC) in first- or 
second-degree relatives, with at least one being diagnosed before the age of 
50 years; or
• Three or more cases of DGC in first- or second-degree relatives, independent 
of age of diagnosis. 
These IGCLC criteria were updated in 2010 by adding two criteria: “One individual 
with DGC before the age of 40 without a family history of gastric cancer” and 
“A personal or family history of DGC and LBC with one diagnosis before the 
age of 50”.3 We have evaluated the detection rate of these CDH1 testing criteria 
(Chapter 2). In this study CDH1 mutation analysis results of 499 families tested 
in the Radboud university medical center (reference centre in the Netherlands) 
as well as the corresponding clinicopathological data, and information on close 
relatives were collected and analyzed. Of the 499 families, 118 (24%) did and 
236 (47%) did not meet the HDGC criteria. In 145 (29%) families this could not be 
evaluated as data were incomplete. In 18 families, pathogenic CDH1 mutations 
were detected (4% of all families); 16 of these mutations were found in the 
118 families meeting the HGDC criteria for testing (14% detection rate). One 
pathogenic CDH1 mutation was detected in the 236 families that did not meet 
HDGC criteria and one in the 145 families with incomplete data. CDH1 germline 
mutations were not found in 67 families with intestinal-type gastric cancer or 
in 31 families with combined diagnoses of diffuse-type, intestinal-type and/or 
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mixed-type gastric cancer (GC), which confirms that the histological subtype is 
important in selecting patients for CDH1 screening. One of the major problems 
in clinical genetic counseling procedures is the lack of histopathological 
gastric cancer classification in pathology reports. Review of pathology reports 
led to classification in 181 of 229 patients (79%), however the conclusions of 
most reports were not clear (i.e. ‘poorly differentiated adenocarcinoma’) and 
classification was often based on interpretation of the microscopic description 
or pathological review of slides. Therefore, it is important that pathologists 
are involved in the counseling procedures to interpret pathology reports or, 
preferably, review slides of gastric specimens. 
NEW CRITERIA – DEFINITIONS
The HDGC criteria were updated in 2015 after the Nijmegen consensus meeting 
(March 2014), and testing of germline CDH1 mutations is currently recommended 
in families (including first- and second-degree relatives) fulfilling one of the 
following criteria (Chapter 3):
• Two or more documented cases of GC at any age with at least one confirmed 
DGC;
• Personal history of DGC before the age of 40 years;
• Personal or family history of DGC and lobular breast cancer, one diagnosed 
before the age of 50 years;
• Personal or family history of bilateral or multiple cases of lobular breast 
cancer before the age of 50 years; 
• Families with clustering of DGC and cleft lip/cleft palate and; 
• Any patient that is diagnosed with in situ signet ring cells and/ or pagetoid 
spread of signet ring cells. 
The	HDGC	criteria	were	principally	set	up	in	1999	to	define	the	HDGC	syndrome	and	
were broadened as CDH1 testing criteria in 2010 and 2015 to reduce the amount of 
undiagnosed	families	with	this	serious	syndrome.	The	definition	of	a	HDGC	family	
and	the	differentiation	from	CDH1 testing criteria is not put forward in the current 
guideline,	while	it	would	be	better	to	distinguish	the	HDGC	definition,	referring	to	
the original criteria, set by Caldas et al in 19992, from the broad CDH1 testing criteria, 
referring to the updated 2015 criteria.4	 In	my	opinion	 the	definition	of	 ‘a	HDGC	
family’ should be a family that is diagnosed with a proven pathogenic mutation 
in CDH1 or CTNNA1	or,	in	case	no	mutation	was	identified,	a	family	that	fulfills	the	
210
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HDGC criteria by Caldas et al.2	All	other	families	with	aggregation	of	diffuse	gastric	
cancer	 and	an	 index	 case	with	DGC,	but	not	 fulfilling	 the	original	 IGCLC	criteria	
for	HDGC,	should	be	classified	as	familial	diffuse	gastric	cancer	(FDGC)	or	familial	
gastric	cancer	(FGC)	when	the	histology	is	unknown	or	a	combination	of	diffuse,	
intestinal and/or mixed histology (Table 1, criteria summarized).
Table 1. Criteria familial gastric cancer
Criteria – definition Criteria
CDH1 testing criteria (updated 2015 
criteria)4
Two or more documented cases of GC at any age in first- or second-degree relatives, with 
at least one confirmed DGC; or
Personal history of DGC before the age of 40 years; or
Personal or family history (first- or second-degree relatives) of DGC and lobular breast 
cancer, one diagnosed before the age of 50 years; or
Families with bilateral or multiple cases of lobular breast cancer before the age of 50 
years; or
Families with clustering of DGC and cleft lip/cleft palate and; or
Any patient that is diagnosed with in situ signet ring cells and/ or pagetoid spread of 
signet ring cells. 
EOGC (EODGC/EOIGC) Early-onset gastric cancer, under the age of 50, with or without confirmed diffuse- 
(EODGC) or intestinal-type GC (EOIGC), without a family history of gastric cancer.
Endoscopic screening criteria for first-
degree relatives of patients with DGC
The current guideline advises annual gastroscopy according to the Cambridge protocol in 
all patients fulfilling CDH1 testing criteria in an expert centre. 
National guideline in the Netherlands: annual gastroscopy in first-degree relatives of 
families that fulfill the criteria: ‘at least two diagnoses of GC, one confirmed DGC<50 
years of age’ (www.stoet.nl). 
FDGC All families with two or more documented cases of GC at any age in first- or second-
degree relatives, with at least one confirmed DGC
FGC All families with two or more documented cases of GC at any age in first- or second-
degree relatives, pathology is not confirmed or consists of mixed or a combination of 
intestinal and diffuse histology
FIGC2 Two or more documented cases of intestinal gastric cancer (IGC) in first- or second-degree 
relatives, with at least one being diagnosed before the age of 50 years; or
Three or more cases of IGC in first- or second-degree relatives, independent of age of 
diagnosis.
GAPPS29,30 Gastric adenocarcinoma and proximal polyposis of the stomach:
Gastric polyps restricted to the body and fundus with no evidence of colorectal or 
duodenal polyposis; 
>100 polyps carpeting the proximal stomach in the index case or >30 polyps (the 
greatest number of FGPs in our uncertain cases) in a first-degree relative of another case; 
Predominantly FGPs, some having regions of dysplasia (or a family member with either 
dysplastic FGPs or gastric adenocarcinoma); and 
An autosomal dominant pattern of inheritance. 
Exclusions include other heritable gastric polyposis syndromes and use of PPIs.
HDGC2 Two or more documented cases of diffuse gastric cancer (DGC) in first- or second-degree 
relatives, with at least one being diagnosed before the age of 50 years; or
Three or more cases of DGC in first- or second-degree relatives, independent of age of 
diagnosis. 
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ENDOSCOPIC SCREENING OF FIRST-DEGREE 
RELATIVES OF PATIENTS WITH GASTRIC CANCER
In the current guideline (chapter 3), endoscopic screening in a research setting is 
recommended	for	first-degree	family	members	of	gastric	cancer	patients	with	a	
CDH1 variant	of	unknown	significance	or	families	that	meet	CDH1 testing criteria 
but do not have a germline mutation in CDH1. In one case series, intramucosal 
signet ring cell carcinomas (SRCCs) were detected endoscopically in 2 of 7 
CDH1 mutation-negative individuals (1/5 families).5 In chapter 4 the results of 
endoscopic screening in 90 individuals from 40 HDGC families without a CDH1 
mutation are described. By using a protocol in which 30 biopsies per screening 
were	 recommended,	 we	 found	 DGC	 in	 five	 persons	 (6%)	 that	 underwent	
gastroscopy.	SRCC	 foci	 restricted	 to	 the	mucosa	 (pT1a)	were	 identified	 in	 four	
persons (4%) from one family, which afterwards was diagnosed with a germline 
CTNNA1 mutation. Advanced poorly cohesive gastric carcinoma was diagnosed 
in one person of another family. Recently, a study from the Cambridge group was 
published that determined the yield of SRCC foci in 85 individuals with a pathogenic 
CDH1 mutation (n=54) compared with those without (n=31).6 Their results in 
family members without a CDH1 mutation are in the same range compared to our 
study. They found a SRCC yield of 61.1% in CDH1 mutation carriers compared with 
9.7% in non-carriers, and mutation positive patients had a 10-fold risk of SRCC on 
endoscopy compared with those without a mutation (p<0.0005).6 
As discussed above the new CDH1 testing criteria are quite broad and do not 
define HDGC. It is not clear whether the CDH1 testing criteria are suitable 
endoscopic screening criteria for proven CDH1 negative families as well. The two 
families with endoscopic lesions in our study (chapter 4) were both from large, 
highly suspected families with multiple GC cases. However, the first family, in 
which four individuals were diagnosed with mucosal SRC after gastroscopy, 
were included based on a family history of multiple unconfirmed gastric cancer 
cases and two first-degree relatives with confirmed DGC above the age of 50. 
Therefore this family actually did not fulfill the original HDGC criteria set by 
Caldas et al. nor the updated 2010 criteria. The second family had four confirmed 
diagnoses of DGC in four first-degree relatives (siblings) and a fifth DGC was 
detected by endoscopy. This family did meet the HDGC criteria. Since only two 
families in our study revealed abnormalities, it is impossible to define precise 
endoscopic screening criteria. In the study by the Cambridge group, also two 
families were identified. SRCCs were detected in two siblings from a family with 
a strong history of DGC (with two first-degree members with DGC) and in a third 
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patient from another family of which no data was reported.6 Based on these 
two studies, especially families with at least two first-degree members with 
confirmed diagnoses of DGC seem to be at risk, but follow-up of these cohorts 
and research in other cohorts is needed. 
In our cohort of 90 individuals, intestinal metaplasia was diagnosed in 38 
persons (42%) and low-grade dysplasia in four persons (4%). This high frequency 
of dysplasia and intestinal metaplasia may be influenced by a more intensive 
inspection and biopsy protocol; a 30-biopsy protocol has, to our knowledge, 
not been described in a healthy control group of persons without a family 
history of gastric cancer. Another possibility is that gastric cancer in families 
without a confirmed monogenic cause is a pathophysiologically different, more 
heterogenic, kind of cancer. 
Although in the 285 endoscopies performed in this study no serious adverse 
events happened, in 40 persons (44%) scar tissue was observed in the gastric 
mucosa, which can hinder the endoscopic detection of small white lesions typical 
for HDGC. Screening may be justified in this population, but adjustments in the 
endoscopic interval and stricter inclusion criteria for the screening program 
could be considered.
THE MORPHOLOGICAL, IMMUNOHISTOCHEMICAL 
AND MOLECULAR PROFILE OF HDGC
Gastric adenocarcinoma is a heterogeneous disease and has various 
morphological phenotypes. Commonly used histopathological classification 
systems divide gastric cancer into intestinal, diffuse and mixed/indeterminate 
type GC7 or into five subtypes (papillary, tubular, mucinous, poorly cohesive or 
mixed)8. The Cancer Genome Atlas (TCGA) proposed a molecular system that 
classifies GC into four subtypes, namely, adenocarcinomas that are Epstein-
Barr virus positive, microsatellite unstable tumors, genomically stable tumors 
and chromosomal instable tumors.9 Genomically stable tumors are enriched for 
diffuse-type GC. This subtype has a more aggressive course than the intestinal 
type.10 Gastric cancer can be further divided into its location within the stomach 
with a distinction between the body and distal portion of the stomach (noncardia) 
and carcinomas arising from the proximal (cardia) region. The distinction of 
cardia versus noncardia GC is important since there is evidence that the two 
entities have different etiologies. Several reports indicate that gastric cardia 
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cancer and gastroesophageal junction cancers are increasing in incidence and 
are related to gastroesophageal reflux disease but not with Helicobacter pylori 
infection. Generally, especially intestinal GC is divided into cardia and non-
cardia. Diffuse-type GC is often not divided into cardia and non-cardia, since 
patients with DGC often present with linitis plastica and the relationship of 
gastroesophageal reflux disease or H. pylori and diffuse-type GC is less clear. 
In chapter 5 we have investigated histopathological characteristics of 
gastric cancer in patients with a hereditary cancer syndrome and the role of 
immunohistochemistry to define these cases. Morphological characteristics 
were assessed in patients with gastric carcinoma and a germline CDH1 mutation 
(n= 27), Lynch syndrome (n= 29), or with early-onset or positive family history 
without a known germline mutation (n= 122). The morphological phenotype of 
HDGC associated with CDH1 germline mutation includes a variable spectrum 
of precursor, early and advanced lesions, namely: (1) precursor lesions (pTis), 
including in situ SRCC and pagetoid spread of SRCs; (2) intramucosal HDGC 
(pT1a), showing typical SRC morphology (“indolent phenotype”); and (3) 
advanced HDGC (pT > 1) composed of a mixture of SRCs and poorly cohesive, 
pleomorphic cells (“aggressive phenotype”).11 Although almost all advanced 
CDH1-associated gastric cancers in our series had at least focal pure signet ring 
cell morphology, only 22% were predominantly of the signet-ring cell type. In 
fact, the tumors were quite heterogeneous with respect to morphology including 
glandular and mucinous components. In our young and familial gastric cancer 
patients, precursor lesions are pathognomic for a germline CDH1 mutation. No 
other histological criteria are specific and only the minority of cases is of the 
signet-ring cell type. In individuals with Lynch syndrome most gastric cancer 
cases showed microsatellite instability (MSI) or loss of mismatch repair protein 
expression indicating an etiological role for mismatch repair deficiency, a 
hallmark of Lynch syndrome. However, in 14% of cases no indication of such 
deficiency was observed, suggesting that these gastric carcinomas developed 
independent of the Lynch syndrome genotype. 
Individuals with a germline CDH1 mutation, have a single functional CDH1 allele. 
When this wild-type allele becomes inactivated by a somatic second-hit molecular 
mechanism - promoter hypermethylation, loss of heterozygosity or a mutation - 
this leads to biallelic inactivation of the CDH1 gene and the development of DGC.12 
Consistent with the bi-allelic CDH1 inactivation and subsequently E-cadherin 
loss of function, E-cadherin protein expression by immunohistochemistry (IHC) 
is often abnormal in HDGC, in contrast to the normal complete membranous 
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expression in adjacent normal (nontumoral) epithelium.13-17 However, bi-allelic 
CDH1 gene inactivation does not invariably lead to complete loss of E-cadherin 
protein expression. Other aberrant E-cadherin staining patterns include reduced 
membranous and cytoplasmic staining. Also, independent of CDH1 germline 
mutation and HDGC tumor stage, E-cadherin immunohistochemical expression 
can be strong but irregular (‘dotted’) membranous. Gastric cancer from patients 
without a CDH1 germline mutation show similar E-cadherin expression (Chapter 5). 
Therefore,	immunohistochemical	analysis	of	E-cadherin	in	diffuse-type	GC	lesions	
(early and advanced) is neither a valid marker to select patients for CDH1 testing nor 
can it be used to predict whether an early lesion will evolve to invasive cancer.
E-cadherin	forms	part	of	the	cadherin-catenin	complex,	together	with	β-catenin,	
α-catenin	 and	 p120-catenin,	which	 plays	 an	 essential	 role	 in	 epithelial	 integrity.	
Disrupting	 this	 complex	 does	 not	 only	 affect	 the	 adhesive	 repertoire	 of	 a	 cell,	
but also the Wnt-signaling pathway. This complex can be disturbed by somatic or 
germline (epi)genetic alterations, of which CDH1 and CTNNA1 mutations are known 
causes of HDGC. At the junction of two neighboring cells in normal epithelium, 
α-	,	β-	and	p120-catenin	bind	to	the	cytoplasmic	domain	of	E-cadherin	and	forms	
a signaling platform.18, 19 Functionally, E-cadherin and p120 stabilize the complex 
to	 the	 membrane,	 while	 β-catenin	 is	 inhibited	 by	 E-cadherin	 in	 normal	 gastric	
epithelium.20	Abnormal	expression	patterns	of	both	α-	and	β-catenin	in	early	HDGCs	
were described, suggesting that the absence of a normal E-cadherin protein may 
lead to the disruption of the cell-cell adhesion complex.21 Furthermore, junctional 
proteins	β-actin,	p120	catenin,	and	Lin7,	markers	of	adherens	junction	structure,	
stability and maturity, were shown to be reduced or absent in early HDGC.15 
Recently, it was discovered that e-cadherin next to the important role in cell-cell 
adhesion, also plays a direct role in epithelial cell division. E-cadherin mediates 
the successive, cell-cycle dependent recruitment of leucine-glycine-asparagine 
repeat protein (LGN) and nuclear mitotic apparatus (NuMA), two essential factors 
for spindle orientation, to cell-cell contacts.22 On mitotic entry, NuMA is released 
from the nucleus and competes LGN from E-cadherin to locally form the LGN/
NuMA complex. This mediates the stabilization of cortical associations of astral 
microtubules at cell–cell adhesions to orient the mitotic spindle, essential for 
normal epithelial cell division.22 Additional research using immunohistochemistry, 
immunofluorescence	and/or	mutation	analysis	 in	 early	 and	advanced	HDGC	will	
gain more knowledge about the development and progression of these tumors. 
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In chapter 6 we describe a cohort of patients that presented with both breast and 
gastric cancer, either synchronously or metachronously, which may be indicative 
for genetic predisposition leading to an increased risk of multiple primary tumors. 
Therefore, it is important to evaluate whether such tumors represent the same 
or multiple primary tumors that may be morphologically indistinguishable. We 
showed that, next to CK20, HNF4A expression is suggestive for GC origin, while 
breast-associated immunomarkers are ER, BRST-2 and mammaglobulin. 
GENETICS OF FAMILIAL GASTRIC CANCER
In	 the	 majority	 of	 gastric	 cancer	 families	 fulfilling	 the	 CDH1 testing criteria, a 
germline CDH1 mutation is not detected and these families remain genetically 
unexplained. This has major consequences for these families. Without a known 
genetic defect and concomitant cancer risk estimates, it is not possible to perform 
adequate surveillance and pre-symptomatic interventions in these families.
The search of new gastric cancer susceptibility genes is challenging, as is shown 
in chapter 7. In this chapter, the results of germline whole exome sequencing in 
54 patients from 53 families did not show obvious candidate GC predispostion 
genes besides MYD88. In MYD88 a germline homozygous missense variant was 
identified	in	a	patient	with	diffuse-type	GC	at	the	age	of	23.23 In vitro experiments 
suggests the MYD88 mediated immune response of the patient is impaired, which 
may have led to a vulnerability to infections and associated gastric cancer risk. 
The patient was diagnosed with H. pylori infection and recurrent candidiasis which 
may have triggered GC development. Histopathological review of gastric biopsies 
and gastrectomy specimen showed a poorly cohesive carcinoma with signet ring 
cells and a background of chronic active gastritis.23 
Another family with clustering of gastric cancer and a possible impaired immune 
response	was	reported	by	our	group.	This	family	presented	with	three	first	degree	
relatives with intestinal-type gastric cancer and heterozygous mutations in the 
immunity gene IL12RB1.24	Additional	research	in	families	with	mutations	affecting	
immune response genes is required to determine an increased gastric cancer risk.
Other possible GC susceptibility genes that were revealed by whole exome 
sequencing by other research groups include INSR, FBXO24 and DOT1L which 
were all three reported in a single Finnish family.25 Mitogen-activated protein 
kinase kinase kinase 6 (MAP3K6) was identified by Gaston et al. in 2014.26 In 116 
non-CDH1 FGC families, variants were identified in six families.26 MAP3K6 was 
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considered a strong candidate based on the known associations of MAP3K6 and 
other MAP kinases with cancer.26 In this study, penetrance was incomplete and 
age of gastric cancer diagnosis variable; most patients presented with gastric 
cancer above 50 years of age. Therefore, it was hypothesized that additional 
environmental and/or genetic factors apart from MAP3K6 may play a role in 
the progression to gastric cancer.26 The reported families did not fulfill HDGC 
criteria, since gastric carcinomas in these families showed variable histology 
with some diffuse, some intestinal-type GCs and some mixed histologies with 
solid and glandular components. A background of chronic gastritis and intestinal 
metaplasia was noted with H. pylori in some patients.26 These are all arguments 
that make this this either a new hereditary gastric cancer syndrome, or, more 
likely, a coincidential finding. In chapter 8 we could give a solution to this issue.
In chapter 8 we present results of sequencing for germline variants affecting 
CTNNA1, MAP3K6 and MYD88 with a targeted next generation sequencing 
approach, using single-molecule molecular inversion probes (smMIPs). We 
have sequenced a large European cohort of unexplained young and/or familial 
gastric cancer patients without a CDH1 germline mutation (n=286). Predicted 
deleterious germline variants were recurrently observed in CTNNA1 and MAP3K6 
in GC patients. Only two heterozygous variants affecting MYD88 were detected 
and these are likely benign. The relevance of biallelic MYD88 mutations remains 
to be established. In contrast to deleterious variants in CTNNA1, deleterious 
variants in MAP3K6 also occur frequently in the general population. In fact, 
strong loss-of-function germline variants affecting MAP3K6 are encountered in 
approximately 0.5% of the general population, strongly conflicting with a high-
penetrant predisposing effect of such variants to the development of a rare 
pathogenic phenotype like GC. Based on our results, we anticipate that germline 
aberrations affecting MAP3K6 are unlikely to be involved in GC predisposition. 
Deleterious CTNNA1 variants were confirmed as an infrequent cause of GC 
susceptibility. Taken together with previous reports, in 450 GC families only 
five CTNNA1 mutation-positive families were detected. These families show a 
clinical picture similar to CDH1 mutation-positive families with HDGC, although 
no lobular breast cancer or cleft lip/palate has been reported thus far. Ages 
from confirmed CTNNA1-mutation carriers with gastric cancer vary from 22 till 
72 years. Our data confirm that germline mutations in CTNNA1 are rare in GC 
families, but are strongly associated with HDGC. 
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Gastric cancer is also seen in individuals that carry variants in genes associated 
with other cancer-predisposition syndromes, including (gastric) polyposis 
syndromes (as FAP, MAP, Peutz-Jeghers, Juvenile polyposis and Cowden) 
and other cancer syndromes such as BRCA1/2 and Lynch syndrome. Using 
multiplexed panel sequencing, Hansford et al. found germline mutations 
in HDGC families in BRCA2 (associated with hereditary breast and ovarian 
cancer), STK11 (Peutz-Jeghers syndrome susceptibility gene), SDHB (associated 
with familial paraganglioma/pheochromocytoma), PRSS1 (associated with 
hereditary pancreatitis) and MSR1 (associated with esophageal and prostate 
cancers).27 They also detected pathogenic germline mutations in ATM, and 
PALB2, both associated with hereditary breast, ovarian, and pancreatic 
cancers.27 Recently, Sahasrabudhe et al. also found germline variants in PALB2, 
BRCA1 and RAD51C in patients with gastric cancer using whole-exome sequence 
analysis.28 Histology was variable and these families presented with intestinal, 
diffuse and mixed-type gastric cancer.28 PALB2 and RAD51C are both critical in 
homologous recombination, a major DNA repair pathway. PALB2 mutations 
have been reported in breast cancer families whereas RAD51C is associated 
with an increased risk of ovarian cancer. Further research regarding variants of 
unknown significance and variants in non-coding regions in CDH1 is ongoing. 
The ongoing search for novel GC predisposing germline aberrations will 
undoubtedly	lead	to	the	identification	of	new	variants	in	candidate	genes.	All	next-
generation methodologies, including whole exome and whole genome sequencing 
and panel-testing of multiple cancer-predisposition genes generates a lot of data. 
The interpretation of variants in genes and risk they may confer has to be careful 
as was shown by our studies: a mutation in a gene does not always imply that 
it is relevant for the disease studied. Preferably, international multidisciplinary 
research groups combine their clinicopathological and molecular data which 
will	 probably	 lead	 to	 the	 highest	 success	 rate	 to	 define	 new	GC-predisposition	
syndromes and to develop proper clinical management strategies. 
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Table 2. Possible predisposing gastric cancer genes beyond CDH1
Gene Phenotype* Mutation type Mode of 
inheritance
Number of 
families reported 
in context of 
gastric cancer
Remarks References 
APC FGC/ GAPPS Point mutations 
in the gene 
promoter 1B
AD 9 APC germline mutations are 
usually associated with (A)FAP, 
but these specific mutations 
give the phenotype of GAPPS
29-32
ATM FGC and HDGC Truncating / 
missense 
AD 7 Also reported, with conflicting 
risk estimates, in context of 
hereditary breast, ovarian and 
pancreatic cancers
27, chapter 7
BRCA2 HDGC Truncating AD 1 Usually associated with 
hereditary breast cancer
27
CTNNA1 HDGC, EODGC, 
FGC
Truncating AD 5 Although rare, strongest HDGC 
predisposition gene besides 
CDH1
27, 33, chapter 8
INSR, FBXO24 
and DOT1L
HDGC Truncating AD 1 All three frameshift mutations in 
these genes were described in a 
single family (confirmed in three 
family members)
25
IL12RB1 FIGC Truncating AD 1 Biallelic mutations in IL12RB1 
cause a rare immunodeficiency 
syndrome
24
MAP3K6 FGC Missense/ 
truncating
AD 22 Unlikely to be involved in 
GC predisposition. Strong 
loss-of-function germline 
variants affecting MAP3K6 are 
encountered in approximately 
0.5% of the general population.
26, chapter 8
MSR1 HDGC , FGC, 
EODGC 
Frameshift AD 4 Germline mutations were 
reported in patients with 
esophageal or prostate cancer.
27
MYD88 EODGC Homozygous 
missense 
mutation
AR 1 Single case with impaired 
MYD88 mediated immune 
response, which may have led to 
a vulnerability to infections and 
associated gastric cancer risk.
23
PALB2 HDGC Truncating AD 2 Also reported, with conflicting 
risk estimates, in context of 
hereditary breast, ovarian and 
pancreatic cancers.
27, 28
PRSS1 HDGC Truncating AD 1 Associated with hereditary 
pancreatitis
27
RAD51C HDGC Truncating AD 1 Associated with hereditary 
breast and ovarian cancer
28
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SDHB FGC Missense AD 1 Associated with familial 
paraganglioma/
pheochromocytoma and with 
the cancer risk disorder Cowden-
like syndrome
27
STK11 HDGC , EODGC Missense AD 3 Peutz-Jeghers syndrome 
susceptibility gene
27
*See phenotype explanation in table 1. Other abbreviations: AD= automal dominant; AR= autosomal 
recessive; (A)FAP= (attenuated) familial adenomatous polyposis
Table 2. Continued
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NEW INSIGHTS IN THIS THESIS
Clinical criteria and guidelines
• In a minority of families (14%) that fulfill CDH1 (2010) testing criteria a 
germline mutation in CDH1 can be identified in a diagnostic setting.
• When the diffuse subtype of GC is confirmed, the HDGC criteria of 2010 is 
an adequate tool for clinical geneticists to select patients for CDH1 mutation 
analysis.
•  In the Netherlands, all individuals reported to date with a pathogenic CDH1 
mutation had a personal or family history of diffuse-type GC.
• The updated HDGC guidelines include revised CDH1 testing criteria. The 
revised criteria now cover families for whom detailed pathology is incomplete. 
Expert histopathological confirmation of HDGC is recommended.
Diagnostics: gastroscopy and histopathology
• With endoscopic surveillance, diffuse-type GC was diagnosed in 6% of first-
degree relatives of HDGC patients without a CDH1 germline mutation. Quite 
often there was scar formation after endoscopic screening with the extended 
biopsy protocol. 
• Advanced HDGC associated with a germline CDH1 mutation often presents as 
heterogenous gastric cancer with areas of glandular growth, mucinous lakes 
and cords of tumor cells. 
• Immunohistochemical E-cadherin presence or absence does not discriminate 
between HDGC associated with and without a CDH1 germline mutation.
• Gastric cancer in patients with Lynch syndrome or HDGC/FIGC, not associated 
with a mutation, does not show discriminative morphological features.
• HNF4A immunohistochemistry is useful to discriminate between primary and 
metastatic gastric and breast carcinomas.
Predisposing genetic causes of gastric cancer
• Exome sequencing to identify candidate predisposition genes for familial gastric 
cancer generates a lot of data, with a large number of potentially interesting 
variants.	Even	though	almost	400	variants	were	identified	that	may	be	relevant	
for GC development, it did not reveal any clear candidate genes. 
• Deleterious CTNNA1 variants are confirmed as an infrequent cause of 
GC susceptibility. MAP3K6 variants are probably not directly related to 
GC predisposition. The relevance of biallelic MYD88 mutations remains to 
be established.
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FUTURE PERSPECTIVES
The research described in this thesis provides numerous directions for future 
research to further elucidate the molecular alterations underlying the genetic 
predisposition to gastric cancer. 
Clinical criteria and guidelines
• In a future IGCLC consensus meeting recommendations have to be made on 
definitions of HDGC that should be different from the CDH1 testing criteria;
• New studies can be performed that evaluate the new CDH1 testing criteria, 
including positive predictive value;
• Future studies and recommendations are needed for the use of panel testing 
and its interpretation of predisposing GC genes beyond CDH1. 
Diagnostics: gastroscopy and histopathology
• Longer follow-up of upper endoscopic screening and research in other 
expert centers in first-degree relatives of familial or early-onset gastric 
cancer patients without a germline mutation in CDH1 are needed. Intensive 
endoscopic surveillance is preferably performed in a research setting and 
in expert centers. Hopefully, this will lead to criteria which patients or 
first-degree relatives need to undergo endoscopic surveillance, including 
recommendations on the intensity and biopsy protocol.
• More knowledge of histopathological characteristics of lobular breast cancer, 
including evaluation of prophylactic specimens in patients with germline 
CDH1 mutations is needed. 
• There has been no systematic study of somatic genetic and epigenetic 
alterations in genes other than CDH1 in HDGC from CDH1 germline mutation 
carriers. Thus, there remains a lack of understanding of the cascade of genetic 
or epigenetic events taking place after CDH1 inactivation by a second-hit. 
Therefore, it is unclear how long early lesions of HDGC remain indolent, 
and how to predict their progression to widely invasive carcinomas. Such 
knowledge is necessary to shed light onto the players involved in the evolution 
from early to invasive HDGC lesions. Studies in a series of HDGC caused either 
by CDH1 or CTNNA1 germline mutations, and in different progression stages, 
would undoubtedly help to disclose the somatic mutation landscape of this 
disease. Not only genetic analysis but also future research in the expression 
and functioning of proteins involved in the Cadherin-Catenin complex may 
give more insight in the development of HDGC after inactivation of CDH1.
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Predisposing genetic causes of gastric cancer
• Due to the limited number of CTNNA1 families identified, proper estimation of 
disease penetrance and evidence-based advice on preventive measurements 
is not yet possible. International cooperation and follow-up of these families 
is needed to learn more about the presentation of gastric cancer associated 
with a germline CTNNA1 mutation and to develop risk-reducing strategy 
options.
• International collaboration and novel genetic testing strategies may also lead 
to more knowledge about gastric cancer predisposing genes. 
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Maagkanker is wereldwijd een veelvoorkomende ziekte en patiënten presenteren 
zich vaak in een laat stadium waardoor er weinig behandelingsopties zijn. De 
incidentie van maagkanker kent grote geografische verschillen met een hoge 
incidentie in een aantal Aziatische landen, waaronder Japan. De incidentie van 
maagkanker is gerelateerd aan de incidentie en virulentiesoort van Helicobacter 
pylori, een maagbacterie die via de ontwikkeling van maagontsteking kan leiden 
tot metaplastische veranderingen en vervolgens via voorstadia uiteindelijk 
tot maagkanker. In Nederland is de incidentie van maagkanker de afgelopen 
decennia sterk gedaald met in 1990 circa 1900 gevallen en in 2016 zo’n 1300 
gevallen. In vergelijking met bijvoorbeeld dikke darmkanker (15427 gevallen in 
2016) en borstkanker (14608 in 2016) is maagkanker een relatief zeldzame vorm 
van kanker in Nederland (http://www.cijfersoverkanker.nl). De meerderheid van 
maagkanker treedt op in een zogenaamde sporadische manier, waarbij we de 
oorzaak vaak niet weten. In circa 10-20% van de patiënten zien we familiaire 
clustering, waarbij niet alleen genetische factoren een rol kunnen spelen, maar 
ook gelijke omgevingsfactoren en leefgewoonten. In ongeveer 1-3% kan er 
een genetische oorzaak achterhaald worden. Aangezien de meeste patiënten 
met maagkanker pas in een gevorderd stadium worden gediagnosticeerd en 
daardoor een slechte prognose hebben is het voorkomen dan wel opsporen van 
maagkanker in een vroeg stadium erg belangrijk.
Maagkanker kan onder de microscoop histologisch grofweg worden verdeeld 
in intestinaal- en diffuus-type maagkanker. Familiaire vormen van maagkanker 
worden ingedeeld aan de hand van de histologische vorm, in erfelijke diffuse 
maagkanker, familiaire intestinale maagkanker en wanneer het type maagkanker 
niet bekend is als het een combinatie betreft, familiaire maagkanker. Tevens 
zijn er familiaire vormen bekend die gepaard gaan met het optreden van 
maagpoliepen. Dit proefschrift richt zich op de klinische, microscopische en 
genetische kenmerken van familiaire maagkanker. In slechts een klein deel van 
families zijn er erfelijke oorzaken bekend; mijn onderzoek heeft zich gericht op 
de kenmerken van maagkankerpatiënten met een bekende erfelijke oorzaak en 
op de verbetering van genetische en histologische diagnostiek, endoscopische 
surveillance en behandeling van families waarin geen erfelijke oorzaak is 
gevonden (hoofdstuk 1). 
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Erfelijke diffuse maagkanker is een kanker predispositiesyndroom dat 
veroorzaakt kan worden door een verandering in het CDH1 gen. Dit werd in 
1998 ontdekt door onderzoekers in Maori families in Nieuw-Zeeland. In deze 
families werden meerdere (soms zelfs tientallen) familieleden vaak al op zeer 
jonge leeftijd met maagkanker gediagnosticeerd. Sindsdien zijn kiembaan-
mutaties in het CDH1 gen beschreven in meer dan 150 families met maagkanker 
over de hele wereld. CDH1 codeert voor het eiwit E-cadherine, een eiwit dat 
een belangrijke rol speelt in de organisatie en structuur van ons weefsel door bij 
elkaar te houden. Mensen die geboren worden met een aangeboren afwijking 
(kiembaan mutatie) in het CDH1 gen hebben een levenslang sterk verhoogd 
risico op het ontwikkelen van diffuus-type maagkanker (tot 70%) en lobulair-
type borstkanker (ca 40%). Tevens treedt er vaker schisis op in deze families. Er 
zijn door de internationale erfelijke maagkanker expertgroep criteria ontwikkeld 
voor het opsporen van families met een kiembaan-mutatie in het CDH1 gen. 
Sinds 1999 worden in Nederland dan ook families getest op mutaties in het 
CDH1 gen. Hoofdstuk 2 bevat het onderzoek naar de waarde van deze criteria 
door het analyseren van uitkomsten van CDH1 mutatie-analyse en de klinische-
pathologische data van 499 families die getest zijn in Nederland. Er werden 
16 CDH1 gen afwijkingen (pathogene mutaties) gevonden in 118 families die 
voldeden aan de criteria (14%). Niet altijd kon het histologische type worden 
bevestigd doordat er geen informatie bekend was van familieleden of doordat 
de diagnose te lang geleden was en er geen medische documenten beschikbaar 
waren. Verder zijn er veel families getest die niet voldeden aan de criteria, 
maar waarin wel veel gevallen van maagkanker of andere vormen van kanker 
voorkwamen. In families zonder diagnoses van diffuus-type maagkanker, maar 
intestinaal-type of andere vormen van kanker werden geen mutaties in CDH1 
gevonden. 
In maart 2014 organiseerde onze onderzoeksgroep de internationale, 
multidisciplinaire erfelijke maagkanker workshop in het Radboudumc te Nijmegen 
met als doel actuele kennis te delen en samen te brengen in een nieuwe uitgave 
van de internationale erfelijke maagkanker richtlijn (hoofdstuk 3). De richtlijn 
werd verbeterd naar aanleiding van nieuwe ontwikkelingen in mutatie-analyse 
technieken, operatie-mogelijkheden en uitkomsten, endoscopische surveillance 
en verbeterde pathologische verslaglegging van families met familiaire diffuus-
type maagkanker met en zonder bewezen CDH1 gen mutatie. De inbreng van 
patiënten werd sterk gewaardeerd, waarbij er een hoofdstuk is opgenomen 
met het perspectief van deze patiënten op het leven met dit syndroom 
en het ondergaan van een preventieve maagresectie en de consequenties 
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psychologisch, fysiologisch en metabool (dieet). Naar aanleiding van deze 
workshop werden de criteria om op CDH1 gen mutaties te testen verbreed 
teneinde zoveel mogelijk families op te sporen met deze ernstige aandoening. 
In deze vernieuwde richtlijn werden de volgende criteria opgenomen, waarbij 
families getest kunnen worden op een aangeboren afwijking in het CDH1 gen 
wanneer ze voldoen aan tenminste één van de volgende criteria (m.b.t. eerste- 
en tweedegraadsverwanten): 
•  Twee of meer gevallen van maagkanker op elke leeftijd, waarvan tenminste 
één bevestigde diagnose van diffuus-type maagkanker; 
• Diffuus-type maagkanker onder de leeftijd van 40 jaar;
• Het tegelijkertijd optreden van diffuus-type maagkanker en lobulair-type 
borstkanker, waarvan tenminste één diagnose onder de leeftijd van 50 jaar;
• Meerdere gevallen van lobulair-type borstkanker onder de leeftijd van 50 jaar; 
• Families met diffuus-type maagkanker en schisis; 
• In-situ zegelringcellen en/of pagetoide verspreiding van zegelringcellen in de 
maag. 
Veel families die voldoen aan deze criteria, hebben geen mutatie in het CDH1 
gen en blijven onverklaard. Als er geen mutatie aangetoond kan worden, is het 
ook niet mogelijk om deze families preventieve maatregelen aan te bieden. 
De internationale richtlijn beveelt jaarlijkse maagonderzoeken aan in families 
die sterk verdacht zijn voor erfelijke diffuse maagkanker. Hoofdstuk 4 bevat 
het onderzoek naar de uitkomsten van jaarlijkse gastroscopie (endoscopische 
maagonderzoeken) in eerstegraads familieleden van patiënten die op jonge 
leeftijd diffuus-type maagkanker ontwikkelde of uit families komen waarin 
meerdere familieleden werden gediagnosticeerd met maagkanker. 
Endoscopische screening werd verricht bij 90 familieleden van 40 erfelijke 
diffuse maagkanker families zonder CDH1 mutatie in twee expertise centra, te 
weten het Radboudumc te Nijmegen en Antoni van Leeuwenhoekziekenhuis 
te Amsterdam. De gastroscopische procedure betreft een uitgebreid 
protocol waarbij er 30 willekeurige biopten van alle regio’s van de maag per 
screening wordt aanbevolen. Met dit protocol werden er bij vijf personen 
maagcarcinomen gevonden tijdens gastroscopieën. Bij vier patiënten (van een, 
wat later bleek, CTNNA1 familie) betroffen dit vroege stadia en in één patiënt 
van een andere familie betrof het een gevorderd stadium van maagkanker 
tijdens de eerste screeningsprocedure. Dit onderzoek toont aan dat er op deze 
wijze maagcarcinomen opgespoord kunnen worden al betreft het een relatief 
laag percentage. Het verder vervolgen van deze families en het uitvoeren van 
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dergelijk onderzoek in andere expertise centra kan meer inzicht geven in de 
effectiviteit van dergelijke screening. 
Hoofdstuk 5 omvat de histologische karakteristieken van maagkanker in 
patiënten met familiaire maagkanker, waarvan 27 met een bewezen kiembaan 
mutatie in CDH1, 29 met Lynch-syndroom en 122 zonder bewezen erfelijke 
afwijking. De maagkanker-samples van patiënten met een kiembaan mutatie 
in CDH1 toonden vaak een gecombineerde groeiwijze met - naast vaak een 
klein focus van zegelringcellen - ook mucineuze en glandulaire componenten. 
In bijna de helft van de patiënten die een maagresectie voor een gevorderd 
stadium maagkanker hadden ondergaan, konden specifieke voorstadia 
aangetoond worden in omgevend maagweefsel op afstand van de tumor. Deze 
voorstadia werden alleen gevonden in patiënten met een CDH1 mutatie. In de 
maagresecties van de 122 patiënten zonder bewezen mutatie werden geen 
specifieke kenmerken gevonden. 
CDH1 codeert voor het eiwit E-cadherine en bij het uitvallen van beide allelen 
van CDH1 (een aangeboren en een verworven mutatie) kan E-cadherine niet 
meer zijn werk doen, waardoor er maagkanker kan ontstaan. Het gebruik van 
immuunhistochemie om verlies van de eiwit-expressie van E-cadherine aan te 
tonen wordt veel gebruikt, soms ook in de diagnostiek van erfelijke maagkanker. 
Wij vergeleken vier verschillende E-cadherine antilichamen in maagkanker 
samples van patiënten met en zonder CDH1 mutatie om de waarde van deze 
kleuring te onderzoeken. In beide groepen vonden we vrijwel even vaak verlies 
dan wel behouden, maar onregelmatige membraneuze expressie. Derhalve 
heeft E-cadherine immuunhistochemie geen waarde in de diagnostiek van 
erfelijke maagkanker. 
In patiënten met Lynch syndroom konden we in de meeste gevallen ‘mismatch 
repair deficiëntie’ aantonen, wat het waarschijnlijk maakt dat de maagtumor 
is ontstaan in de context van Lynch syndroom. Er werden zowel intestinale als 
diffuus-type maagcarcinomen gezien en ook enkele patiënten met medullair-
type maagcarcinoom. Er werden echter geen specifieke kenmerken gevonden. 
Het komt regelmatig voor dat patiënten zich met maag- en borstkanker 
presenteren. Soms zijn dit twee primaire tumoren, soms is de ene tumor een 
uitzaaiing van de andere tumor. Klinisch en radiologisch is dit onderscheid 
moeilijk te maken en ook histologisch kunnen beide vormen sterk op 
elkaar lijken. Aangezien patiënten met twee primaire tumoren een andere 
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behandeling nodig hebben en dit ook kan wijzen op een erfelijk syndroom is 
het belangrijk om toch dit onderscheid te maken. Wij hebben onderzocht welke 
immuunhistochemische markers bruikbaar zijn in deze differentiaal diagnose en 
vonden dat de nieuwe marker HNF4A een belangrijke aanvulling is op het panel 
met specificiteit voor maagkanker (hoofdstuk 6). 
Zoals meermaals vermeld, kan in het grootste deel van families met meerdere 
gevallen van maagkanker geen erfelijke oorzaak gevonden worden. Door 
innovatie in moleculaire technieken zijn er nieuwe testen beschikbaar waarbij 
niet alleen een beperkt aantal genen, maar het gehele exoom of genoom getest 
kan worden op een beperkte hoeveelheid DNA. We hebben exoomsequencing 
uitgevoerd op kiembaan DNA van 54 patiënten die verdacht worden van erfelijke 
maagkanker. Met verschillende analyses werden een aantal kandidaat-genen 
gevonden, die nader geëvalueerd moeten worden in andere cohorten. 
In hoofdstuk 8 staan de resultaten beschreven van een groot Europees cohort 
waarbij we veranderingen in drie genen hebben onderzocht in 286 families 
die geen mutaties in CDH1 hadden. Deze families werden getest op mutaties 
in CTNNA1, MAP3K6 en MYD88 (drie genen die eerder beschreven waren als 
mogelijke maagkanker predispositie genen). Hierin vonden wij twee families 
met mutaties in het CTNNA1 gen. Mede door onze studie zijn er nu wereldwijd 
vijf families gerapporteerd met mutaties in het CTNNA1 gen, een gen dat 
qua functie nauw betrokken is bij het CDH1 gen. Er werden ook varianten in 
het MAP3K6 gen gevonden, maar - aangezien we afwijkingen in dit gen ook 
frequent terugzagen in een gezonde controlepopulatie - toont onze studie aan 
dat het zeer onwaarschijnlijk is dat dit een maagkanker predispositie gen is. 
Nieuwe patiënten met afwijkingen in het MYD88 gen hebben wij niet gevonden 
en, aangezien slechts één patiënt met afwijkingen in dit gen is beschreven, blijft 
het vooralsnog onduidelijk of dit gen een belangrijke predispositie geeft op het 
ontwikkelen van maagkanker. Verder onderzoek is hiervoor nodig. 
In hoofdstuk 9 worden de hierboven beschreven hoofdstukken bediscussieerd 
en wordt ingegaan op mogelijk vervolgonderzoek. Het is belangrijk dat er bij 
zeldzame afwijkingen als erfelijke maagkanker op nationaal - en het liefst ook op 
internationaal - niveau intensief wordt samengewerkt. In een nieuwe consensus-
meeting is het beter definiëren van criteria belangrijk, waarbij er mijns inziens 
onderscheid gemaakt moet worden tussen i) criteria die erfelijke maagkanker 
definiëren, ii) criteria waarbij er geadviseerd wordt om te testen op bepaalde 
genen en iii) criteria welke families endoscopische surveillance zouden moeten 
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onder gaan. Het blijft bij patiënten met, maar ook zonder CDH1 mutatie onbekend 
hoe diffuus-type maagkanker ontstaat vanuit kleine zegelringceltumoren, en 
of en zo ja hoe deze tumoren zich ontwikkelen van relatief goed behandelbare 
vroege stadia naar uitgebreide stadia waarbij tumorcellen de gehele maagwand 
doorwoekeren en uitzaaien naar organen op afstand. Toekomstig onderzoek 
kan hier mogelijk meer inzicht in geven. Verder kunnen uitkomsten verzameld 
worden van patiënten die lobulair borstkanker of voorstadia hiervan ontwikkeld 
hebben, zodat er meer inzicht komt in het ontstaan van borstkanker bij 
kiembaan mutaties in het CDH1 gen; iets wat we tot op heden vrijwel niet zien 
in andere families met erfelijke maagkanker. Er zijn diverse predispositie genen 
voor maagkanker gevonden waarvan de precieze implicaties voor de patiënt en 
zijn/haar familieleden onduidelijk zijn. Door samenwerking en het bundelen van 
resultaten komt er meer kennis over de risico’s die afwijkingen in deze genen 
met zich meebrengen en welke therapeutische en diagnostische opties voor 
patiënten en hun families mogelijk zijn. 
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